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The HIV-1 genome contains RNA sequences and structures that control many aspects of 
viral replication including, but not limited to transcription, splicing, nuclear export, 
translation, packaging and reverse transcription. Despite this extensive existing catalogue 
of RNA sequences that are critical to its replication, chemical probing and targeting 
mutagenesis studies suggest that the HIV-1 genome may contain many more RNA 
elements of unknown important function. To determine whether there are additional, 
undiscovered cis-acting RNA elements in the HIV-1 genome that are important for viral 
replication, we conducted a global synonymous mutagenesis experiment. 
Sixteen mutant proviruses containing clusters of ~50 to ~200 synonymous mutations 
covering nearly the entire HIV-1 protein coding sequence were designed and synthesized. 
Analyses of these mutant viruses resulted in their division into three phenotypic groups. 
Group 1 mutants exhibited near wild-type replication, Group 2 mutants exhibited 
replication defects accompanied by perturbed RNA splicing, and Group 3 mutants had 
replication defects in the absence of obvious splicing perturbation. The three phenotypes 
were caused by mutations that exhibited a clear regional bias in their distribution along 
the viral genome, and those that caused replication defects all caused reductions in the 
level of unspliced RNA. We characterized in detail the underlying defects for Group 2 
mutants. Second-site revertants that enabled viral replication could be derived for Group 
2 mutants, and generally contained point mutations that reduced the utilization of proximal 
splice sites. Mapping of the changes responsible for splicing perturbations in Group 2 
viruses revealed the presence of several RNA sequences that apparently suppressed the 
use of cryptic or canonical splice sites. Some sequences that affected splicing were 
diffusely distributed, while others could be mapped to discrete elements, proximal or distal 
to the affected splice sites. This data from the Group 2 mutants indicates complex 
negative regulation of HIV-1 splicing by RNA elements in various regions of the HIV-1 
genome that enable balanced splicing and viral replication. 
In silico analysis of the Group 3 mutants revealed that our mutagenesis had significantly 
increased the frequency of CG dinucleotides in sections of the viral genome to that of 
random sequence. This is important due to the remarkable CG suppression in both the 
HIV-1 and human genomes, and we had therefore disrupted the dinucleotide congruence 
that exists between HIV-1 and the genome of its host. We recoded these mutants to 
selectively remove either only the CG dinucleotides or only remove the mutations that did 
not encode a CG dinucleotide. Analysis of these mutants clearly demonstrated that the 
addition of CG dinucleotides were the causative mutations entirely responsible for the 
observed replication defects. qPCR analysis and smFISH microscopy revealed that the 
addition of CG dinucleotides to HIV-1 resulted in a depletion of the cytoplasmic mRNA 
molecules where the CG-dinucleotides were encoded as exons. A targeted siRNA screen 
for proteins that destabilize cytoplasmic RNA identified the Zinc-finger Antiviral Protein 
(ZAP) as responsible for the restriction of the CG-high HIV-1, specifically by targeting CG-
high viral RNA. CLIP-Seq experiments demonstrate that ZAP binds directly to CG 
dinucleotides in both cellular and viral RNA. Collectively these studies implicate ZAP as 
a cellular protein that can recognize CG-high viral RNA and is possibly a cellular 
mechanism for determining self from non-self RNA based on the CG composition. 
TRIM25 has previously been identified as a cofactor for two cytosolic RNA binding 
proteins that have antiviral functions, RIG-I where it is an essential cofactor, and ZAP 
where it functions as an enhancing cofactor. The mechanism by which TRIM25 enhances 
the antiviral activity of ZAP currently remains unclear. Through CLIP-Seq experiments in 
cells knocked out for TRIM25, we determined that ZAP does not require TRIM25 to 
recognize CG-high RNA. Using full length mutants of TRIM25 that are deficient for either 
RNA binding, E3 ligase activity, or formation of higher order multimers, our data suggest 
that the key biological activity required for TRIM25 to enhance ZAP is the formation of 
higher order multimers.  Analyzing the replication of CG-high HIV-1 in different cell lines 
indicates that ZAP is not equally potent across all cell lines. The degree of potency ZAP 
possess against CG-high HIV-1 does not correlate with TRIM25 expression, suggesting 
the possibility of an additional ZAP cofactor that is heterogeneously expressed in varying 
cell lines. siRNA screens have been used in an attempt to identify a yet undiscovered 
cofactor, but so far these experiments have not yielded any such factor. 
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Chapter 1. Introduction 
Biology is the study of all areas pertaining to bacteria, archaea and eukaryotes, or the 
tree of life. Viruses, because they are not considered to be alive, do not occupy a branch 
in the tree of life, yet have unquestionably been an important area of study within biology. 
Whether or not viruses should be considering living, they have significantly shaped and 
impacted every area of life, as evidenced by the fact that examples of viruses have been 
found to infect each domain of life (Koonin et al., 2006). If they were considered alive, 
they would make up the most abundant life form on earth. It is estimated that there are 
4.8 x 1031 phages on earth, while prokaryotes, the most abundant cellular organisms, only 
total 4.1 x 1030 cells (Cobian Guemes et al., 2016). In addition to being the most abundant 
biological entities, they also pose one of the greatest threats to life, capable of killing 
single cellular prokaryotes and organisms as complex as humans which are composed 
of trillions of cells. A brief survey of the last decade reveals many different viral pandemics 
that have plagued human life in the world ranging from swine flu (H1N1), Zika virus, Ebola 
virus, West Nile Virus, and chikungunya. For the last 40 years, illnesses related to Human 
Immunodeficiency Viruses (HIV) have persisted as a global public health concern, 
resulting in over 30 million human deaths globally and nearly one million deaths still 
occurring annually. 
Human Immunodeficiency Viruses: structure and replication 
HIV-1 is a member of the Retroviridae family of viruses, commonly referred to as 
retroviruses. The two defining features of retroviruses are (i.) the synthesis of a double 
2 
stranded DNA intermediate from a positive strand RNA genome followed by (ii.) the 
integration of the newly synthesized genome into the host chromosomal DNA. The family 
of Retroviridae is composed of two subfamilies: Orthoretrovirinae and Spumaretrovirinae. 
Within Orthoretrovirinae are six genera: Alpharetroviruses, Betaretroviruses, 
Gammaretroviruses, Deltaretroviruses, Epsilonretroviruses, and Lentiviruses (Sharp and 
Hahn, 2011). HIV is a member of the Lentivirus genus and viruses in this genus are 
broadly associated with long incubation times in their host as well as causing progressive 
diseases that often result in severe immunological defects (Swanson and Malim, 2008). 
Acquired immunodeficiency syndrome (AIDS) in humans is caused by two types of HIV, 
type 1 and type 2 (HIV-1 and HIV-2, respectively) (Sharp and Hahn, 2011). HIV-1 is the 
more prevalent and pathogenic of the two types, and therefore will be the focus in this 
thesis. 
The HIV-1 genome is approximately 10kb and encodes nine genes, including gag, pol 
and env, which are core components of all functional retroviruses (Figure 1.1A).  The 
coding region of the genome is flanked by long terminal repeats (LTRs). The function of 
the 5’ LTR is to act as a promoter that initiates the transcription of the viral genomes after 
integration. The 3’ LTR is important for the addition of the polyadenylation signal (poly(A) 
tail). The HIV-1 pol gene encodes three viral enzymes critical to its replication: protease 
(PR), reverse transcriptase (RT), and integrase (IN). The genome also encodes two 
structural genes; gag and env. The Gag polyprotein consists of the three main structural 
domains: matrix (MA), capsid (CA), and nucleocapsid (NC) as well a p6 domain and two 
spacer peptides (SP1 and SP2) (Freed, 2015). The env gene encodes two subunits: a 
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transmembrane domain (TM) gp41 and the surface domain (SU) gp120 (Figure 1.1B). In 
addition to these proteins found in all retroviruses, HIV encodes six additional 
accessory/regulatory genes: vif, vpr, vpu, nef, rev and tat. The proteins Vif, Vpr, Vpu, and 
Nef function as accessory genes that are not essential to replication per se, but counteract 
the innate and adaptive immune system of the host. The Rev protein binds to the Rev 
response element (RRE), which is a cis-acting sequence located in the env gene, and 
mediates the efficient nuclear export of the unspliced and partially spliced viral messenger 
RNA (vmRNA). The Tat protein binds to the trans-activating response (TAR) sequence in 
the viral RNA during transcription to promote transcription elongation. The mature virion 
has a diameter of approximately 100 nm and contains two copies of the positive stranded 
RNA genome (Figure 1.1B). The conical shaped capsid encases the copies of the 
nucleocapsid-coated genome as well as molecules of IN, PR, and RT. Surrounding the 
capsid is a layer of matrix surrounding the inner lipid membrane taken from the lipid 
bilayer of the host cell’s membrane (Sundquist and Kräusslich, 2012). 
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Figure 1.1: Organization and structure of the HIV-1 genome 
 (A) Organizational schematic of the open reading frames in HIV-1. Polyproteins Gag, Pol 
and Env are further subdivided into their respective individual proteins. Approximate 
length in base pairs represented on the X-axis. (B) Structure of a mature HIV-1 particle 
with labeled proteins. (Adapted from Petersen et al. 2006).  
Replication Cycle 
The first step in the replication cycle of any virus is the attachment of the virion to the host 







will infect. For HIV-1, the Envelope protein gp120 is restricted to only functionally binding 
the human protein CD4, which is a transmembrane protein expressed on the cell surface 
of a subset of T cells (CD4+ T cells) (Kowalski et al., 1987). As a member of the 
immunoglobulin family, the physiological role of CD4 is the enhance the T cell receptor 
(TCR)-medicated signaling. Beyond binding to CD4, for HIV-1 to infect a cell it must also 
engage with one of two different chemokine receptors, CCR5 or CXCR4, present on the 
surface of different CD4+ T cells (Berger et al., 1999; Wilen et al., 2012) (Figure 1.2). A 
recent structure of the CD4-gp120-CCR5 complex suggests that the coreceptor functions 
by stabilizing the conformation change in Env induced by binding to CD4 (Shaik et al., 
2019). Ultimately, this co-receptor interaction allows gp120 to insert its hydrophobic fusion 
peptide into the target cell membrane, which effectively crosslinks the viral and host 
membranes (Wilen et al., 2012). This insertion initiates the folding of the gp41 subunits 
and brings together the amino terminal helical region and the carboxyl terminal helical 
region of gp41, resulting in the formation of the six-helical bundle (Chan et al., 1997) 
(Figure 1.3). 
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Figure 1.2: Overview of HIV-1 replication cycle 
Schematic representation of the HIV-1 replication cycle from entry to production and 
maturation. (1) Receptor interaction and attachment, (2) membrane fusion and entry, (3) 
uncoating, (4) reverse transcription, (5) nuclear import, (6) integration, (7) mRNA and 
gRNA expression, (8) nuclear export of mRNA, (9) protein synthesis, (10) virion assembly, 
(11) budding, and finally (12) maturation (Adapted from Engelman and Cherepanov 2012). 
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Figure 1.3: Mechanism of HIV-1 attachment and fusion to a CD4+ t cell 
Schematic representation of HIV-1 entry. (1) HIV-1 Env is made up of gp120 containing 
variable loops for attachment and gp41, which is the transmembrane domain, (2) gp120 
protein binds to the cellular transmembrane protein CD4, which initiates a conformation 
change in Env, (3) this change allows the co-receptor to bind and the insertion of the gp41 
fusion peptide into the host cell membrane, (4) formation of the six helical bundle finally 
results in membrane fusion (adapted from Wilen et al. 2012).  




Traditionally, after fusion the next stages of HIV-1 replication are in the discrete order of 
uncoating, reverse transcription, and nuclear import (Campbell and Hope, 2015). There 
is some evidence to suggest that the core remains intact until it docks at the nuclear pore, 
while other studies have found uncoating occurs during transport of the genome to the 
nucleus and is stimulated by reverse transcription (Arhel et al., 2007). Additionally, there 
is clear evidence that indicates CA is a key determinant in the ability for HIV to infect non-
dividing cells, indicating nuclear import requires more than the reverse transcribed 
genome (Yamashita et al., 2007). The confluence of data surrounding this process of 
uncoating, reverse transcription, and nuclear import belie the emergence of a clear model 
concerning the timeline of events. Though, the conflicting data surrounding this topic 
demonstrates that  HIV is a dynamic and adaptable virus and is therefore difficult to 
broadly characterize in a way that is applicable to all scenarios. Additionally, the 
limitations of techniques available (e.g. live cell imagining or experimentation on bulk cell 
populations) to study this process potentially stands in the way of a more clear and robust 
model. 
It is well established that after fusion of the envelope to the target cell, the viral core is 
released into the cytoplasm with a single stranded RNA (ssRNA) genome that must serve 
as the template for the synthesis of the double stranded DNA (dsDNA) genome by the 
viral enzyme RT (Baltimore, 1970; Telesnitsky and Goff, 1997)(Figure 1.4). The process 
of reverse transcription has been well characterized and broadly follows these steps: (i.) 
Initially, a short section of the minus-strand DNA must be synthesized from the 3’-OH of 
the tRNA bound to the primer binding site (PBS). (ii.) The RNaseH domain of the viral RT 
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then digests the RNA portion of the newly synthesized RNA-DNA hybrid, thus freeing the 
short single stranded DNA fragment, also known as the minus strand strong-stop DNA (-
sssDNA). (iii.) This –sssDNA is transferred to the 3’ end of the genome by hybridizing to 
the repeated region (R region). (iv.) Upon hybridization to the R region, minus strand 
synthesis occurs using the –sssDNA as a primer. This is followed by the digestion of the 
RNA from the RNA–DNA hybrid by RNaseH, intentionally excluding digestion of the 
polypyrimidine tract (PPT). (v.) The remaining RNA bound to the minus-strand DNA at 
the PPT then serves as a RNA primer for the plus-strand DNA synthesis to occur until the 
tRNA primer. (vi.) Following plus-strand synthesis of the tRNA primer, the tRNA is 
removed by RNaseH, exposing the PBS at the 3’ end of the plus-strand DNA to hybridize 
at the 3’ end of the minus-strand DNA, which is known as the second-strand transfer. (vii.) 
Finally, plus-strand and minus-strand DNA synthesis results in the completion of the 
double stranded DNA provirus that is capable of integrating into the host cell genome 
(Telesnitsky and Goff, 1997).  The synthesis activity of RT is highly error prone making 
approximately 2 x 10-5 substitutions per base and allows for the virus to test a large 
number of different sequences over a small number of replication cycles, contributing the 
ability of HIV to quickly adapt and find escape mutants under different cellular pressures 
(Hu and Hughes, 2012). 
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Figure 1.4: Stepwise process of reverse transcription 
 Schematic representation of the reverse transcription of a retroviral genome. Steps 
outlining the RT-dependent synthesis of the dsDNA are described in the main text. Black 
line: RNA; Orange line: minus-strand DNA; Red line plus-strand DNA.  
Retroviruses: coffin, hugues, Varmus
Overview of reverse transcription
Figure 1.4
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Upon completion of reverse transcription, the double-stranded viral DNA must associate 
with IN and other viral and cellular proteins to form the pre-integration complex (PIC) 
(Craigie and Bushman, 2014). The lentivirus genera are capable of replicating in non-
dividing cells by translocated through nuclear pores, a process that is dependent on CA 
(Yamashita and Emerman, 2004). While it is not completely understood how the PIC 
transverses the nuclear pore, there is a clear consensus on some of the cellular proteins 
that are required. Multiple genome-wide short interfering RNA (siRNA) screens have 
confirmed the importance of transportin 3 (TNPO3) and nucleoporins (Nup) 358 and 153 
in nuclear entry (Brass et al., 2008; Konig et al., 2008). Consistent with the opacity and 
complexity surrounding the process of uncoating/nuclear import, a recent study 
demonstrated how nuclear pore heterogeneity of different cell lines, an innate immune 
restriction factor that can block nuclear import (MX2), and CA mutations to circumvent 
these two factors are all obstacles to HIV gaining entry to the genome of a cell (Kane et 
al., 2018). This tour de force study clearly demonstrates that a myriad of factors can 
profoundly affect how the PIC can adapt and respond to different conditions in order the 
complete infection. 
Once inside the nucleus the viral enzyme IN is responsible for integrating the dsDNA viral 
genome into the host DNA genome. Initially, IN removes  two nucleotides from the 3’ end 
of the viral dsDNA, generating a reactive 3’-hydroxyl group at both ends. These newly 
formed 3’-hydroxyl ends will ligate to the host DNA through binding to a pair of 
phosphodiester bonds five nucleotides apart and on opposing stands of the host DNA, 
creating the integration intermediate. The final step of integration requires trimming the 
12 
two remaining nucleotides of the 5’ viral DNA and the extension from the 3’ end of the 
genomic DNA (Craigie and Bushman, 2014). High-throughput sequencing has provided 
insights regarding the integration site preference, suggesting that HIV-1 prefers to 
integrate into active transcription units (Mitchell et al., 2004; Schroder et al., 2002). The 
viral genome targets these sites of active transcription through interacting with the host 
transcription factor LEDGF, which was initially discovered through an affinity-based 
screen for proteins that interact directly with IN (Cherepanov et al., 2003). LEDGF is 
capable of recruiting the PIC to integration sites even at very low levels, and only a 
complete knockout of LEDGF will result in decreased levels of infectivity (Llano et al., 
2006). Because LEDGF is a transcription factor and is only in the nucleus when it is at 
site of active transcription, the strong affinity of IN to LEDGF ensures that the PIC will be 
recruited to sites of active transcription. 
After the viral genome has integrated into the host cell genome, it must initiate 
transcription. Transcription initiation of the viral mRNA is remarkably efficient and initiated 
by the U3 regions in 5’ LTR, which consists of DNA regulatory elements that recruit 
cellular transcription factors (Rittner et al., 1995) (Figure 1.5) . The LTR core promoter is 
finely tuned to effectively recruit the cellular transcription factors and is made up of three 
tandem Sp1 binding sites (Jones et al., 1986), a TATA box (Garcia et al., 1989), and a 
highly active initiator (INR) sequence (Zenzie-Gregory et al., 1993). The non-core 
promoter consists of the transactivation-response region (TAR) and the enhancer region 
with two NF-KB binding motifs (Nabel and Baltimore, 1987). RNA polymerase II (RNAP 
II) is recruited to the 5’ LTR through an interaction with transcription factors IID (TFIID),
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IIH (TFIIH), and the TBP-associated factor (TAF). Along with TFIIH, the cyclin-dependent 
kinase (CDK7) is recruited to this complex in order to partially phosphorylate the RNAPII. 
Progression of this complex will stall at TAR due to the presence of the negative 
elongation factor (NELF) (Yamaguchi et al., 1999). The transcription elongation of this 
complex is inefficient when it is only comprised of cellular factors, and for this reason HIV 
encodes the transcriptional transactivator protein Tat that binds TAR and stimulates 
RNAP II processivity, thus increasing the elongation of the transcripts to the end of the 
virus (Sodroski et al., 1986). Concurrent with transcription of the full viral genome, HIV 
uses alternative splicing to create three distinct species of mRNA: (i.) fully spliced 
transcripts that are efficiently exported from the nucleus by cellular factors, (ii.) partially 
spliced and (iii.) unspliced transcripts that are not exported from the nucleus by cellular 
factors. For the partially and unspliced transcripts to be exported from the nucleus the 
fully spliced rev transcripts must be exported and translated. The Rev protein is then 
imported into the nucleus to bind the rev response element (RRE) present in the partially 
and unspliced mRNA for proper nuclear export (Karn and Stoltzfus, 2012; Legrain and 
Rosbash, 1989). 
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Figure 1.5: Mechanism of HIV-1 transactivation by Tat 
Initiation: RNAP II is recruited to the 5’ :LTR by TFIID, TFIIH and the cofactor TAF. TFIIH 
phosphorylates the CTD of RNAP II to initiate elongation. Pausing: Once transcription 
encounters the TAR element NELF and DSIF are recruited to the complex and the whole 
complex pauses. Elongation: Tat/P-TEFb bind to TAR and CDK9 initiates the 
phosphorylation of NELF resulting in its release as well as phosphorylation of Spt5 and 




Karn nd Stoltzsfus 2012
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Figure 1.6: HIV-1 mRNA splicing 
(A) Early phase of RNA expression: Only the fully spliced 1.8kb mRNA (tat, rev and nef) 
are capable of being exported from the nucleus into the cytoplasm efficiently for 
translation. Unspliced and partially spliced transcripts are retained in the nucleus where 
they will undergo degradation. (B) Late phase of mRNA expression: The Rev protein is 
expressed and translocates into the nucleus, where it binds to the RRE of the fully and 
partially spliced mRNA, facilitating their export into the cytoplasm (adapted from Karn and 





HIV-1 protein synthesis relies entirely on the host cell translation machinery. This is made 
possible through that addition of a 5’ 7-methyl-guanosine cap and a 3’ poly(A) tail. As with 
eukaryotic protein synthesis, the synthesis of HIV proteins can be divided into four 
discrete phases: (i.) recruitment of the small 43S ribosomal complex to the mRNA to scan 
until it locates an initiating AUG start codon; (ii.) the 60S ribosomal subunit joins this 
complex and forms the 80S ribosomal complex which begins elongation where the mRNA 
is decoded and the nascent polypeptide chain begins to form; (iii.) when the ribosome 
comes to a termination codon it releases the polypeptide chain; (iv.) and finally the 
ribosome is recycled for the translation of another mRNA (de Breyne et al., 2013). With 
the exception of Env and Vpu, all of the other viral proteins are synthesized on free 
ribosomes in the cytoplasm. The Env and Vpu are synthesized in the rough endoplasmic 
reticulum (RER) for proper insertion into the plasma membrane, decoration with sugar 
groups, and targeting the cells plasma membrane (Checkley et al., 2011). Expression of 
the Gag-Pol polyprotein requires translational suppression of the Gag stop codon, and 
this is accomplished by the presence of the Gag-Pol frame shift RNA sequence that sits 
between the gag and pol open reading frames. The frameshift sequence is a series of six 
uracil nucleotides followed by an adenosine codon upstream of the gag stop codon. This 
“slippery” sequence results in a ribosome shift that skips the gag termination codon and 
proceeds through to translation of the pol gene 5% of the time  (Karn and Stoltzfus, 2012). 
Upon completion of translation the virus must bring all of the components together to 
assemble a nascent virion. The assembly of the virion occurs at the plasma membrane 
of the host cell and is primarily driven by the Gag polyprotein, which is capable of forming 
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particles in the absence of pol or env (Campbell and Vogt, 1997). Gag is critical to the 
formation of what will become an infectious virion, coordinating the recruitment of Pol, 
which is accomplished through the targeting of the Gag-Pol polyprotein, as well as 
recruiting both copies of the viral genomic RNA (vgRNA) through the NC domain (Kutluay 
and Bieniasz, 2010; Kutluay et al., 2014). Gag itself is targeted to the plasma membrane 
through the MA domain, specifically by the myristate group and basic amino acid motif 
that facilitate a direct interaction with specific phospholipids at the plasma membrane 
(Saad et al., 2006). As stated previously, Envelope is trafficked to the plasma membrane 
through the secretory pathway, but the exact process by which the Env protein is 
incorporated into the nascent particle is still not fully understood. It has been 
demonstrated that MA interacts with gp41, but this interaction is not strictly necessary for 
Env incorporation (Sundquist and Kräusslich, 2012). It remains possible that incorporation 
of the HIV envelope to the viral particle is not highly specific and is supported by the ability 
easily psuedotype HIV virions with other envelopes. However, the consistent 
incorporation of 7 to 14 Env trimers into each viral particle might suggest some level of 
control surrounding the process of Envelope recruitment (Chertova et al., 2002; Zhu et 
al., 2006). 
Once all of the necessary components are present at the plasma membrane, the virus 
particle needs to detach from the host cell. For budding the occur, the cellular ESCRT 
machinery must be recruited to the site of viral egress to stop Gag multimerization as well 
as catalyze the excision of the cell and viral membranes (Bieniasz, 2009). HIV-1 contains 
two late domains in the p6 domain of Gag, and these late domains are responsible for the 
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recruitment of early acting ESCRT factors (Carlton and Martin-Serrano, 2009). 
Specifically, the primary late domain contains a PTAP motif that binds the TSG101 
subunit of the ESCRT-I complex for recruitment to the budding virion (Garrus et al., 2001). 
The presence of PTAP motifs in other cellular proteins suggests that the HIV-1 late 
domains are a mimicry of the cellular mechanism to recruit the ESCRT pathway (Ren and 
Hurley, 2011). After the virion is released from the cell via the ESCRT pathway, the final 
stage is virion maturation. During a late stage of virion assemble the viral PR is cleaved 
by autoproteolysis and freed to cleave the Gag-Pol polyproteins upon virion release. Pol 
is cleaved by PR into the viral enzymes RT and IN, while Gag is cleaved into the structural 
proteins MA, CA, NC, p6, p1 and p2. The cleavage of these proteins produces a dramatic 
conformational rearrangement. Specifically, CA monomers assemble into hexamers to 
form the structural core, while the spontaneous formation of capsid pentamers results in 
the irregularities in capsid organization and produces the cone structure emblematic of 
the HIV particle (Ganser et al., 1999; Pornillos et al., 2009). The fully matured virion is 
now poised to infect a target cell that it comes in contact with, thus starting the process 
over again. 
RNA elements in HIV-1 
As briefly discussed above, HIV-1 genome contains a variety of RNA elements that have 
important cis-acting function. Some of these RNA sequences are multi-functional in that 
they lie in open reading frames and therefore encode proteins as well as performing 
functions as RNA that are critical during viral replication. Additionally, there are several 
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genes in the HIV genome that overlap with adjacent genes and it has been suggested 
that this multifunctional coding actually helps constrain the evolution of the virus and 
provides a fitness advantage (Fernandes et al., 2016).  Known cis-acting RNA elements 
in the HIV-1 genome that lie within protein-coding sequences include splice donors, 
acceptors, and branch points (Purcell and Martin, 1993), splicing regulatory elements that 
enhance or inhibit the use of proximal splice site (Madsen and Stoltzfus, 2006), the Rev-
responsive element (Heaphy et al., 1990; Malim et al., 1990), the central polypurine tract 
and termination sequence (Charneau and Clavel, 1991), the Gag-Pro-Pol ribosomal 
frameshift regulatory element (Parkin et al., 1992) and components of the viral genome 
packaging signal (Kutluay et al., 2014; Kuzembayeva et al., 2014). 
Because the replication of HIV is constrained to a human cell and much of the replication 
machinery in the cell, it must efficiently recruit the set of required cellular factors while 
avoiding cellular proteins that are deleterious to its replication. This is often studied in the 
context of protein-protein interactions, more specifically with cellular proteins that have 
evolved a specific role in actively antagonizing a stage in the HIV-1 life cycle, referred to 
as restriction factors. This is no less true when considering the fate of the HIV-1 mRNA. 
Of the proteins encoded in the human genome, approximately 8% of them are RNA 
binding proteins that accomplish a variety of tasks in the post-transcriptional regulation of 
RNA in the cell (Gerstberger et al., 2014). All of the HIV-1 mRNA molecules must properly 
recruit the necessary cellular factors for post-transcriptional regulation while avoiding any 
cellular factors that might actively seek to recognize the non-self RNA or process it 
through an aberrant pathway. To accomplish this, the HIV-1 genome has either (i.) 
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mimicked RNA sequences in cellular pathways to recruit the required cellular factors, or 
(ii.) uses its own viral RNA binding proteins that have a strong affinity for both an RNA 
sequence in its genome and also the cellular protein factors that it needs to recruit. Little 
is known about whether HIV-1 mRNA avoids cellular detection, but this is also possible if 
not likely. Additionally, a recent study described how the mRNA of HIV-1 might be 
recognized and induce the production of IFN through a yet undiscovered pathway 
(Akiyama et al., 2018; McCauley et al., 2018). Here we will review some of the cis-acting 
RNA elements in the HIV-1 genome that recruit either trans-acting cellular and/or viral 
factors to ensure the proper replication of the virus. 
TAR-Tat 
As discussed previously, HIV uses its LTR as the promoter, which is a common feature 
among all retroviruses. Initially, the viral LTR was cloned into a simple plasmid as the 
promoter for chloramphenicol actyl-transferase (CAT) gene, but high CAT expression was 
only detected in cells that were infected with HIV-1, suggesting that there must be some 
viral factor supplied in trans that activates the LTR (Sodroski et al., 1985b). This factor 
was quickly discovered through iterative cloning regions of the HIV-1 genome into this 
plasmid by the same group and named Tat for its homologous function to other retroviral 
proteins (Sodroski et al., 1985a). Through deletion studies of the viral LTR, Tat was found 
to bind to the transactivation-response region (TAR), and this sequence is the first fifty-
nine nucleotides after the initiation site for transcription. TAR does not work like most 
transcriptional elements, but is only functional with placed in a precise location and 
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orientation in the LTR (Muesing et al., 1987). Genetic studies revealed that TAR is as a 
RNA stem-loop with a highly stable structure (Berkhout et al., 1989; Selby et al., 1989). 
Biochemical assays revealed a direct and specific interaction between Tat and TAR, and 
later work mapped this interaction to the uridine-rich (U-rich) bulge present within the stem 
of TAR (Dingwall et al., 1990; Dingwall et al., 1989). Binding of Tat to TAR results in a 
conformational change in the RNA structure that stabilize the RNA-DNA hybrid (Puglisi 
et al., 1992). This interaction between Tat the U-rich bulge of TAR blurs the lines between 
protein recognition of an RNA molecule by sequence or structure, cumulatively 
suggesting that the sequence, structure and function of this interaction are inextricably 
linked (Figure 1.5). 
The apical loop of TAR is inconsequential in its affinity for Tat, yet mutational analysis of 
this loop revealed that it is critical to the function of TAR. (Feng and Holland, 1988). This 
finding suggested that some additional factor binds the apical loop of TAR and is critical 
to its function. This hypothesis was confirmed by a multitude of studies identifying many 
more factors that are recruited to this complex and are essential to function. 
Concomitantly, further investigation revealed that Tat regulates transcriptional elongation 
rather than initiation. These studies demonstrated that in the absence of Tat a majority of 
RNA polymerases that initiate transcription are recruited and stalled near the promoter, 
while when Tat is present the polymerases are more frequently found downstream the 
promoter (Kao et al., 1987). This idea that Tat is involved in transcriptional elongation was 
further confirmed when the well characterized positively acting elongation factor, CDK9, 
was found to strongly interact with Tat. While critical to function, the CDK9 complex was 
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not a fit for the factor that bound the apical stem-loop of TAR. Finally, the cyclin 
component CycT1 was discovered to bind the CDK9 complex, which then recruits Tat. 
Only when Tat is bound to this CycT1-CDK9 complex can it then efficiently bind the TAR 
stem-loop (Wei et al., 1998). 
A variety of mechanisms are observed to be employed by HIV to ensure processive 
transcription. Transcription initiation is recruited intrinsically through the HIV LTR, but this 
is not sufficient for full gene expression. Importantly, this weak transcription is viable 
enough for low levels of Tat production by purely cellular mechanisms, which is then 
necessary for transcriptional elongation of the full HIV genome through further recruitment 
of additional cellular machinery. 
Splicing 
HIV-1 requires alternative splicing to generate all the mRNAs needed for proper 
replication.  The execution of proper mRNA splicing is highly complicated and requires 
dozens of cellular proteins in a proper order and location on the mRNA. To accomplish 
this, HIV-1 has mimicked many cis-acting RNA elements that control splicing in human 
cells in order to process its genome though alternative splicing pathways in the nucleus. 
Alternative splicing is executed by a macromolecular complex commonly referred to as 
the spliceosome (Chen and Manley, 2009) (Figure 1.6). Spliceosome assembly is initiated 
by (i.) the recognition of the 5’ splice donor by the small nuclear ribonucleoprotein particle 
U1 (snRNP U1) and by the binding of the splicing factor 1 (SF1) to the branch point 
sequence in the RNA, forming the E’ complex (Berglund et al., 1997). (ii.) The U2 auxiliary 
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factor (U2AF) binds to the polypyrimidine tract to create the E complex ((Nelson and 
Green, 1989; Zamore and Green, 1989). (iii.) SF1 dissociates from the branch point and 
is replaced by the U2AF to form the A complex. (iv.) Additional recruitment of the U4/U6-
U5 tri-snRNP complex forms the B complex, which is still inactive. (v.) Finally, drastic 
conformational rearrangements of these components form the catalytically active 
spliceosome, the C complex. In the human genome, exons have an average length of 50-
250 nucleotides. This is much shorter than the introns separating them, which are often 
thousands of nucleotides in length. For this reason, spliceosome assembly usually occurs 
around exons (Sterner et al., 1996). This process is referred to as “exon definition” and 
involves some interaction occurring between the SF1/U2AF complex at the 5’ splice site 
and the U1 protein at the 3’ splice site of the same exon (Berger et al., 1999). Eventually, 
exon definitely must be complemented by “intron definition”, and this is thought to occur 
through interactions between the U1 and U2 snRNPs (Kotlajich et al., 2009; Lim and 
Hertel, 2004). The ability of the splice site to recruit the U1 or U2 snRNPs has the largest 
impact on the recognition on that particular slice site. 
The ability of a splice site to recruit U1 and U2 snRNP proteins is widely thought to depend 
on two factors: the intrinsic affinity of the snRNP proteins for a particular splice site and 
the cis-acting elements proximal to the splice site (Graveley, 2000). These cis-acting 
elements can either enhance or suppress the recruitment of snRNP proteins and are 
found in either introns or exons and are divided into four categories: exonic splicing 
enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs), 
and intronic splicing silencers (ISSs) (Long and Caceres, 2009; Tacke and Manley, 1999). 
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The silencing elements are thought to be frequently bound by heterogenous nuclear 
RNPs (hnRNPs), while the enhancing elements are bound by Serine-Arginine (SR) 
proteins (Dreyfuss et al., 2002; Smith and Valcárcel, 2000). A small number of SR 
proteins have a known RNA sequence that they bind to, primarily thought a RNA 
recognition motif (RRM), yet the majority of SR proteins do not have a specific RNA 
sequence that they have an affinity for (Chen and Manley, 2009). Similarly, there are 
some members of the hnRNP family of proteins that have a specific sequence known that 
they recognize through their RRM domains.  Most known hnRNPs though are thought to 
recognize sequences that are rich in a particular nucleotide, while some examples such 
as hnRNP L or LL are thought to recognize RNA that is rich in cytosine and adenosine 
(Chen and Manley, 2009). In light of the limited data supporting the definition of cis-acting 
RNA sequences that recruit hnRNP and SR proteins, it remains unclear exactly how these 
proteins are recruited to splice acceptors and donors, and the precise mechanism of their 
regulation of splice sites remains incompletely understood. Yet, these and likely many 
other factors work in coordination to properly regulate the inclusion of correct exons and 
frequencies that are required for the particular cell type dependent splicing. 
In the case of HIV-1, the virus employs four salient splice donors (D1, D2, D3, D4) and 
eight acceptors (A1, A2, A3, A4a,b,c, A5 and A7, S1 Table) to generate a large number 
of mRNAs that enable expression of nine viral open reading frames in a temporally 
biphasic manner (Holmes et al., 2015; Purcell and Martin, 1993). Additional, ‘cryptic’ 
splice sites may be used at very low frequency, and are not required for expression of the 
viral ORFs . HIV-1 splicing is, by necessity, inefficient as a substantial fraction of the viral 
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transcripts must remain unspliced so as to provide viral genomes and Gag-Pol mRNA 
(Martin Stoltzfus, 2009). 
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Figure 1.7: Representation of alternatively spliced mRNA in HIV-1 
(A) Schematic representation of the HIV-1 genome and open reading frames. (B) 
Locations of the 5’ and 3’ splice sites in the HIV-1 genome (Genomic/unspliced mRNA). 
Exons present in the partially spliced (4-kb mRNA) and fully spliced (1.8-kb mRNA) and 
the corresponding genes they encode. Non-coding exons are show in black rectangles. 
(C) Locations of some of the known splicing regulatory elements shown in their relation 




 All HIV-1 splicing involves D1, while splice acceptor sites 5’ to each initiation codon are 
used to generate mRNAs encoding the HIV-1 proteins Vif (A1), Vpr (A2), Tat (A3) Rev 
(A4a,b,c), Vpu/Env (A4a,b,c and A5) and Nef (A5 and A7) (Figure 1.7) (Madsen and 
Stoltzfus, 2006; Purcell and Martin, 1993). In addition, some HIV-1 mRNAs include short 
noncoding exons (SX1 (A1-D2)) and (SX2 (A2-D3)) positioned 5’ to the expressed open 
reading frame. The relative frequencies that the various splice sites are used, which can 
be measured using next-generation sequencing approaches (Ocwieja et al., 2012), likely 
contributes to ensuring that the optimal levels of viral proteins are synthesized for viral 
replication. 
RNA sequence and structure must play a key role in alternative splicing. RNA secondary 
structure surrounding the major 5’ splice donor affects splicing and SHAPE analysis 
revealed a novel stem loop that influences splicing (Emery et al., 2017; Pollom et al., 
2013). With a nearly 10kb genome, it is almost certain that the RNA secondary and tertiary 
structures of the HIV-1 genome are dynamic and complex, making them difficult to study. 
Secondary structures could function either as sites for RNA binding proteins such as 
hnRNP or SR proteins, or as mechanisms for occluding nucleotide sequences that are 
sites of binding for splicing regulator proteins. Taken together, whether in the human 
genome or HIV-1 genome, characterizing the direct contributions of sequence homology, 




As discussed previously, of the three classes of HIV-1 mRNA, only one is capable of 
export from the nucleus by only cellular factors. The unspliced and incompletely spliced 
transcripts, if retained in the nucleus, will be recognized as aberrant cellular mRNA 
molecules and degraded. To overcome this, HIV-1 encodes the viral protein Rev to bind 
the RRE present in the unspliced and partially spliced transcripts and efficiently export 
them through the nuclear pore. The initial discovery of Rev described it as an additional 
transactivating protein that acted post transcriptionally and relieves a negative regulatory 
pressure on the capsid and envelope protein expression (Sodroski et al., 1986). It was 
later discovered that Rev acts on these transcripts through binding the highly-structured 
351 nucleotide stem-loop in the envelope gene, RRE (Malim et al., 1989). Subsequent 
biochemical studies found that when Rev binds to the high affinity site in RRE at the Rev-
binding stem-loop (SLIIB), the binding event induces a conformational change that 
stabilizes the complex, reminiscent of the interaction between Tat and TAR (Daly et al., 
1989; Heaphy et al., 1990). This binding of Rev to the RRE results in the recruitment of 
additional Rev monomers, with the degree of Rev oligomerization correlating to efficient 
nuclear export (Malim et al., 1990). NMR studies reveal that Rev inserts its alpha-helix of 
the arginine rich domain (ARD) binds along the major grove of the SLIIB. This is mediated 
by several nucleotide specific contacts and the arginine’s of the ARD (Battiste et al., 1996; 
Tan et al., 1993).  
Once Rev is bound and oligomerized to the RRE, it transports the RNA through the 
nuclear pore complex (NPC) (Kohler and Hurt, 2007).  Rev interacts with the cellular 
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protein Crm1, a member of the karyopherin family, through its nuclear export signal at the 
carboxyl terminus of Rev (Fornerod et al., 1997). Crm1 will only bind the Rev/RRE 
complex in the presence of the GTP-bound form of Ran GTPase, after which they go 
through the NPC the GTP is hydrolyzed to GDP and the destabilizing the complex and 
disassociating it (Fischer et al., 1995). Rev returns to the nucleus alone through an 
interaction between a nuclear import signal overlapping with its RNA binding domain, 
recruiting the nuclear import factor, importin-B (Henderson and Percipalle, 1997). 
Other RNA Considerations 
That additional RNA sequences function in cis may exist in the HIV-1 genome is 
suggested by studies employing chemical probing approaches. For example, SHAPE 
experiments indicate that individual nucleotides in HIV-1 RNA have widely divergent 
tendencies to be base-paired (Wang et al., 2008; Watts et al., 2009; Wilkinson et al., 
2008). These findings, along with phylogeny-based approaches, strongly suggest that 
secondary structures form in HIV-1 RNA that are conserved between strains, and might 
therefore serve a function in HIV-1 replication. One example of a recently suggested 
function for HIV-1 RNA secondary structure is the regulation of translational rate, whereby 
translation is periodically slowed to enable folding of one protein domain of the 
multidomain HIV-1 Gag protein before synthesis of the next (Watts et al., 2009). 
Despite the suggestion that novel RNA secondary structures may be important for HIV-1 
replication, targeted mutagenesis of putatively important individual stem loops has not 
generally yielded evidence that is strongly supportive of a role for these potential 
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structures in HIV-1 replication (Knoepfel and Berkhout, 2013). Conversely, some studies 
in which portions of the HIV-1 genome were synonymously mutated have suggested a 
role for RNA (as opposed to protein) sequence or structure in HIV-1 replication (Keating 
et al., 2009; Martrus et al., 2013; Schwartz et al., 1992). However, the precise nature of 
defects induced by synonymous mutations are unclear, and possibly pleiotropic. 
It is not known whether the aforementioned represent a complete catalogue of cis-acting 
RNA elements, or whether additional RNA-based functionality exists in the HIV-1 genome. 
Of the known elements listed above, they mostly function through the direct recruitment 
of a specific RNA binding protein by either their RNA sequence or structure. In addition 
to the RNA sequence recruiting cellular or viral proteins, there are also elements that exist 
to avoid detection by cellular RNA binding proteins. One such example is in the RNA 
stabilizing element (RSE) in Rous Sarcoma Virus (RSV) that recruits PTBP1 to avoid 
detection from Upf1 and the nonsense mediated decay pathway (Ge et al., 2016). It is 
likely that more of these types of viral RNA elements exist to avoid cellular detection, but 
have been thus far difficult to discover. 
Innate Antiviral Immunity 
Vertebrate genomes have a variety of mechanisms to detect and respond to viral and 
bacterial infections, broadly classified as either the innate or adaptive immune systems. 
Within the innate immune system, antiviral proteins act as the first molecular lines of 
defense against viral infections. Broadly, there are five common features among antiviral 
proteins (Blanco-Melo et al., 2012; Malim and Bieniasz, 2012): (i.) they are dominantly 
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acting proteins that exhibit their antiviral activity in cell-culture assays, (ii.) they are often 
constitutively expressed and/or are further induced by interferon (IFN) stimulation, (iii.) 
they use unique mechanisms to inhibit specific steps in the viral life cycle, (iv.) they 
possess an unusually diverse amino acid sequence as a consequence of antagonistic co-
evolution of viruses and (v.) they can be antagonized by viral proteins. The first restriction 
factor was identified in the early 1970’s and was shown to specifically protect cells against 
MLV infection (Lilly, 1970). Currently, more than 20 proteins have been identified as 
restriction factors against a large variety of viruses across animal species, with more 
being added each year (Kluge et al., 2015). The reminder of this chapter will focus on a 
selected range of antiviral proteins that execute their function through a variety of 
mechanisms. 
Tetherin 
It had been long known that HIV-1 required the accessory protein Vpu for efficient particle 
release from CD4+ T cells (Bour and Strebel, 2003). Curiously, electron microscopy 
reveals that a Vpu-deficient HIV-1 remained attached to the cell surface as mature viral 
particles, suggesting some defect in viral release (Klimkait et al., 1990). Further 
characterization through different cell type, species specific, and heterokaryon 
experiments suggested that Vpu-deficient HIV-1 was due to the expression of a yet 
undiscovered dominant acting restriction factor (Neil et al., 2006; Varthakavi et al., 2003). 
Experiments demonstrated cells permissive to Vpu-decificent HIV-1 were made 
restrictive upon the addition of interferon and that virions trapped on the cell surface could 
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be released through treatment with protease, together indicating the presence of an IFN 
induced protein tether that prevented virus release (Neil et al., 2007). Finally, comparative 
gene expression of permissive and non-permissive cell type identified the protein BST-2 
as the restriction factor antagonized by Vpu that can tether budding virions to the cellular 
membrane, appropriately named “tetherin” (Neil et al., 2008). 
Tetherin is a transmembrane glycoprotein with a highly unusual domain architecture. It is 
comprised of a short N-terminal cytoplasmic tail, a single pass transmembrane helix (TM), 
a helical coiled-coil ectodomain (CC) that drives homodimeriation and a C-terminal 
glycophosphatidylinositol membrane anchor (GPI). Remarkably, elegant experiments 
replacing each of the domains of tetherin demonstrated that it is the domain architecture 
rather than primary amino acid sequence that are responsible for the ability of tetherin to 
directly tether virions to cells (Perez-Caballero et al., 2009). It remains unclear exactly 
how tetherin might target budding virions beyond homogenous expression along cellular 
membrane, though some evidence might suggest that it is recruited to sites of Gag-
induced membrane curvature during budding (Grover et al., 2013). As mentioned, tetherin 
is antagonized by the HIV-1 accessory gene Vpu, a small N-terminally anchored 
transmembrane protein. Vpu antagonizes tetherin through a direct interaction in their 
respective transmembrane domains that a species specific (Kobayashi et al., 2011; 
McNatt et al., 2009). This interaction between tetherin and Vpu results in in ESCRT-
dependent degradation of tetherin in lysosomal compartments (Sauter, 2014). 
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TRIM5α 
Early studies demonstrated that the infection of non-human primate cells by HIV-1 was 
inefficient in an envelope-independent matter (Hofmann et al., 1999). A following study 
screened for rhesus macaque genes that restricted HIV-1 infection when exogenously 
expressed in human cells and identified TRIM5α (Mahadeo et al., 1994). TRIM5α is a 
member of the tripartite motif (TRIM) family of proteins, characterized by a RING domain 
with E3 ubiquitin ligase activity, B-box domains, a coiled-coil domain for dimerization, with 
some also encoding a PRY/SPRY domain that are involved in protein-protein interaction 
(Rahm and Telenti, 2012; Zheng et al., 2012). TRIM5α recognizes HIV through a direct 
interaction with CA on incoming viral cores, on which TRIM5 assembles into a three-
dimensional lattice mediated through its SPRY domain (Ganser-Pornillos et al., 2011; 
Mahadeo et al., 1994). While the precise mechanism of this are not fully understood, this 
interaction results in a premature destabilization of the viral CA and degradation of its 
components before reverse transcription can complete (Stremlau et al., 2006). 
Unlike tetherin, TRIM5α is not known to be antagonized by a viral protein in HIV-1. Rather, 
HIV-1 evades TRIM5α restriction through sequence variations within CA as well as the 
recruitment of the cellular protein CyclophilinA (CypA) that together allow efficient 
replication in human cells. The initial discovery that HIV-1 GagPR55 interacted with CypA 
was significant because CypA was known to bind tightly to a known immunosuppressive 
drug, CyclosporinA (CsA) (Handschumacher et al., 1984; Luban et al., 1993). CypA was 
later found the be incorporated into HIV-1 virions and is necessary for the production of 
infectious virus (Franke et al., 1994). 
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Very shortly after the discovery of TRIM5 studies demonstrated that disruption of the 
interaction between CypA and CA rescued infectivity in owl monkey, the opposite effect 
it has in human cells (Towers et al., 2003). This contradictory observation was rectified 
by siRNA experiments against CypA in owl-monkey cells, which rescued replication of 
HIV-1 and lead to the identification of a new chimeric protein (Sayah et al., 2004). 
Surprisingly, LINE-1 mediated retrotransposition in owl-monkeys created a CypA-
TRIM5α fusion protein, aptly named TRIMCyp, that potently inhibits HIV-1 infection. This 
remarkable adaption of both vertebrate cells and the virus to coopt cellular proteins to 
either evade or enhance restriction of HIV represent a salient example of how protein-
protein interactions drive the evolution host and viral genomes. 
RIG-I 
Beyond protein-protein interactions that recognize non-self viral proteins, cells have also 
evolved mechanisms of detecting non-self RNA. One of the most studied class of these 
proteins are the RIG-I like receptors (RLRs), which are a family of DExD/H box RNA 
helicases. RLRs are characterized by their recognition of pathogen associated molecular 
patterns (PAMPS) in viral RNA followed by a downstream signaling to transcription factor 
activation that drives the production of type 1 IFN (Loo and Gale, 2011). The RLRs are 
melanoma differentiation association gene 5 (MDA5), and laboratory of genetics and 
physiology 2 (LGP2), and RIG-I, the founding member for which the group is named for 
and therefore the member of which this section will primarily focus (Chow et al., 2018). 
RIG-I was initially described as a double stranded RNA (dsRNA) binding protein that 
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induced IFN production in response to synthetic dsRNA poly(IC) (Yoneyama et al., 2004). 
Subsequently, RIG-I was shown to act as a major factor that controlled permissiveness 
to the replication of hepatitis C virus (Sumpter et al., 2005). RIG-I recognizes RNA 
sequences that contain a 5’-triphosphorylated (5’ppp) end (Hornung et al., 2006). Beyond 
dsRNA with a 5’ppp end, it is thought that RIG-I prefers shorter RNA fragments and can 
also bind single stranded RNA (ssRNA) (Kato et al., 2008). Multiple studies have further 
characterized other factors in RNA that might contribute to the activation of RIG-I, 
indicating that sequence composition is an important determinant, with a preference for 
polyuridine motifs that are interspersed with cytosines (poly-U/UC) (Saito et al., 2008). In 
support of this, the deletion of the poly-U/UC in the hepatitis C virus genome abolished 
activation of RIG-I signaling, despite the inclusion of a 5’ppp in the virus, suggesting that 
the 5’ppp alone is not sufficient for activation in certain viral contexts (Saito et al., 2008). 
In the absence of an activating RNA molecule, RIG-I is held in an autorepressed state 
that is inactive. Upon binding RNA, RIG-I undergoes a conformational change where the 
CARDs and RD domains are dephosphorylated, allowing the RD domain to become 
ubiquitinated at K63. The Ubiquitination is essential for function and catalyzed through 
interactions with the E3 ubiquitin ligase TRIM25 and the RING finger protein Riplet 
(RNF135) (Cadena et al., 2019; Gack et al., 2007; Oshiumi et al., 2009). The K63-linked 
ubiquitination keeps RIG-I in its “open” conformation through oligomerization with other 
RIG-I molecules. This homo-oligomerization allows RIG-I to associate with the molecular 
adaptor MAVS, which subsequently recruit additional E3 ubiquitin ligases and the 
downstream proteins TNF receptor associated factor 2 (TRAF2), TRAF3, and TRAF6, 
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thus creating an active “signalosome” (Cai et al., 2014; Schmitz et al., 2014). The 
signaling cascade that follows induces the phosphorylation and nuclear translocation of 
IRF3, IRF7, and NF-kB, the transcription factors that drive the expression of type I and III 
IFN as well as other inflammatory genes that limit viral replication (Loo et al., 2006; Seth 
et al., 2005). There is no evidence to suggest that RIG-I degrades the bound RNA, but 
the RIG-I complex bound to its activating RNA might undergo proteasomal degradation 
as a negative regulation of the activation of IFN signaling (Arimoto et al., 2007).  
It is reported that a RIG-I is capable of detecting and becoming activated by a host of viral 
genera including but not limited to: paramyxoviradae, rhabdovirade, orthomyxoviridae, 
filoviridae, and coronoaviridae (Chow et al., 2018). Considering such a diverse group of 
viruses are sensitive to RIG-I it is no surprise that there are a variety of different ways that 
viruses have avoided detection. Mechanisms of avoidance range from (i.) viral RNA 
modifications, (ii.) viral RNA sequestration, (iii.) post translational modification of RIG-I, 
(iv.) targeting of RIG-I/MAVS for proteasomal degradation, (v.) and modulation of 
downstream signaling components (Liu et al., 2017). 
Because the key hallmark of RNA detected by RIG-I is the presence of a 5’ppp end, a set 
of viruses has evolved to posttranscriptionally remove the 5’ppp group from their genome. 
This feature of viral RNA modification has been reported in the Crimean-Congo 
hemorrhagic fever virus, Borna disease virus (BDV), and hantavirus (HTNV) (Garcin et 
al., 1995; Marq et al., 2010; Schneider et al., 2005; Wang et al., 2011).  In the case of 
BDV, the 5’ppp is converted in to a monophosphate, which has a significantly lower affinity 
for RIG-I (Schneider et al., 2005), while the poliovirus genomic RNA is processed through 
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the cellular RNA-capping pathways, capping the 5’ppp dsRNA with a 7-methyl guanosine 
and methylated at the 5’-OH to make the viral RNA indistinguishable from the cellular 
RNA (Decroly et al., 2012; Devarkar et al., 2016; Lee et al., 1977). In contrast the 
modifications of the viral RNA that make it less distinguishable from host cellular RNA, 
viruses can also sequester their RNA so that is it not detectable by RIG-I. Ebola virus 
(EBOV) uses the viral protein VP35 to sequester the viral RNA by competing with RIG-I 
for the 5’ppp and forms a protein “end-cap” complex with the dsRNA, preventing 
recognition by RIG-I (Cardenas et al., 2006; Leung et al., 2010). Similarly, Influenza A 
virus (IAV) uses the non-structural protein 1 (NS1) to shield the viral RNA from RIG-I 
(Donelan et al., 2003). Further avoidance of RNA recognition is through RNA the re-
localization of the viral RNA into a sub-cellular compartment, exemplified by DENV, which 
is thought to conceal its RNA in the intracellular membranes during replication ((Uchida 
et al., 2014)). There are multiple reports of how changes in the poly-U/UC motif present 
in the HCV RNA contributes to the activation or avoidance of RIG-I (Schnell et al., 2012; 
Uzri and Gehrke, 2009), yet more extensive study of this motif and how the presence or 
absence of the motif in other viruses contributes to recognition to RIG-I sensing does not 
exist and could be an additional mechanism of avoidance. The remaining mechanisms of 
RIG-I avoidance involve viral protein interactions with RIG-I other proteins downstream 
the cascade pathway. These mechanisms range from modulating the PTM of either RIG-
I or MAVS that alter signaling efficiency (Kathum et al., 2016; Rajsbaum et al., 2012), 
Targeting RIG-I and MAVS for proteasomal degradation (Barral et al., 2009; Feng et al., 
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2014), and negatively regulating the JAK-STAT pathways that drive the expression of IFN 
(Grant et al., 2016; Stevenson et al., 2013). 
The remarkable diversity of viruses that RIG-I can antagonize is matched by the 
numerous ways a variety of viruses have evolved mechanism of evading sensing by RIG-
I. Most of the viral mechanisms circumventing RIG-I are based on protein-protein 
interactions, primarily because of the technologies readily available to study these types 
of interaction. While there are some viral mechanisms employed to avoid detection of 
their RNA by RIG-I, the technical limits in RNA biology have hindered a more complete 
characterization. Therefore, it would not be surprising to discover that novel viral 
countermeasures exist between viral RNA and cellular proteins. 
ZAP 
As compared to the other proteins discussed in this section, the Zinc-finger Antiviral 
Protein (ZAP) is a less well characterized innate antiviral protein with RNA binding activity. 
A cDNA screen for factors that inhibit MLV replication discovered a protein fragment with 
four CCCH-type zinc-fingers that had homology to protein in the mouse genome. Simply, 
the protein was named rZAP, for rat Zinc-finger Antiviral Protein due to its restriction of 
MLV (Gao et al., 2002). ZAP expression had no effect on the initiation of reverse 
transcription, plus-strand DNA synthesis, or nuclear entry, but displayed a potent block to 
viral gene expression. As a control, different reporter genes were tested for ZAP 
sensitivity, but ZAP had only a modest effect on their expression compared to the potent 
restriction of MLV gene expression, suggesting that the MLV genome was somehow 
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specifically targeted by ZAP. Northern blot analysis of MLV gene expression in whole 
cells, nuclear extracts, and cytoplasmic extracts revealed that ZAP does not affect nuclear 
levels of MLV mRNA, but specifically targets the cytoplasmic mRNA. 
This initial discovery elegantly described ZAP as a cytosolic sensor that specifically 
targeted the expression of MLV mRNA, but had no effect on the expression of cellular 
genes or a small effect on report genes. How ZAP distinguished between viral RNA and 
cellular RNA was an obvious next question to address. This was addressed in part by 
comparing a panel of viruses for ZAP sensitivity. The viruses tested in this initial 
characterization were primarily alphaviruses, consisting of Sindbis virus (SINV), Semliki 
Forest virus (SFV), Ross River virus (RRV) and Venezuelan equine encephalitis virus 
(VEE), but also included Herpes Simplex Virus 1 (HSV-1) from the Herpesviridae, Yellow 
Fever from the Flaviviridae family, and Vesicular stomatitis virus (VSV) from the 
Rhabdoviridae family (Bick et al., 2003). Infecting cells over expressing the rZAP 
construct originally used to identify ZAP with the alphaviruses revealed a strong inhibition 
of viruses from this genus, ranging from over 10-fold to 10,000-fold restriction in the case 
of SINV, even when infected at an MOI as high as 5.0. Equally clear was how the 
remainder of the viruses tested were not sensitive to ZAP. Even at MOI far below 1.0, 
none of these viruses displayed any effect on replication in the presence of ZAP. The 
findings of this study were particularly perplexing due to the groups of viruses sensitive 
to ZAP. Like SINV, both YF and poliovirus are positive stranded RNA viruses that replicate 
entirely in the cytoplasm, yet YF and poliovirus are both clearly insensitive to ZAP while 
SINV is profoundly sensitive. Similarly perplexing was the lack of any obvious sequence 
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homology that SINV shares with MLV, the virus used to discover ZAP. Importantly, this 
study described different viruses that are sensitive and insensitive to ZAP, yet no common 
feature emerged among the sensitive viruses that indicated how ZAP might recognize 
their RNA as non-self (Bick et al., 2003). 
Using a different approach, a study came shortly after attempting to determine what are 
the viral RNA determinants that drive ZAP recognition. While the pervious experiments 
set out to broadly survey viruses sensitivity to ZAP with the goal of understanding a 
common feature among them, this group set out on a much more brute force approach, 
determined to unearth some sequence motif that ZAP recognizes (Guo et al., 2004). To 
do this, they used a luciferase reporter gene expression construct transfected in the 
presence of rZAP. As a 3’ UTR to the luciferase were different segments of the SINV 
genome used as a bait for ZAP because SINV was previously shown to be exquisitely 
ZAP sensitive. The genome was originally unevenly divided into seven regions, tested as 
3’UTR, and ZAP inhibition was measured by luciferase activity relative to cells not 
expressing ZAP. The regions found to be most sensitive were further divided into smaller 
segments and cloned into the luciferase construct, all of this done in both the sense and 
anti-sense orientation. This process continued until the genomic fragment was as small 
as 110 nucleotides from the original fragments of ~3,000 nucleotides. While this 
experimentation led to a fragment of 653 nucleotides in length that was significantly 
inhibited by ZAP, overall the strongest correlation between ZAP sensitivity and the 
genomic fragments was with the length of the fragment. The conclusion from these 
experiments was either that ZAP might recognize a complex tertiary structure in large 
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RNA sequences that computer programs were unable to predict, or that there might exist 
a small unidentified motif that only conferred sensitivity when the when the cumulative 
addition of the motif crossed a threshold that allowed ZAP to bind to the RNA (Guo et al., 
2004). 
Additional biochemical studies were carried out in the following years in an attempt to 
identify an element in RNA that ZAP recognized. A systematic evolution of ligands by 
exponential enrichment (SELEX) approach was used to identify the RNA sequence or 
structure that ZAP bound in RNA (Huang et al., 2010). Through 21 rounds of selection, 
the group identified a ZAP-binding aptamer that was guanosine rich and predicted top 
form stem loops. Despite the identification of these sequences, when they were placed in 
the context of luciferase reporter construct as done previously they did not confer 
sensitivity to ZAP, suggesting that this identified element might not be a bona-fida ZAP 
target. A structure of an N-terminal rZAP fragment was determined with the first 225 
residues (Chen et al., 2012). This structure identified two RNA-binding cavities in ZAP, 
but a co-crystal structure with RNA bound was not solved. The researchers proposed key 
residues that are important for RNA binding and specific recognition of viral RNA, but 
without a co-crystal structure they could not further determine how ZAP is able to 
distinguish viral RNA from cellular RNA, other than through the complex RNA structures 
yet unsolved (Chen et al., 2012). 
Mechanistically, once ZAP binds to a viral mRNA, it was clearly shown in the initial 
discovery that the RNA is degraded and the protein that it encodes is not expressed (Gao 
et al., 2002). Some work has gone into trying to characterize how the RNA is degraded 
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yet a clear consensus on how this is accomplished has not been reached. Co-
sedimentation assays identified a number of components in the RNA exosome were 
pulled down with ZAP (Guo et al., 2007) The group went on to show that specifically the 
exosome component EXOSC4 (hRrp46p) directly interacts with ZAP in in vitro pull-down 
assays and that knock down of this component correlated with a significant decrease in 
ZAP activity against a Luciferase-SINV construct. Notably, the decrease in ZAP activity 
was only 2-fold, indicating that knockdown only confers a partial rescue to the RNA 
stability (Guo et al., 2007). A follow up studies similarly identified the protein p72 DEAD 
box RNA helicase (DDX17) and DEXH-Box protein (DHX30) as cofactors for ZAP (Chen 
et al., 2008; Ye et al., 2010). As with EXOSC4, when overexpressed, DDX17 and 
DEXH30 co-immunoprecipitated with ZAP, and when overexpressed they decrease the 
expression of a luciferase construct with a SINV fragment as a 3’UTR. Furthermore, when 
these proteins are knocked down the both decrease the effect ZAP has on the expression 
of the same reporter construct by 2-fold. While a luciferase is used as a control, crucially, 
these experiments do not include an experiment where these proteins are overexpressed 
or knocked down in the absence of ZAP to more precisely implicate their effects as being 
entirely ZAP dependent. The most recent study on the how ZAP degrades the RNA target 
came from a study characterize the relationship between ZAP degradation and 
translational repression (Zhu et al., 2012). The predominant view in the field is that 
translational repression of mRNA precedes RNA degradation by translocating the mRNA 
into processing bodies (p-bodies) where the ribonucleases degrade the mRNA (Iwakawa 
and Tomari, 2015). This experiments from this study are in agreement with this model, 
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demonstrating that ZAP excludes the target mRNA from polysomes and that this 
translational repression is independent from the mRNA degradation (Zhu et al., 2012). 
Taken together, these studies suggest that the exosome might be an important factor in 
the degradation of mRNA targeted by ZAP, but because key experiments are missing to 
definitely implicate them in the ZAP pathway combined with the lack of other studies from 
different groups that verify these results it remains unclear how exactly ZAP degrades the 
mRNA it targets. 
In addition to cofactors that are downstream of ZAP and promote mRNA degradation, 
there has been interest in identifying a cofactor that is either necessary for or enhance 
the activity of ZAP. The first study that presented evidence that ZAP might require a 
cofactor for maximal activity came testing a variety of different cell lines ZAP activity in 
the presence or absence of IFN treatment.  They found that BHK (a hamster kidney cell 
line) and mouse embryonic fibroblasts (MEF) have significantly less capable of restricting 
SINV replication when IFN is either not present or IFN signaling inhibited (MacDonald et 
al., 2007). Crucially, short hairpin RNA (shRNA) silencing of ZAP abrogated the effects 
of IFN on the replication of SINV, supporting the conclusion that the IFN effects observed 
were ZAP dependent. This study was followed up ten years later by the identification of 
a cofactor that fits this description through a genome wide RNA interference (RNAi) based 
screen. TRIM25, the E3 ubiquitin ligase previously shown to be a necessary cofactor for 
RIG-I, was found the enhance the antiviral activity of ZAP against SINV (Li et al., 2017). 
ZAP and TRIM25 were shown to directly interact via the SPRY domain in TRIM25, and 
TRIM25 demonstrated no antiviral activity against SINV in the absence of ZAP, with both 
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the RING domain, Coiled-coil domain, and SPRY domain all required for activity. Further, 
evidence is presented that TRIM25 ubiquitinates ZAP, yet ubiquitination of ZAP does not 
affect its activity. This compelling evidence presented in the initial study, was shortly 
followed up and confirmed by an additional group, further supporting the role of TRIM25 
as an enhancer of the antiviral activity of ZAP (Zheng et al., 2017). 
Since the initial discovery of ZAP and the following description of the viruses that ZAP 
restricts, additional viruses have been shown to be sensitive to ZAP. Viruses sensitive to 
ZAP have included Hepatitis B, specific spliced transcripts of HIV-1, Influenza A virus 
(IAV) and Japanese Encephalitis Virus (JEV) (Chiu et al., 2018; Mao et al., 2013; Tang 
et al., 2017; Zhu et al., 2011). Despite a broader understanding of the viruses that are 
sensitive to ZAP, this had not yielded a clearer understanding of how ZAP might restrict 
the replication of such a diverse group of viruses. Complementing these studies, there is 
some suggestion that viral proteins counteract ZAP. A study of HSV1 presented evidence 
the viral protein UL41 degrades the ZAP mRNA and significantly decreases its expression, 
thus allowing HSV1 the replicate. Removal of UL41 activity from HSV-1 sensitizes the 
virus to ZAP, while the wild-type virus can replication with normal kinetics (Su et al., 2015). 
Interestingly, this same group has published multiple reports of UL41 similarly degrading 
the mRNA of other known restriction factors such as cGAS, Viperin, and IFIT3 (Jiang et 
al., 2016; Shen et al., 2014; Su and Zheng, 2017). Additionally, two studies have 
demonstrated that ZAP might have some intracellular function beyond viral restriction. 
One study suggested that ZAP might inhibit retrotransposition, while another study 
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presented evidence that ZAP regulate the expression of the cellular mRNA TRAILR4 
(Goodier et al., 2015; Moldovan and Moran, 2015; Todorova et al., 2014). 
Due to the limited study of ZAP compared to other restriction factors, as of recently, there 
are still many outstanding questions related to how it recognizes self from non-self RNA, 
are there other cofactors that are required for activity, how is the RNA bound by ZAP 
degraded, and does ZAP possess some other cellular function beyond its role as a 
cytosolic viral sensing protein. 
CG dinucleotide suppression 
Over ten years ago, an interesting study was published that demonstrated radical 
alteration of the replication of poliovirus by simple re-coding the genome with synonymous 
mutations (Coleman et al., 2008). To do this, the authors took advantage of the 
redundancy of tRNAs that encode the same amino acid, whereby an Alanine can be 
encoded in RNA by either GCC or GCG, with the former occurring four times more 
frequently than the later in the human genome. Similarly, pairs of codons in the human 
genome occur at remarkably different frequencies. For example, the amino acid pair Ala-
Glu could be encoded by either GCCGAA or GCAGAG, but the former codon pair is 
dramatically underrepresented in the human genome compared to the later. The group 
tested whether adding these rare codon pairs might affect the replication of poliovirus, 
and synthesized viral mutants with recoded capsid sequences with increasing amounts 
of rare codon pairs. Remarkably, the replication of the recoded virus was decreased by a 
1,000-fold compared to the wild-type virus (Coleman et al., 2008).  They concluded that 
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the cumulative addition of these rare codon pairs added up to dramatically inhibit the 
replication of the virus, and replicated these findings in other viral systems, notable with 
respiratory syncytial virus (Le Nouen et al., 2014). 
Other groups attempted to recode RNA viruses with a similar rational, i.e. using 
synonymous mutations at the codon boundaries, yet they claimed they were changing 
different aspects of the viral sequence. Rather than the rare codon pair, per se, affecting 
the viral replication, they claimed what they were actually changing was the dinucleotide 
composition of the viral genome, specifically increase the CG and UA frequency (Atkinson 
et al., 2014). By specifically increasing the CG and UA Content of an echovirus, they 
observed a severe attenuation in the replication compared to the wild-type virus. The 
authors believed that the mechanism of attenuation was the same as the group that was 
recoding their viruses by codon pair basis. They published a follow up study that directly 
challenged codon pair biases, claiming that codon pair deoptimization is merely an artifact 
of increasing the CG and UA frequencies in the viral genomes (Tulloch et al., 2014). This 
drew a swift and critical response from the group who put forth the idea of codon pair 
deoptimization, with a letter in PNAS defending their theory over the competing 
dinucleotide enrichment theory (Futcher et al., 2015). Both sides presented informatics 
analysis that suggested that their theory was correct, but a third parties analysis finally 
brought resolution to the debate. Admittedly, they had set out to prove that codon pair 
bias was the driving factor in viral genomes rather than dinucleotide composition. To do 
this, they conducted an in-depth analysis of the codon pair basis of viral genomes and 
the genomes of the species the viruses infect to demonstrate a correlation between the 
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two. Remarkably, they did not find a correlation between codon pairs usage, but rather a 
strong correlation in dinucleotide composition, specifically in the frequency of CG and UA 
dinucleotides (Kunec and Osterrieder, 2016). 
Vertebrate genomes exhibit marked CG-suppression, that is lower than expected 
numbers of 5’-CG-3’ dinucleotides (Karlin et al., 1994). This feature is likely due to C-to-
T mutations that have accumulated over hundreds of millions of years, driven by CG-
specific DNA methyl transferases and spontaneous methyl-cytosine deamination. 
Remarkably, many RNA viruses of vertebrates that are not substrates for DNA methyl 
transferases mimic the CG-suppression of their hosts (Karlin et al., 1994; Karlin and 
Mrazek, 1997; Rima and McFerran, 1997). This striking property of viral genomes is 
unexplained. The HIV-1 genome is also particularly suppressed for CG dinucleotides and 
matches the CG dinucleotide composition of its host (Cheng et al., 2013; Futcher et al., 
2015; Greenbaum et al., 2008). The evidence presented above suggests that this 
property of RNA viruses might be essential to their replication, but the reason for this 
suppression had previously not been identified. 
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Chapter 2. Materials and Methods 
Plasmid construction 
The mutated regions of the HIV-1 genome were synthesized (Genewiz) and cloned into 
HIV-1NHG using restriction digest sites that were proximal to the mutated regions. Division 
of the original mutants blocks into two new derivative mutants was achieved using overlap 
extension PCR based approaches with mutant and WT templates. Revertant mutations 
acquired through passage of the virus were reconstituted into the original mutant provirus 
from which they arose through site directed mutagenesis and overlap extension PCR. A 
HIV-1NHG reporter provirus was used in the initial construction of the synonymous mutants 
(GeneBank: JQ585717.1). This proviral construct contains a GFP reporter in the place of 
the non-essential gene, nef. This provirus is primarily comprised of NL4.3 sequence, with 
small segments of the genome derived from HXB2. 
A ZAP exon 1-targeting guide sequence: 5’-GGCCGGGATCACCCGATCGGTGG-3’ was 
inserted into a lentiviral based CRISPR plasmid from Addgene (52961) to generate ZAP-
/- cells. A TRIM25 exon 1-targeting guide sequence: 5’-
GAACACGGTGCTGTGCAACGTGG-3’ was inserted into the same Addgene vector to 
generate TRIM25 knock out cell lines. 
 A ZAP-S and TRIM25 cDNA that was rendered resistant to the CRISPR resistant through 
introduction of synonymous mutations in the guide target sequence was generated by 
overlap extension PCR and inserted into a tetracycline inducible HIV-1 based vector 
(pLKO.dCMV.TetO/R). An epitope tagged (ZAP-3xHA) cDNA used for CLIP was inserted 
into the MLV expression vector, LHCX. A Firefly luciferase cDNA (fluc) was designed to 
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remove CG dinucleotides through synonymous substitution, reducing the bringing the 
total number of CG dinucleotides from 97 to 8.  This CG-low fluc cDNA was inserted into 
the expression vector pCR3.1 using EcoRI and NotI. Various sequences were then 
inserted 3’ to the fluc cDNA using NotI and XhoI. Specifically, sequences from the Indiana 
strain of VSV-G and P, and the Influenza A/WSN/1933 NP open reading frames were 
inserted, as were derivatives with synonymous mutations that maximized CG-
dinucleotide content. A CXCR4-2A-CD4 cassette was generated by overlap-extension 
PCR and inserted into LHCX using HindIII and HpaI. The TRIM25 constructs were cloned 
into pCR3.1 using EcoRI and NotI restriction sites, and point mutations were introduced 
using overlap PCR. 
 Cell culture 
The adherent cells 293T, HOS and HeLa were grown in DMEM with 10% fetal bovine 
serum. MT4 cells were cultured in RPMI supplemented with 10% fetal bovine serum. 
Primary lymphocytes were isolated from human blood by Ficoll-Paque gradient 
centrifugation and removal of the plastic adherent fraction. Cells were activated with 
phytohaemagglutinin (Sigma, 5 μg ml−1) and cultured in the presence of interleukin-2 (50 
U ml−1) in RPMI with 10% fetal bovine serum. 
ZAP-deficient cells were generated by transduction with the lenti-CRISPR vector followed 
by selection in 5 μg ml−1 blasticidin. Single-cell clones were derived by limiting dilution 
and maintained in the appropriate media with 5 μg ml−1 blasticidin. Loss of ZAP protein 
and gene was confirmed by PCR amplification and sequencing the genomic locus and by 
50 
western blotting. In some CRISPR knockout clones, protein species that reacted with an 
anti-ZAP antibody arose after extended passage and likely represent truncated forms of 
ZAP-L whose translation initiated at methionine codons 3’ to the CRISPR target site (that 
was near the ZAP N-terminus). The appearance of these protein species did not affect 
the ability of the cells to support replication of WT or mutant viruses.  Doxycycline-
inducible ZAP-S expression in MT4 cells was reconstituted by stable transduction with 
the LKO ZAP-S expression vector followed by selection in 2.5 μg ml−1 puromycin. These 
reconstituted cells were used as a pool. Cells (293T) stably expressing either ZAP-S 
3xHA or ZAP-L 3xHA were generated by transduction with the LHCX vector containing 
followed by selection in 50 μg ml−1 hygromycin. A single cell clone was derived by limiting 
dilution and maintained in DMEM with 50 μg ml−1 hygromycin. HOS cells were stably 
transduced with LHCX CXCR4-2A-CD4 followed by selection in 25 μg/ml hygromycin. A 
single cell clone was derived by limiting dilution and maintained in the appropriate media 
with 25 μg/ml hygromycin. 
 Virus production 
All HIV-1 virus stocks were generated by transfection of 293T cells 10cm dishes with 
10μg of proviral plasmid using polyethyleneimine (Polysciences). HIV-1WT and mutant 
viruses usually contained a GFP reporter and were generated by transfection with HIV-
1NHG-derived proviral plasmids. The yields of infectious virus from transfected 293T cells 
for each of the mutants was similar, despite their differing properties in spreading 
replication assays. This is very likely due to gross overexpression of the viral genome in 
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transfected 293T cells. Viruses used in primary lymphocyte replication and CLIP assays 
were generated by transfection with HIV-1NL4-3. Viruses used to infect CD4-negative HeLa 
cells in the single cycle replication siRNA screen, or 293T cells in the CLIP assays, were 
generated by transfection with 10μg of proviral plasmid and 1μg of VSV-G expression 
plasmid. 
Titers of viral stocks were determined by performing 3-fold serial dilutions in a 96 well 
plate and infecting 5x104 MT4 cells per well. At 16-18 hours post infection, dextran sulfate 
was added to each well at a concentration of 50 μg ml-1 to prevent reinfection by nascent 
virions. At 48 hours after infection, cells were fixed in 4% PFA and enumerated by FACS 
analysis using a CyFlow Space cytometer (Partec) coupled to a Hypercyte Autosampler 
(Intellicyt). 
For spreading replication assays with GFP reporter viruses, viral stocks generated from 
transfected 293T cells were adjusted to the same number of single cycle infectious units 
(determined on MT4 cells as described above). Thereafter, 2x105 MT4 cells were infected 
at an MOI of 0.002 in 2 mL of RPMI. Aliquots of infected cells were withdrawn each day, 
fixed in 4% PFA and the proportion of infected cells determined by FACS analysis of GFP 
expression. For spreading replication assays in PBMCs, cells were infected at an MOI of 
0.001. At 18 hours post infection the cells were washed four times with PBS and cultured 
in RPMI with 50 U ml−1  interleukin-2. Supernatants were collected every 24 hours. Viral 
particle release was determined by measuring the reverse transcriptase activity with a 
PCR based assay, as previously described (Pizzato et al., 2009). 
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For single cycle replication MT4 cells were infected at an MOI of 1.0, with HIV-1NHG-
derived viruses, washed three times with PBS 18 hours post infection, and resuspended 
in RPMI with 50 μg ml-1 of dextran sulfate to prevent reinfection. At 48 hours post infection, 
cells and supernatants were collected for analysis. Half of the cells were lysed in SDS 
sample buffer for western blot analysis and half allocated for RNA extraction and to 
determine levels of unspliced RNA as described below. The supernatants were filtered 
with a 0.22 μm filter. An aliquot of filtered supernatant was used to determine infectious 
viron yield by titration on MT4 cells. The remaining supernatant was centrifuged over a 
20% sucrose cushion at 14,000 rpm at 4o C for 90 minutes. Pelleted virions were 
resuspended in SDS sample buffer for western blot analysis. 
 Western blot assays 
Cells were counted, normalized for cell number, lysed in SDS sample buffer, separated 
by electrophoresis on NuPage 4-12% Bis-Tris gels (Novex) and blotted onto nitrocellulose 
membranes (GE Healthcare). Antibodies for PTBP1 (ab5642), Drosha (ab12286), DICR 
(ab14601), EXOSC6 (ab50910), EXOSC10 (ab50558), and PARN (ab188333) were 
obtained from Abcam. Antibodies for Upf1 (A300-036A), METTL3 (A301-567A), EXOSC4 
(A303-775A), EXOSC5 (A303-887A), and Xrn1 (A300-443A) were obtained from Bethyl 
Labs. The antibody against ZAP (16820-1-AP) was obtained from Proteintech. The HIV-
1 capsid antibody (183-H12-5C) was obtained from the NIH AIDS reagent repository. The 
GFP (G1546) antibody was obtained from Sigma. The HIV Env (12-6205-1) antibody was 
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obtained from American Research Products. The HA (HA.11) antibody used in the CLIP 
assays was obtained from Biolegend. 
Cross-linking Immunoprecipitation and Sequencing (CLIP-Seq) 
The CLIP method used in this study has been previously described (Kutluay et al., 2014) 
and was adapted from previously reported HITS-CLIP and PAR-CLIP(Hafner et al., 
2010)(Hafner et al., 2010)(Hafner et al., 2010)(Hafner et al., 2010)(Hafner et al., 
2010)(Hafner et al., 2010)(Hafner et al., 2010)(Hafner et al., 2010) protocols (Hafner et 
al., 2010; Licatalosi et al., 2008). In brief, RNA and proteins were cross linked by feeding 
cells overnight with 4-thiouridine irradiating them at 0.15 J/cm2 UV (λ = 365 nm) in a 
Stratalinker 2400 UV crosslinker (Stratagene). Thereafter ZAP-3xHA was immunopurified 
using Protein G-conjugated magnetic Dynabeads and a mouse monoclonal anti-HA 
antibody, and the RNA was radiolabeled with 0.5 μCi/μl γ-32P[ATP] ATP. Protein-RNA 
adducts were separated by SDS-PAGE, transferred to nitrocellulose and detected by 
autoradiography. Next, sequential 3’ and 5’ adaptor ligations were performed as 
previously described (Kutluay 2014) attaching a known sequence that contains primer 
binding sites for reverse transcription and PCR-amplification of the cDNA library. 
Sequencing of the cDNA library was done on an Illumina HiSeq 2000 platform. 
The analysis pipeline used in this study has previously been described. Processing of raw 
reads was performed with the FASTX toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), 
excluding reads with fewer than 15 nucleotides. Reads were then aligned to the human 
genome (hg38) concatenated with the HIV-1NL4-3 genome or to the viral genome alone. 
Cluster analysis was performed using PARalyzer (Corcoran et al., 2011). 
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 siRNA transfection assays 
ON-TARGET plus siRNAs were ordered from Dharmacon, and contain 4 individual 
siRNAs against the target gene to ensure efficient knockdown. Stock concentrations were 
made at 100uM.  Working dilutions were prepared at 10uM and stored in small aliquots 
to prevent freeze thawing. 5uL of the 10uM siRNA was added to 200uL of Opti-MEM 
(Gibco), separately, 5uL of RNAiMAX (ThermoFisher) was added to a 200uL of Opti-MEM. 
After mixing, the siRNA and RNAiMAX Dilutions are added to a 6 well plate, mixed, and 
incubated for 5-10 minutes. After incubation, 1x105 HeLa cells were added in DMEM with 
10% FBS. 24 hours post transfection, the cells were trypsanized and reseeded into two 
wells of a 12-well plate. 48 hours post transfection, the cells were infected with either HIV-
1NHG or a CG-high HIV-1NHG. 16-18 hours post infection the cell were washed three times 
with sterile PBS, and replaced with fresh DMEM with 10% FBS. 48 hours post infection 
the supernatant was filtered and collected to determine the viral titer released. Additionally, 
the infected cells were collected for western blot analysis. 
The siRNA screens were generated using cherry-pick siRNA libraries from Dharmacon, 
also containing ON-TARGET plus siRNAs with 0.5nmol per well. Stock concentration 
plates were made at 10uM and working dilution plates were made at 1uM to avoid freeze 
thawing. To transfect in 96 well plates, 20 μL of Opti-MEM was added to each well of a 
96-well plate with a multichannel. 5uL of the respective siRNA is added to the 96-well 
plate. Separately, a master mix is made with 23.5 μL Opti-MEM and 1.5 μL RNAiMAX / 
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well, mixed thoroughly, added to the 96well plates that already contain the siRNA and 
Opti-MEM, and left of incubate for 5-10 minutes at room temperature. Separately, HeLa 
cells are prepared and four 96-well plates were seeded with 8x104 cells in 100 μL of 
DMEM with 10% FBS. After plating Hela cells, 10uL of the siRNA transfection mixture is 
added, created enough plates for two virtues infections done in technical duplicate. 48 
hours post transfection, the HeLa cells are infected at an MOI of 1.0 in 50 μL of DMEM 
with 10% FBS. 16-18 hours post infection, the media aspirated and replace with fresh 
DMEM with 10% FBS. 48 hours post infection, the supernatants are collected and added 
to 5x104 MT4-GFP cells to determine the titer of the produced virus. Additionally, the 
infected HeLa cells from the screen are trypsinized and fixed in 4% PFA for analysis by 
flow cytometry to determine what percentage of the cells were infected, using the GFP 
reported in the HIV-1 viruses in the place of the nef gene. 
 Analysis of HIV-1 splicing with fluorescent primer PCR 
RNA from 293T cells transfected with mutant provirus was extracted using the Nucleospin 
RNA extraction kit (Machery Nagel). RNA was reverse transcribed using SuperScript III 
reverse transcriptase (ThermoFisher) with gene specific primers for either fully spliced 
(8483R: 5’-CCGCAGATCGTCCCAGATAAG-3' and partially spliced (6223R: 5'-
CAAGTGCTGATATTTCTCCTTCAC -3') mRNA classes. The cDNA templates were then 
used in a 10μL PCR reaction with fluorescent reverse primers specific to the splice class 
(labelled at their 5’ ends with IRD800) and a forward primer position 5’ to the major splice 
donor (499F: 5' -CTGAGCCTGGGAGCTCTCTGGC-3') and run for 25 cycles with an 
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annealing temperature of 54°C. Alternatively, to determine use of the activated cryptic 
splice site in mutant A, a forward primer, positioned 5’ to the mutations (763F 5’- 
TGACTAGCGGAGGCTAGAAGGAGAGAG -3’) and the fluorescent reverse primer for 
the fully spliced class (8483R) were used in a PCR reaction with the cDNA templates. To 
determine use of the activated cryptic splice site in mutant B, the forward primer 499F 
and a fluorescent reverse primer 5’ to the mutations in B (1557R 5’- 
GATAGGTGGATTATGTGTCATCC -3’) were used in a PCR reaction with the cDNA 
template. Then, 10μL of 2x TBE-Urea sample buffer was added to the PCR reaction which 
was then run on a 6% TBE-Urea gel for 90 minutes at 180V (Novex). A LI-COR Odyssey 
scanner was used to detect fluorescent signals directly from the gels. 
 Primer-ID-based deep sequencing analysis 
Determination of splice site utilization using the Primer ID-based deep sequencing assay 
was done substantially as described with minor modifications (Emery et al., 2017). Briefly, 
RNA was extracted from cells transfected with HIV-1NHG or mutants thereof using the 
RNeasy Plus minikit (Qiagen). Primers used for cDNA synthesis were 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNCAGTTCG
GGATTGGGAGGTGGGTTGC for 1.8 kb spliced transcripts and 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNNNGCTACTA
TTGCTATTTGTATAGGTTGCATTACATG for 4 kb spliced transcripts. Indexed primers 
were obtained from Integrated DNA Technologies Custom Oligos. Total cell RNA (8 μg) 
was subjected to cDNA synthesis, purification and cleanup and an initial PCR 
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amplification. An aliquot of the product from this first PCR was used as the template for 
the second PCR to add the Illumina adapter and bar codes to allow multiplexing in the 
Illumina sequencing reaction. PCR products were visualized on a 2% agarose gel and 
then cleaned. Libraries were mixed/multiplexed and sequenced using the 300-base 
paired-end read for the Illumina Miseq platform. Reads were sorted using the Illumina 
bcl2fastq pipeline (v.1.8.4) to separate the multiplexed samples. Subsequent Data 
analysis and splicing quantification were done using the previously described in-house 
pipeline (Emery et al., 2017) written in Ruby and adapted to accommodate the mutated 
sequences.  This program uses the combined sequence information from the paired-end 
reads to identify splice site usage and transcript type.  Reads are condensed by Primer 
ID to prevent skewing in the PCR steps. Cryptic alternative donor and acceptor splice 
sites were identified using a program that compares data reads to a reference sequence 
and identifies the base where a splice discontinuity occurs and the base it splices to. 
 qPCR quantification of unspliced viral RNA 
RNA was collected from infected cells using the Nucleospin RNA kit (Macherey Nagel). 
The RNA concentration was determined using a NanoDrop 2000c (ThermoFisher). Equal 
amounts of RNA were reverse transcribed using SuperScript III reverse transcriptase with 
random hexamer priming (ThermoFisher). The cDNA was used as a temple for 
quantitative real-time PCR using a StepOnePlus RT-PCR machine (Applied Biosystems). 
Unspliced viral RNA was detected by a TaqMan probe spanning the major splice donor 
D1, using the Fast Start TaqMan Probe master-mix. Serial tenfold dilutions of known copy 
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numbers of HIV-1NHG plasmid was used to generate a standard curve. The sequence of 
the TaqMan probe and primers were: D1 probe: 5’-GGGCGGCGACTGGTGAGT-3’; 
forward primer: 5’-GGACTTGAAAGCGAAAGGGA-3’; reverse primer: 5’-
TCTCTCTCCTTCTAGCCTCCG-3’. 
 Small molecule fluorescence in-situ hybridization microscopy 
HOS CXCR4-2A-CD4 were seeded onto gelatin coated glass bottom 24 well plates 
(MatTek) and infected at an approximate MOI of <1 with HIV-1WT, LCG-HI, or LGC-HI .  
Twenty-eight hours after infection the cells were washed with PBS and fixed with 4% 
paraformaldehyde (Thermo) in PBS for 30 min at RT. After permeabilization with 70% 
ethanol for 2hr at RT the cells were briefly washed with Stellaris RNA-FISH wash buffer 
A for 5 min at room temperature. The cells were then incubated with custom Stellaris 
smFISH probes targeting HIV-1 gag or all viral mRNAs (Biosearch Technologies) at a 
concentration of 0.125 µM in Stellaris RNA FISH hybridization buffer for 16-18 hr at 37oC. 
The cells were then washed two times for 30 min at 37oC in Stellaris RNA FISH wash 
buffer A. The second wash contained Hoechst dye at 1 µg/ml.  After a 5 minute wash with 
Stellaris RNA FISH wash buffer B cells were rinsed three times with PBS and imaged by 
deconvolution microscopy (Deltavision).  Image stacks were generated by maximum 
intensity projection using the Z project function in ImageJ (Version 2.0.0-rc-59/1.51n). 
RNA spots were counted using Find Maxima function in ImageJ. 
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Chapter 3. Synonymous mutagenesis of the HIV-1 genome 
To determine whether there are important, undiscovered cis-acting elements in the HIV-
1 genome, a mutant HIV-1 sequence was designed that contained a maximum number 
of synonymous mutations in the open reading frames while leaving known RNA elements 
that are important for virus replication intact (Table 3.1). 
 Design of global synonymous mutants 
Mutations were designed so as to maximize the probability of disrupting base pairing in 
which a given nucleotide might participate. Thus, where multiple synonymous mutation 
possibilities were available, transversion mutations (purine to pyrimidine or vice versa) 
were preferred over transition mutations. To avoid the creation of new splice acceptors 
and donors, no new AG or GU dinucleotides were introduced. Moreover, sequences 
encoding overlapping open reading frames were not altered, and all known RNA elements 
that control HIV-1 splicing, gene expression and reverse transcription remained intact in 
the mutant viral genome. Mutations were designed so as to maximize the probability of 
disrupting base pairing in which a given nucleotide might participate. Thus, where multiple 
synonymous mutation possibilities were available, transversion mutations (purine to 
pyrimidine or vice versa) were preferred over transition mutations. To avoid the creation 
of new splice acceptors and donors, no new AG or GU dinucleotides were introduced. 
Moreover, sequences encoding overlapping open reading frames were not altered, and 
all known RNA elements that control HIV-1 splicing, gene expression and reverse 
transcription remained intact in the mutant viral genome (Table 3.1). 
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This designed HIV-1 sequence contained 1,976 synonymous mutations and was divided 
into 150-500 nucleotide blocks, that were synthesized separately. Each synthetic mutated 
fragment was introduced into a replication competent HIV-1 proviral plasmid (HIV-1NHG) 
that carried GFP in place of the nonessential gene Nef. Thus, sixteen different mutated 
proviral plasmids, designated A through P, with each carrying a mean of ~125 
synonymous mutations were generated (Figure 3.1A). 
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Table 3.1 : Sequences containing known cis-acting elements left undisturbed in 














































Figure 3.1: Design and analysis of panel of synonymously mutated HIV-1 viruses 
(A) Schematic of HIV-1 proviral DNA, indicating open reading frames, splice sites, and 
blocks of nucleotides that were synonymously mutated in the 16 proviral plasmids (A-P).  
(B) Single-cycle infectious titers (measured using MT4 cells) 48h following transfection of 
293T cells with each of the WT(HIV-1NHG) and mutant (A-P) proviral plasmids. Values are 
given as  mean±sd. (n=3) *p<0.05, **p<0.005 by students t-test, calculated with relative 
values normalized to WT values in each experiment. (C) Western blot analysis of protein 
levels in transfected cells (and virion particles where indicated) at 48h after transfection 
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 Viral replication analysis of panel of synonymous mutants 
Each of the synonymously mutated HIV-1NHG proviral plasmids was transfected into 293T 
cells and the infectious virion yield was determined in a single-cycle infection assay in 
MT4 cells (Figure 3.1B). Many of the mutants yielded WT, or close to WT, levels of 
infectious virions in this transfection/titration assay format. However, mutants A, B, I, and 
J yielded between 5-fold and 1000-fold fewer infectious virions (Figure 3.1B). Western 
blot analysis of the transfected 293T cells and extracellular virions showed that mutants 
A and B expressed additional Gag protein species of unexpected sizes, and mutant B 
displayed a particle release defect, possibly a consequence of the expression of the 
aberrant Gag protein (Figure 3.1C). Mutants I and J displayed reduced Gag, Pol, Env and 
Vif protein, and slightly elevated GFP levels. Mutant J also grossly overexpressed the Vpr 
protein (Figure 3.1C). 
We next examined whether each of the mutants could replicate in MT4 and CEM T-cell 
lines (Figure 3.2 and Figure 3.3). Seven of the mutants (D, E, F, G, H, N and P) replicated 
with WT, or close to WT, kinetics while eight other mutants, (A, B, I, J, K, L, M, and O) 
were replication defective, or highly impaired, in both cell lines (Figure 2.2 and Figure 2.3). 
Mutant C was somewhat impaired in MT4 cells, but replicated with close to WT kinetics 
in CEM cells. Thus, an apparent discrepancy was evident in the ability of some of the 
mutants to generate infectious virions in 293T cells, versus their ability to generate a 
spreading infection in T-cell lines. 
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Figure 3.2: Spreading replication properties of mutant viruses 
(A-P) MT4 cells were infected with the indicated virus (harvested from the supernatant of 
293T cells transfected with each of the WT(HIV-1NHG) or mutant (A-P) proviral plasmids 
at an MOI of 0.002. Aliquots of infected cells were withdrawn each day, fixed in 4% PFA 
and the proportion of infected cells determined by FACS analysis of GFP expression. a 
Representative replication curve for WT(HIV-1NHG) is plotted in each chart as grey 




















































































































































































































































Figure 3.3: Spreading replication properties of mutant viruses in CEMx174 cells 
(A-P) CEMx174 cells were infected with the indicated virus (harvested from the 
supernatant of 293T cells transfected with each of the WT(HIV-1NHG)  mutant (A-P) 
proviral plasmids at an MOI of 0.002. Aliquots of infected cells were withdrawn each day, 






















































































































































































































































 Splicing defects detected by multiple assays 
The viral mutants were designed to avoid altering RNA sequences in the HIV-1 genome 
that are known to be important for replication, including those that participate in or regulate 
splicing (Table 3.1). Nevertheless, the aberrant pattern of viral protein expression in two 
of the synonymously mutated viruses (I, J), and the appearance of novel Gag-related 
protein species in two others (A, B), suggested that HIV-1 splicing might have been 
perturbed in at least some of the mutant viruses (Figure 3.1C). Therefore, we next used 
two approaches to determine whether the mutations affected splicing in each of the 
mutant viruses. We used a recently described Primer ID-based deep sequencing 
approach to globally quantify the relative utilization of the various splice donors and 
acceptors in the mutant viruses (Figure 3.4A-E). We also used a fluorescent primer-based 
PCR-PAGE assay to more conveniently, albeit less quantitatively, track the generation of 
the major mRNA species in the canonical spliced 1.8 kb class of HIV-1 mRNAs (Figure 
3.4F). These two assays yielded results that were in good agreement. Of the canonical 
splice acceptors in the central portion of the genome (A1, A2, A3 A4a,b,c, and A5, Figure 
3.4A), the WT HIV-1NHG most frequently spliced to A5, with lower levels of splicing to A1, 
A2, A3, A4a,b,c (Figure 3.4A, C, F). 
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Figure 3.4: Analysis of HIV-1 splicing in WT and synonymously mutated HIV-1 
(A) Schematic representation of segments of HIV-1 proviral DNA, focused on mutants 
exhibiting perturbed splicing. Canonical splice sites (black) and cryptic splice sites (red) 
are indicated, as are blocks of nucleotides that were synonymously mutated in the viruses 
exhibiting perturbed splicing. (B-E) Nextgen sequencing analysis of HIV-1 splicing, 
heatmaps indicate relative proportion of sequencing reads that indicate splicing at the 
sites indicated at the bottom of the heatmaps (B, C), or inclusion of the short exons (SX1 
and/or SX2) indicated at the bottom of the heatmap (D). For panel (C) only direct splicing 
to the indicated acceptor sites is indicated in the heatmap Alternatively, the relative 
abundance of the various 1.8 kb mRNA species is indicated (E). (F) Fluorescent primer 
PCR analysis of HIV-1 splicing. 293T cells were transfected with the indicated proviruses, 
RNA extracted and cDNA synthesized. A sense PCR primer situated 5’ to the major splice 
donor, along with an antisense primer positioned either 3’ to A7 or 3’ to D4 (labelled with 
IRD800) were used to amplify cDNAs derived from the 1.8 kb (top) or 4 kb (bottom) 
classes of spliced HIV-1 mRNAs respectively. PCR products were subjected to PAGE 
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A splicing defect was observed for mutants A and B, which contained synonymous 
changes toward the 5’ end of the HIV-1 genome, within gag. For each of these mutants, 
the relative levels of canonical splice site utilization were only marginally perturbed, but 
the Primer ID-based sequencing assay revealed that cryptic splice sites near the 5’ end 
of the genome were activated (Figure 3.4B, C, D). These mutants were designated Group 
2a. For mutant A, a cryptic splice acceptor at position 955 (A955) and a donor at position 
1169 (D1169) were activated, neither of which was used at a measurable level in WT HIV-
1NHG (Figure 3.4A, B). While A955 was used rarely (~1% of 1.8 kb mRNAs) in mutant A, 
~14% of the 1.8 kb mRNAs were spliced using D1169. (Figure 3.4B). Splicing events 
involving D1169 were selective with respect to which of the downstream acceptors were 
used: A3, A4, or A5, were used as acceptors for D1169 but A1 or A2 were not. MaxEnt 
scoring, which employs an in silico analysis tool that predicts the intrinsic splicing 
efficiency of splice acceptors and donor sequences (Yeo and Burge, 2004), indicated that 
our mutagenesis increased the score of the cryptic acceptor A955 from -9.88 to 1.75, 
suggesting that it became a stronger splice acceptor (Table 3.2). Thus, the minimal 
activation of A955 (used in 1% of spliced reads) in mutant A, could possibly be explained 
by a direct effect of the mutations. However, the predominant defect in mutant A was the 
activation of D1169, which lies outside the mutated region (Figure 3.4A) and whose MaxEnt 
score was not altered. Thus, activation of D1169 could not be due to increased intrinsic 
efficiency of this cryptic donor, but rather due to some other mechanism acting via RNA 
sequences distal to D1169. 
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Table 3.2: MaxEnt scores of splice acceptors and donors in wild type and mutated 
sequence 
Donor MaxEnt Score Sequence
D1 10.1 CTGGTGAGT
D1169 (wt) 7.16 CAGGTCAGC
D1509 (wt) -4.77 CTAGTACCC
D1725 (wt) 7.3 GAGGTAAAA
D1a (wt) 10.77 CAGGTAAGA
D1a (mut) 5.28 CAGGTTCGC
D2 (wt) 5.73 AAGGTGAAG
D2b (wt) 5.99 CAGGTGATG
D3 (wt) 9.45 AAGGTAGGA
D3 (G5463A mut) 3.63 AAAGTAGGA
D4 (wt) 9.07 GCAGTAAGT
Acceptor MaxEnt Sequence
A955 (wt) -9.88 CCTTTTAGAGACATCAGAAGGCT
A955 (mut) 1.75 GCTACTTGAAACTTCTGAAGGAT
A1231(wt) -2.94 GTTTTCAGCATTATCAGAAGGAG
A1231 (mut) 7.03 GTTCTCTGCTCTTTCTGAAGGCG
A1231 (mut, T1311C) 6.09 GTTCTCTGCCCTTTCTGAAGGCG
A1a (wt) 2.47 ATACTTCCTCTTAAAATTAGCAG
A1a_mut -3.69 TTATTTTCTACTTAAACTTGCTG
A1 (wt, IB mut) 6.41 AATTTTCGGGTTTATTACAGGGA
A1 (I, IA mut) 7.41 AATTTTCGCGTTTATTACAGGGA
A1 (IA mut, T4904A) 6.57 AATTTTCGCGTATATTACAGGGA
A1 (IB mut, G4912A) -2.34 AATTTTCGGGTTTATTACAAGGA
A2 (wt) 9.43 CTATTTTGATTGTTTTTCAGAAT
A2 (J mut) 9.71 TTACTTCGATTGTTTTTCAGAAT
A3 (wt, K mut) 9.76 CTGCTGTTTATCCATTTCAGAAT
A3 (K mut, C5774T) 10.05 CTGCTGTTTATCCATTTTAGAAT
A5 (wt) 4.01 TTAGGCATCTCCTATGGCAGGAA
A7 (wt) 7.15 ATTCACCATTATCGTTTCAGACC
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For mutant B, the major perturbation was activation of a cryptic splice acceptor at position 
1321 (A1321, Figure 3.4A, B). This splicing event, involving ~12% of mRNAs in the 1.8 kb 
class, appeared to enable a cascade of further alternative splicing events, 50% of which 
subsequently involved cryptic splice donor activation at either D1509 or D1725, outside the 
B mutant region (Figure 3.4B). However, the most obvious outcome of the aberrant 
splicing event was the generation of a truncated ~40 kD Gag protein (Figure 3.1C). This 
protein would be the expected translation product of an mRNA in which a D1- A1321 splice, 
and no further splicing, had occurred. Specifically, translation initiation at the second Met 
codon in the gag gene would generate a truncated ~40 kD Gag protein lacking MA, that 
likely accounts for the aberrant band on the cell-associated Gag western blot as well as 
the reduced particle yield from cells transfected with the B mutant proviral plasmid (Figure 
3.1C). 
For mutant B, the activation of A1321 may be due to a direct effect of the mutations 
increasing its MaxEnt score from -2.94 to 7.03, again suggesting it became a stronger 
splice acceptor (Table 3.2). The other cryptic sites activated, D1509 and D1725, are both 
outside of the mutated region in mutant B, and their use was likely secondary to activation 
of A1321. 
Viruses containing mutations in the central portion of the genome, specifically mutants I, 
J and K, exhibited a different type of splicing defect, and were designated Group 2b. 
Specifically, mutants I, J and K exhibited increased direct splicing to canonical splice 
acceptors, A1, A2 and A3 respectively, at the expense of direct splicing to downstream 
(3’) acceptors (Figure 3.4C). In the case of mutant I, the primary defect (increased use of 
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A1) was accompanied by increased use of the proximal downstream splice donor (D2) as 
well as a downstream acceptor–donor pair (A2 and D3) and thus the abundant inclusion 
of short exons (SX) 1 and 2 (SX1= [A1-D2] and SX2 = [A2-D3]) into spliced viral mRNAs 
(Figure 3.4D). Some elevation of the use of upstream cryptic splice sites in mutant I (D3569, 
D3969, D4641 and A4834) also generated low levels of novel transcripts (Figure 3.4F).  For 
mutant J, overuse of A2 (which is positioned 3’ to SX1) was accompanied by overuse of 
proximal downstream splice donor D3 and thus overrepresentation of SX2 = [A2-D3] into 
spliced viral mRNAs (Figure 3.4D). Additionally, some utilization of cryptic splice donors 
(D5052, D5434, and D5478) generated low levels of novel transcripts (Figure 3.4F). For mutant 
K, overuse of A3 (which is positioned 3’ to SX1 and SX2) did not result in the more 
frequent inclusion of these short exons (Figure 3.4D). Overall therefore, it appeared that 
one consequence of the overuse of a given splice acceptor (A1 or A2), was a resultant 
overuse of the proximal downstream splice donor (D2 or D3), consistent with an ‘exon 
definition’ model of splicing control (discussed later). 
This overuse of canonical splice acceptors in I, J and K resulted in aberrant representation 
of particular viral mRNAs. Among the 1.8 kb class of mRNAs, for WT HIV-1, Nef2 was 
the dominant mRNA species in both splicing assays (Figure 3.4E, F). Conversely, in 
mutant I, Nef5 was the dominant mRNA, while in mutant J, Nef4, Tat3 and Vpr1 were 
overrepresented (Figure 3.4E, F). These changes were likely responsible for the 
overexpression of GFP (in the nef position) and/or Vpr in these mutants (Figure 3.1C). 
For mutant K, Tat1 mRNA was over-represented (Figure 3.4E, F), but the overall levels 
of protein expression were not greatly affected in transfected cells. 
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 Summary 
For other replication defective mutants (L, M, and O) that we termed Group 3, the relative 
uses of splice sites appeared normal, despite obvious replication defects (Figure 3.2, 
Figure 3.4B-E). These viruses appeared to express a normal complement of viral proteins 
in transfected cells (Figure 3.1C). Overall, therefore, analyses of viral replication and RNA 
splicing led to the classification of the synonymously mutated viruses into three groups 
(Figure 3.5A): Group 1 mutants exhibited near WT fitness, Group 2 mutants exhibited 
replication defects accompanied by perturbed RNA splicing, while Group 3 mutants had 
profound replication defects in the absence of obvious splicing perturbation. The three 
phenotypes were caused by mutations that exhibited a clear regional bias with respect to 
their distribution along the viral genome (Figure 3.5A). Specifically, Group 1 viruses 
carried mutations throughout the pro (D) and pol (E to H) genes or in the 3’ portion of the 
env gene (N, P), and replicated indistinguishably from HIV-1NHG. Conversely, Group 2 
viruses with obvious splicing defects carried mutations in two distinct genomic regions: 
Group 2a viruses (A, B) carried mutations toward the 5’ end of the genome, within gag, 
while Group 2b viruses (I, J, K) carried mutations or in the central portions of the genome, 
within the accessory genes (Figure 3.5A). Group 3 viruses (L, M, O) that were defective 
but exhibited near-normal splicing carried mutations in the env gene (Figure 3.5A). 
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Figure 3.5: Phenotypes of synonymously mutated HIV-1 viruses 
(A) Summary of the properties of HIV-1 viruses carrying blocks of nucleotides that were 
synonymously mutated (A-P). The frequency of splice site utilization was assessed in 
transfected 293T cells (Figure 3.4), Single-cycle replication assays were used to assess 
unspliced RNA levels and infectious virus yield (see panels B and C below). Replication 
competence was determined using spreading replication assays. (B) Infectious virion 
yield measured in the supernatant of MT4 cells, infected with each of the mutant viruses 
at an MOI of 1.0, and harvested 2 days post infection. Values are the  mean ±sd n=3 or 
n=2 experiments, *p<0.05, **p<0.005 by students t-test calculated with relative values 
compared to wild-type virus (*** Values were below the limit of quantitation). (C) Levels 
of unspliced HIV-1 genomes in RNA extracted from MT4 cells, infected with each of the 
mutant viruses at an MOI of 1.0, and harvested 2 days post infection, mean ±sd n=3 or 
n=2 experiments, *p<0.05 by students t-test compared to wild-type virus. (*** Values were 






















Splice sites used at
normal frequency  
Unspliced
RNA levels   ↓ ↓ ↓ ↓    ↓      ↓      ↓ ↓
Single cycle































































Chapter 4. Novel cis-Acting Splicing Elements in HIV-1 
To determine the sequence elements responsible for the perturbations in splicing in 
Group 2a and Group 2b viruses we took two approaches. First, we attempted to derive 
second-site revertant viruses through passage of each viral mutant in MT4 cells. Second, 
we applied a mapping approach, in which each block of mutations in mutants A, B, I, J 
and K was divided into roughly equally sized component segments, and the splicing 
properties of each secondary mutant re-examined. Through an iterative process, 
sometimes combining mapping and second-site revertant derivation, we could determine 
the nature of the defects in each Group 2 mutant and map the responsible cis-acting 
sequences. 
 Group 2a: Activation of cryptic splice sites in gag 
For mutants A and B in which cryptic splice sites within the gag gene were activated by 
the silent mutations, we first attempted to derive revertant viruses by passage in MT4 
cells. For both mutants A and B, passage quickly yielded viruses that replicated more 
rapidly than the parental mutants viruses (Figure 4.2A, B, Figure 4.1). In the case of 
mutant A, passage in MT4 cells yielded a revertant virus that replicated well, albeit with 
delayed kinetics relative to WT HIV-1NHG and contained two nucleotide substitutions 
relative to the A mutant parent. One of these mutations (C819T) was responsible for the 
revertant replication phenotype (Figure 4.2A). The C819T mutation was synonymous, and 
while it occurred at a position that differs from the WT in mutant A, the reversion was not 
to the WT sequence (WT=G819, mutant A=C819, revertant=T819). Thus, if position G819 
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in the WT virus was involved in a hypothetical RNA secondary structure that was 
perturbed or induced in mutant A (C819), then the C to T substitution in the revertant 
would not be expected to affect the perturbation of that secondary structure. The C819T 
revertant largely corrected the predominant splicing defects in mutant A, reducing the use 
of the cryptic splice acceptor (A955) from ~ 1% to ~0.1% and the cryptic splice donor (D1169) 
from ~14% to <1% (Figure 4.2C). Since the reversion mutation C819 was distal to the 
cryptic splice sites (~140 and ~350 nucleotides 5’ to A955 and D1169, respectively, Figure 
4.2D) the mechanism by which it exerts its effect was unclear. Notably, the revertant 
mutation occurred within a few nucleotides of the reported secondary structure that 
includes the HIV-1 packaging sequence, and D1 (which is at position 743). Thus, it may 
be that the revertant mutation acts by modulating the secondary structure surrounding 
D1, rather than on the cryptic A955 and D1169 that were activated in mutant A. 
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Figure 4.1: Spreading replication experiments to recover second-site revertants 
of defective mutants 
MT4 cells were infected with the mutant viruses (A, B, IA, IB, JA, K, as indicated, 
harvested from the supernatant of 293T cells transfected with each of the indicated 
mutant proviral plasmids). Aliquots of infected cells were withdrawn each day, fixed in 4% 






















































































Figure 4.2: Activation of cryptic splice sites by synonymous mutations in Gag 
(A, B) MT4 cells were infected with the indicated virus (harvested from the supernatant 
of 293T cells transfected proviral plasmids representing each of the WT(HIV-1NHG), 
mutant (A, B and revertants (A C819T, A1130G and B T1311C, G1326A) thereof) at an 
MOI of 0.002. Aliquots of infected cells were withdrawn each day and the proportion of 
infected cells determined by FACS analysis of GFP expression. (C) Next gen sequencing 
analysis of HIV-1 splicing. The heatmap indicates relative proportion of sequencing reads 
that used the cryptic splice sites for WT(HIV-1NHG), mutant (A, B and revertants thereof) .
(D,E) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutants A 
(D) and B (F), indicating positions of mutant derivatives (AA, AB, BA, BB) etc, and the 
positions of cryptic splice sites and revertant mutant sites. Blocks colored blue are those 
that conferred overt splicing perturbations when mutated. (F) Fluorescent primer PCR 
analysis of HIV-1 splicing in mutant A. A sense PCR primer situated 5’ to the cryptic donor 
D1169, was used along with an antisense primer positioned 3’ to A7 (labelled with 
IRD800) was used to amplify cDNAs derived from the 1.8 kb class of spliced HIV-1 
mRNAs respectively. (G) Fluorescent primer PCR analysis of HIV-1 splicing in mutant B. 
A sense PCR primer situated 5’ to D1, was used along with an antisense primer 
positioned 3’ to the mutant B block (labelled with IRD800) was used to amplify cDNAs 
derived HIV-1 mRNAs. For panels (F) and (G) PCR products were subjected to PAGE 






































































































































































For mutant B, passage in MT4 or CEM cells yielded two different replicating revertant 
viruses each of which contained a single nucleotide substitution relative to the B mutant 
(G1326A in MT4 cells and T1311C in CEM cells) (Figure 4.2B, Figure 4.1) Both revertant 
mutations were synonymous, at positions that differed in WT and mutant B viruses. Both 
mutations were proximal to the cryptic splice acceptor (A1321) that was activated by the B 
mutations (Figure 4.2E). 
Analysis of the G1326A revertant in the NGS splicing assay indicated reduced use of the 
cryptic acceptor A1321, D1509, and D1725 (from 12%, 2.9%, and 3.9% to <1% respectively 
Figure 4.2C). Given the proximity of the reversion mutations to the silenced cryptic splice 
site, it is likely that these mutations act directly to reduce splicing factor binding, and 
thereby reduce the use of the cryptic A1321. However, only the T1311C mutation had a 
marginal effect on the predicted strength of A1321, reducing the MaxEnt score from7.03 to 
6.09 (Table 3.2), while G1326A had no effect on the MaxEnt score, yet this mutation 
abolished the use of A1321 as an acceptor. Mutations in mutant B may have created or 
revealed a splicing factor binding site that was otherwise limiting for the use of the cryptic 
A1321 in a manner that was reversed by the G1326A and T1311C revertant mutations. 
To map mutations in A and B that were responsible for activating cryptic splice sites D1169 
and A1321 respectively, we generated a set of mutant viruses (AA, AB, AC, AD, AE and 
BA, BB, BC, BD, BE) that contained subsets of the synonymous mutations present in 
mutants A and B (Figure 4.2D, E). We also designed a fluorescent primer-based PCR-
PAGE assay in which a PCR primers were positioned to conveniently and specifically 
monitor the major aberrant splicing event in mutants A and B which, as expected, yielded 
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PCR product consistent with splicing at the respective cryptic splice sites (D1169 and A1321, 
respectively) (Figure 4.2F, G). Surprisingly, none of the secondary mutants containing 
subsets of the A and B mutations recapitulated the effects of the A and B mutations 
(Figure 4.2F, G). Thus, the activation of the cryptic splice sites by the Group 2a mutants 
A and B was the result of multiple synonymous changes in those mutant viruses. 
Additionally, the apparent inability of MaxEnt scoring to consistently predict cryptic site 
utilization in the context of these mutants indicated that splicing defects could not be due 
solely to direct enhancing effects of mutations on specific cryptic sites. 
Group 2b: Overuse of canonical splice sites 
For mutant I, which exhibits overuse of A1 and A2, as well as the corresponding donors 
(D2 and D3) positioned immediately 3’ to A1 and A2, (Figure 4.3A) we failed to obtain 
revertant replication competent viruses, even after extended passage. Therefore, we 
divided the I segment into 5’ and 3’ halves and generated two derivative mutant viruses 
(IA and IB) each of which had approximately half the of the synonymous mutations that 
were present in I (Figure 4.3A). Both IA and IB mutants also exhibited splicing defects 
that were primarily manifested as overuse of A1, but these defects were less complete, 
in that some degree of direct splicing to downstream acceptors (e.g. A5) was present in 
both IA and IB (Figure 4.3B). Notably, IA exhibited oversplicing at A1 and (unlike the 
parent mutant I) the cryptic splice donor D2b. Conversely IB exhibited direct oversplicing 
at both A1 and, to some degree, to A2 but not D2b (Figure 4.3B). 
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Both IA and IB could replicate with delayed kinetics compared to HIV-1NHG, and extended 
passage of IA and IB yielded point mutation revertants that could replicate with kinetics 
close to those of HIV-1NHG (Figure 4.3C, D, Figure 4.1). In the case of IA, a T4904A 
mutation occurred in the A1 polypyrimidine tract (Figure 4.3A, C). This caused a profound 
reduction of splicing at A1 and likely as a consequence, reduction of the inclusion of SX1 
(A1-D2) in spliced RNAs (Figure 4.3B). Use of the cryptic D2b site was also abolished in 
the IA(T4904A) revertant. In fact, other than underuse of A1 and reduced inclusion of SX1, 
the IA(T4904A) revertant had a near normal splicing pattern Thus, activation of canonical 
and cryptic downstream splice donors in mutant IA appeared to be secondary to activation 
of A1. 
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Figure 4.3: Activation of canonical splice acceptor sites (A1 and A2) by 
synonymous mutations in mutant I 
(A) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutant I, 
indicating positions of mutant derivatives (IA, IB, IC….etc), and the positions of splice 
sites and revertant mutant sites (blue arrows). Blocks colored blue are those that 
conferred overt splicing perturbations when mutated. (B) Next gen sequencing analysis 
of HIV-1 splicing in transfected 293T cells. The heatmap indicates relative proportion of 
sequencing reads that indicate direct splicing to the indicated acceptors or inclusion of 
the short exons (SX1 and/or SX2) as indicated at the bottom of the heatmap for WT(HIV-
1NHG), mutants I, IA, IB and revertants thereof. (C, D) MT4 cells were infected with the 
indicated virus (harvested from the supernatant of 293T cells transfected proviral 
plasmids representing WT(HIV-1NHG), mutant (I, IA, IB and revertants thereof) at an MOI 
of 0.002. Aliquots of infected cells were withdrawn each day and the proportion of infected 
cells determined by FACS analysis of GFP expression. (E, F) Fluorescent primer PCR 
analysis of HIV-1 splicing. 293T cells were transfected with the indicated WT and mutant 
proviruses, RNA extracted and cDNA synthesized. A sense PCR primers situated 5’ to 
the major splice donor, was used along with an antisense primer positioned either 3’ to 
A7 (labelled with IRD800) to amplify cDNAs derived from the 1.8 kb class of spliced HIV-
1 mRNAs. PCR products were subjected to PAGE and a LI-COR Odyssey scanner was 
used to detect fluorescent signals directly from the gels. Salient mRNA species 
determined by direct sequencing of extracted gel bands, or inferred from Nextgen 
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For mutant IB, the situation was more complex; a revertant (G4912A) was recovered after 
passage (Figure 4.1), precisely at the A1 acceptor that abolished the use of A1, and 
consequently the inclusion of SX1 into spliced mRNA (Figure 4.3A, B, D). However, 
significant overuse of A2, and consequent inclusion of SX2 (A2-D3) remained evident in 
the IB(G4912A) revertant (Figure 4.3B). Indeed, overuse of A2 was more prominent in 
the IB(G4912A) revertant than in IB, perhaps because of the functional removal of A1 
(Figure 4.3B).  It was therefore apparent that native sequences within IA result in 
suppression of splicing at A1, while sequences within IB cause suppression of splicing at 
both A1 and A2. 
To map elements within IA and IB that control splicing at A1 and A2, we used the 
fluorescent PCR-based assay to analyze the pattern of splicing for viruses containing 
subsets of the IA and IB mutations. For IA, analysis of viruses containing smaller 
component mutant elements (IC and ID, Figure 4.3A) revealed that aberrant splicing was 
conferred only by the ID element (Figure 4.3E). Thereafter, when ID was subdivided into 
ID1 and ID2, it was evident that the controlling element resided primarily within ID2 (Figure 
4.3E). Thus, this analysis revealed a 48 nucleotide sequence that appeared to suppress 
splicing at A1. Notably, a novel ESS/ESE element, termed ESS2b/ESE2b was recently 
identified that nearly precisely coincides with ID2, indicating that our approach has the 
potential to identify novel splicing regulatory signals (Brillen et al., 2017). 
Notably, the unmutated IA segment contained short runs of three G’s (G3) that have been 
reported to constitute hnRNP binding sites which suppress the activation of the cryptic 
splice donor D2b. The mutations in IA disrupted two of these G3 runs (Figure 4.3A) and 
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D2b was used in ~17% of IA spliced reads. The revertant mutation IA(4904) was able to 
inhibit activation of D2b from 17% to 2% (Figure 4.3B), suggesting that the activation of 
D2b is predominately a secondary effect of A1 overutilization, Nevertheless, one of the 
G3 motifs coincides with the ID2 segment and therefore disruption of the G3 motifs may 
also contribute to the activation of the cryptic D2b site. 
For IB the situation was more complex, as mutations in this segment control splicing at 
both A1 and A2. Nevertheless, subdivision of the IB mutations into components IE and IF 
(Figure 4.3A), revealed that the majority the effect of IB mutations were conferred by 
mutations in IF. However, IF did not exhibit as prominent a degree of perturbation as IB 
(Figure 4.3E). Even though the splicing of mutant IE appeared normal, mutations in IE 
made some contribution to the defects present in IB (Figure 4.3E). Subdivision of IF into 
IF1 and IF2 yielded viruses with a normal pattern of splicing (Figure 4.3F). Thus, it was 
evident that multiple sequences acting together in IB, distributed over IE, but primarily 
concentrated in IF1 and IF2, regulate splicing at A1 and A2 and their overall contributions 
could not be mapped through this approach to a single small candidate regulatory 
element. 
For mutant J, which exhibited overuse of A2 and D3 we also failed to obtain revertant 
replication competent viruses, even after extended passage. Therefore, we divided the J 
segment into 5’ and 3’ halves and generated two derivative mutant viruses (JA and JB, 
Figure 4.4A). Although there was some degree of splicing perturbation in JB (Figure 4.4B), 
this perturbation was modest compared to J and JA. Moreover, JB was only marginally 
delayed in spreading replication assays compared to HIV-1NHG. (Figure 4.4C). Therefore, 
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we did not attempt to select JB revertants. Conversely, JA recapitulated the splicing 
perturbation observed in J, and was replication defective (Figure 4.4B, D). Extended 
passage of mutant JA yielded a revertant mutation (G5463A) that enabled replication 
(Figure 4.4D, Figure 4.1). Notably, the reversion mutation was precisely at, and 
inactivated donor D3 (Figure 4.4A), but also abolished splicing to A2 (Figure 4.4B). The 
enhancing effect of D3 on A2 splicing has previously been demonstrated (Stoltzfus, 2009). 
Interestingly, even though D3 appeared to be required for splicing at A2 only a fraction of 
RNAs that are spliced to A2 are also spliced at D3. It was notable that the JB mutants as 
well as the JA(G5463A) revertant exhibited some oversplicing to A1 (and therefore 
elevated inclusion of SX1) even though the J mutant sequences were distal (~440 to 890 
nucleotides) to A1 (Figure 4.4A, B). 
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Figure 4.4: Activation of canonical splice acceptor site A2 by synonymous 
mutations in mutant J 
(A) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutant J, 
indicating positions of mutant derivatives (JA, JB, JC….etc), and the positions of splice 
sites and revertant mutant sites (blue arrows). Blocks colored blue are those that 
conferred overt splicing perturbations when mutated. (B) Next gen sequencing analysis 
of HIV-1 splicing in transfected 293T cells. The heatmap indicates relative proportion of 
sequencing reads that indicate direct splicing to the acceptors or inclusion of the short 
exons (SX1 and/or SX2) indicated at the bottom of the heatmap for WT(HIV-1NHG), 
mutants J, JA, JB and revertants thereof. (C, D) MT4 cells were infected with the indicated 
virus (harvested from the supernatant of 293T cells transfected proviral plasmids 
representing each of the WT(HIV-1NHG), mutant or revertant viruses at an MOI of 0.002. 
Aliquots of infected cells were withdrawn each day and the proportion of infected cells 
determined by FACS analysis of GFP expression. (E, F) Fluorescent primer PCR analysis 
of HIV-1 splicing. 293T cells were transfected with the indicated WT (HIV-1NHG) and 
mutant proviruses, RNA extracted and cDNA synthesized. A sense PCR primer situated 
5’ to the major splice donor, was used along with an antisense primer positioned either 3’ 
to A7 (labeled with IRD800) to amplify cDNAs derived from the 1.8 kb class of spliced 
HIV-1 mRNAs. PCR products were subjected to PAGE and a LI-COR Odyssey scanner 
was used to detect fluorescent signals directly from the gels. Salient mRNA species 
determined by direct sequencing of extracted gel bands, or inferred from Nextgen 







































































































































































To map elements within JA that control splicing, we used the fluorescent PCR-based 
assay for the 1.8 kb HIV-1 mRNAs to analyze viruses containing subsets of the JA 
mutations. We divided the JA mutant segment into 5’ and 3’ halves in two derivative 
mutant viruses (JC and JD, Figure 4.4A) which both exhibited some degree of perturbed 
splicing (Figure 4.4E). Further subdivision of JC into JC1, JC2 and JC3 clearly suggested 
that the 20 nucleotide JC2 segment contained an element whose mutation was primarily 
responsible for the perturbed splicing in JC (Figure 4.4E), but further division of 20 
nucleotide JC2 yielded two mutant segments (JC2A and JC2B) both of which cause 
perturbed splicing to nearly the same degree as the J, JA, JC and JC2 mutant segments 
from which they were derived (Figure 4.4F). Division of the JD segment into JD1 and JD2 
clearly revealed another element within the 46 nucleotide JD1 segment, that when 
mutated yielded a oversplicing pattern similar to that of the J mutant virus (Figure 4.4E). 
Thus, multiple mutations within the JA fragment, contained within the segments JC2 and 
JD1 were capable of causing oversplicing defects similar to those observed in the J 
mutant. 
 Group 2b: A discrete RNA sequence regulates HIV-1 splicing at A3 
For mutant K (Figure 4.5A), which exhibits overuse of A3 (Figure 4.5B), it proved 
straightforward to recover a revertant mutant virus through passage that corrected the 
splicing defect and replicated well (Figure 4.5B, C, Figure 4.1). This revertant contained 
two mutations, one of which (C5774T) was sufficient to restore replication to near WT 
kinetics (Figure 4.5C). This functional reversion mutation was 3 nucleotides from A3. 
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Notably the K(C5774T) revertant not only corrected overuse of A3 but exhibited a splicing 
pattern that was nearly indistinguishable from that of HIV-1NHG (Figure 4.5B). This was 
surprising because previous studies have reported that CAG and TAG are used at a 
similar efficiency as 3’ splice acceptors in the context of HeLa cell nuclear extracts (Smith 
1993). The remarkable diminution of splicing in the K(C5774T) reversion mutant suggests 
that in the context of A3, the TAG is far less well utilized than CAG. Further, the A3 MaxEnt 
score of is increased from 9.76 to 10.05 in the context of the K(C5774T) reversion mutant, 
predicting that A3 is a stronger acceptor in K(C5774T). However, experimentally the 
reverse is the case, demonstrating the limitation of both in silico and in vitro analyses to 
predict splicing phenotypes in the context of a full-length HIV-1 construct in a living cell. 
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Figure 4.5: Activation of canonical splice acceptor site A3 by synonymous 
mutations in mutant K 
(A) Schematic representation of the mutant blocks of nucleotides in HIV-1 mutant K, 
indicating positions of mutant derivatives (KA, KB, KC….etc), and the positions of splice 
sites and revertant mutant sites (blue arrows). Blocks colored blue are those that 
conferred overt splicing perturbations when mutated. (B) Next gen sequencing analysis 
of HIV-1 splicing in transfected 293T cells. The heatmap indicates relative proportion of 
sequencing reads that indicate direct splicing to the acceptors or inclusion of the short 
exons (SX1 and/or SX2) indicated at the bottom of the heatmap for WT(HIV-1NHG), mutant 
K and the C5774T revertant. (C) MT4 cells were infected with the indicated virus 
(harvested from the supernatant of 293T cells transfected proviral plasmids representing 
each of the WT(HIV-1NHG), mutant or revertant viruses at an MOI of 0.002. Aliquots of 
infected cells were withdrawn each day and the proportion of infected cells determined 
by FACS analysis of GFP expression. (D-F) Fluorescent primer PCR analysis of HIV-1 
splicing. 293T cells were transfected with the indicated WT (HIV-1NHG) and mutant 
proviruses, RNA extracted and cDNA synthesized. A sense PCR primer situated 5’ to the 
major splice donor, was used along with an antisense primer positioned either 3’ to A7 
(labeled with IRD800) to amplify cDNAs derived from the 1.8 kb class of spliced HIV-1 
mRNAs. PCR products were subjected to PAGE and a LI-COR Odyssey scanner was 
used to detect fluorescent signals directly from the gels. Salient mRNA species 
determined by direct sequencing of extracted gel bands, or inferred from Nextgen 














































































































































To map sequences within the K mutant that were responsible for causing oversplicing, 
we divided the K mutant segment into two halves (KA and KB, Figure 4.5A) and analyzed 
the pattern of 1.8 kb mRNAs using the fluorescent primer PCR assay. This analysis 
revealed that mutations responsible for A3 overuse resided in KA (Figure 4.5D). Then, 
further subdivision of KA (into KC and KD) revealed that KD contained the controlling 
element(s) (Figure 4.5D). Finally, subdivision of KD (into KD1 and KD2) showed that KD2 
contained RNA sequences whose mutation caused oversplicing (Figure 4.5E), but further 
subdivision of KD2 (into KD2A and KD2B) showed that mutations in both of these KD2 
components contributed its effect (Figure 4.5F). Thus, a 23-nucleotide element (KD2) 
positioned >100nt from A3 contained an RNA element whose sequence influences 
splicing at A3. 
 Summary 
Through synonymous mutations in the HIV-1 genome , these studies demonstrated the 
importance and complexity of the non-coding sequences in relation to alternative splicing. 
We have described a small and discrete element that controls splicing of a single splice 
site, but more frequently, we found large RNA elements that cannot map to a small 
sequence and have effects on multiple splice sites. Additionally, we have shown the 
flexibility of the HIV-1 genome. Our synonymous mutations profoundly attenuated the 
replication of the viruses, yet  acquisition of a single second site revertant mutation was 
able to completely restore replication to the virus, overcoming the deleterious effects of 
hundreds of mutations. 
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Chapter 5. ZAP mediated restriction of CG-enriched HIV 
While the precise mechanism driving splicing defects in the previous chapter remain 
unclear, division of the mutations into smaller segments allowed us to follow which sets 
of mutations were responsible for inhibiting the replication of the virus. Largely using this 
strategy, we catalogued regions of the HIV-1 genome that are responsible for control over 
different splice sites. Pairing this approach with the PCR splicing assay allowed for a fast 
and reliable read out for mapping perturbations to splicing. Initially, we applied this same 
approach to the group 3 mutants, but this yielded limited success due to the absence of 
a clear phenotype beyond fitness in a spreading replication assay. Conversely, initial 
studies with group 1 mutants yielded no detectable defect in splicing, single cycle infection 
mRNA or protein expression, or spreading replication assays, and therefore further 
characterization did not seem relevant. 
Inhibitory effects of CG dinucleotides on HIV replication 
Group 3 mutants yielded near normal infectious titers when proviral plasmids were 
transfected in 293T cells and lacked an obvious splicing defect. Unexpectedly the virions 
collected were only capable of infecting cells in a single cycle and completely  defective 
in spreading replication assays (Figure 5.2A; Figure 5.1B, C). For two defective group 3 
mutant viruses, termed L and M, mapping experiments employing derivatives containing 
smaller mutant segments, termed LA-LF and MA-MD (Figure 5.1A, B, C and D) revealed 
that their replication defects were not caused by perturbation of a single discrete element. 
Indeed, mutants LC, LD, LE, LF, MA, MC, and MD, which collectively represented all 
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mutations in the defective mutants L and M, each replicated with near HIV-1WT kinetics 
(Figure 5.1 C and D). Moreover, when the mutations in four replication-competent pol 
mutants (E though H, Figure 5.1 A) were combined, the resulting mutant virus (EH) was 
defective (Figure 5.1 E). Thus, HIV-1 replication defects could be induced by the 
cumulative effects of synonymous mutations in pol or env. 
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Figure 5.1: Synonymous mutagenesis reveals inhibitory effects of CG 
dinucleotides on HIV-1 replication 
(A) Schematic representation HIV-1NHG GFP provirus, showing locations of synonymous 
mutant blocks, and corresponding phenotypes. (B-E), Spreading replication of HIV-1 
mutants in MT4 cells, as measured by FACS enumeration of infected cells over time. (F), 
Number of CG dinucleotides present in a 200 nucleotide sliding window in the indicated 
viral and random sequences. (G), Spreading replication of HIV-1 mutants in MT4 cells, 
are measured by FACS enumeration of infected cells over time. (H), Spreading replication 
of HIV-1 mutants in primary lymphocytes, as measured by reverse transcriptase activity 
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Analysis of the HIV-1 genome reveals that it is remarkably sparse in C mononucleotides 
and particularly deficient in CG dinucleotides, like many vertebrate viruses  (Figure 5.1F) 
(Cheng et al., 2013). Our synonymous mutagenesis coincidentally increased the CG 
dinucleotide content in mutant segment of viruses L an M, to a level similar to that of 
random sequence, and to a lesser degree in the individual mutants E through H (Figure 
5.1F). We generated derivatives of mutant L, termed LCG and LOTH, respectively, 
containing only mutations that generated new CG dinucleotides (39/145 original 
mutations) or the 117 other mutations. We also generated mutants that maximized the 
CG or GC dinucleotide content in the same segment (LCG-HI and LGC-HI) (Table 5.1). 
Strikingly, LCG and LCG-HI were replication defective in MT4 cells, while LOTH and LGC-HI
replicated with near HIV-1WT kinetics (Figure 5.1G). Mutants L and LCG-HI also replicated 
at ~100-fold lower levels than HIV-1WT and LGC-HI in primary lymphocytes (Figure 5.1H, 
Figure 5.2B, C).This removal a subset of mutations, particularly those that added a CG 
dinucleotide, decisively links the replication defects observed with the increase CG 
content of the HIV-1 genome, with 37 synonymous mutation capable of completely 
inhibiting viral replication in MT4 cells. 
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Table 5.1: Mutations in the HIV-1 L mutant and its derivatives 
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Figure 5.2: CG-enriched HIV-1 clones yield near WT levels of virus from 
transfected 293T cells but are attenuated in replication in primary lymphocytes 
(A) Yield of infectious virus from proviral plasmid transfected 293T cells, as measured by 
infection of MT4 cells (mean ± sd, n=3 to 5 independent experiments). (B, C) Spreading 
replication of HIV-1 mutants in primary lymphocytes from two additional donors as 
measured by reverse transcriptase activity in the supernatant of infected cells over time. 





























Extended Data Fig. 1






























































CG dinucleotides cause depletion of cytoplasmic RNA 
To understand the basis for replication defects in the CG-enriched HIV-1 mutants, we 
infected MT4 cells with equal titers of each virus in single-cycle replication experiments. 
Notably L, LCG and LCG-HI infected cells generated ~1000-fold fewer infectious progeny 
virions than LOTH and LGC-HI infected cells (Figure 5.3A). Infectious virion yields from EH 
infected cells were similarly reduced (Figure 5.4A). Western blot analyses revealed 
abnormally low levels of Gag and Env proteins in cells infected with L, LCG and LCG-HI, but 
HIV-1WT levels for LOTH and LGC-HI (Figure 5.3B). Expression of the gfp reporter that was 
embedded in the nef gene and therefore expressed via an mRNA from which the L 
segment is removed by splicing (Fig 5.3C) was equivalent for each virus, as measured 
by western blotting or flow cytometry (Fig 5.3B, Figure 5.4B). A deficit in Gag levels also 
occurred in EH infected cells. However, normal levels of both Env and GFP proteins, 
whose spliced mRNAs lack the CG-enriched segment, were generated in EH infected 
cells (Figure 5.4C), suggesting that the inclusion of CG dinucleotides into RNA only 
affects the corresponding protein expression when they are included as exons. 
Unspliced viral RNA levels, measured by RT-PCR, in single-cycle infected MT4 cells were 
5 to 10-fold lower in L, LCG, LCG-HI and EH infected cells and at HIV-1WT levels for LOTH, 
LGC-HI, E, F, G, or H infected cells (Figure 5.3D, Figure 5.4D). Single molecule 
fluorescence in situ hybridization (smFISH) experiments using a gag probe revealed that 
the deficit in unspliced viral RNA occurred specifically in the cytoplasm in LCG-HI infected 
cells, while nuclear levels were normal (Figure 5.3E, F, Figure 5.5). Similar smFISH 
experiments employing a probe that detected all spliced and unspliced viral RNAs (Figure 
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5.3C) revealed a marginal, statistically ambiguous deficit for LCG-HI (Figure 5.4E, Figure 
5.6), consistent with the notion that unspliced RNA (that represent only a subset of total 




Figure 5.3: CG dinucleotides cause depletion of cytoplasmic RNA 
(A) Yield of infectious virus, in a single-cycle of replication following infection of MT4 cells 
with equal titers of HIV-1WT and mutants (mean ± sd n=3 independent experiments). (B) 
Western blot analysis (anti-Gag, anti-Env anti-GFP and anti-Tubulin) of viral, reporter and 
cellular protein expression 48h after a single-cycle infection of MT4 cells with WT and 
synonymous env mutant HIV-1. (C) Location of exons for salient mRNAs (black lines), 
mutated segments (red shading) and smFISH probes (green shading) in HIV-1 sequence. 
(D) Q-RT-PCR quantification of unspliced RNA in MT4 cells in a single-cycle infection 
assay (mean ± sd n= 2-4 independent experiments). (E) Quantification of RNA molecules 
(fluorescent spots) by smFISH in cytoplasm (open symbols) and nucleus (filled symbols) 
using a probe for unspliced RNA in gag after infection of HOS/CD4-CXCR4 cells. Each 
symbol represents nucleus or cytoplasm of an individual cell. Horizontal lines represent 
mean values. P-values were determined using Mann-Whitney test. (F) Examples of 
smFISH analysis of an HIV-1WT and mutant infected cell (red=smFISH gag probe, 
green=GFP, blue=Hoescht dye) blue line indicates nucleus/cytoplasm boundary. 
 


































































































































Figure 5.4: Effects of CG dinucleotides on the HIV-1 infectious virion yield, RNA 
and protein levels in a single-cycle replication assays 
(A) Yield of infectious virus in a single cycle of replication following infection of MT4 cells 
with equal titers of HIV-1WT and pol mutants (mean ± s.e.m., n = 3 independent 
experiments). (B) Expression of gfp in MT4 cells, as measured by flow cytometry, 48 h 
after infection with equal titers of the indicated viruses. Numerical values are mean 
fluorescent intensity (MFI) of infected cells (indicated by the dotted box). (C) Western blot 
analysis (anti-Gag, anti-Env, anti-GFP and anti-HSP90) of viral, reporter and cellular 
protein expression, 48 h after a single cycle of infection of MT4 cells with wild-type and 
synonymous pol mutant HIV-1. Representative of three experiments. (D) RT–qPCR 
quantification of unspliced RNA in MT4 cells in a single- cycle infection assay with wild-
type and synonymous pol mutant HIV-1 (mean ± s.e.m., n = 2 or 3 independent 
experiments). (E) Quantification of RNA molecules (fluorescent spots) by smFISH in 
cytoplasm using a probe targeting all spliced and unspliced HIV-1 RNA species after 
infection of HOS/CXCR4-CD4 cells. Each symbol represents an individual cell. Horizontal 
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Figure 5.5: smFISH quantification of unspliced HIV-1 RNA in infected cells 
Examples of smFISH analysis of wild-type and synonymous mutant HIV-1-infected cells 
(red, smFISH gag probe (see Figure 5.3C); green, GFP; blue, Hoescht dye). The boxed 
areas indicate regions selected for expanded views in Figure 5.3F Clusters of RNA 
molecules in the nuclei of some infected cells may represent sites of proviral integration. 
Representative of three independent experiments. Scale bar, 5 μm. 
Extended Data Fig 3







Figure 5.6: smFISH quantification of total HIV-1 RNA in infected cells 
Examples of smFISH analysis of wild-type and synonymous mutant HIV-1-infected cells  
(red, smFISH probe targeting all viral mRNA species (see Figure 5.3C); green, GFP; blue, 
Hoescht dye). Clusters of RNA molecules in the nuclei of some infected cells may 
represent sites of proviral integration. Representative of three independent experiments. 
Scale bar, 5 μm.  
Extended Data Fig. 4







ZAP specifically inhibits CG-enriched HIV-1 replication 
A deficit in levels of CG-containing RNA and their protein products appeared be the 
foundational defect in cells infected with the defective viral mutants L, LCG ,LCG-HI and EH. 
Therefore, we conducted a focused siRNA screen targeting proteins implicated in 
cytoplasmic RNA degradation pathways, e.g. microRNA, nonsense mediated decay, and 
RNA exosome pathways (Figure 5.7A, Figure 5.8A). Single-cycle replication experiments 
in HeLa cells revealed that knockdown of zinc finger antiviral protein (ZAP) nearly 
completely restored infectious virion yield from LCG-HI infected cells (Figure 5.7A). 
Knockdown of TRIM25, which enhances ZAP activity, also substantially restored viral 
yield. 
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Figure 5.7: ZAP specifically inhibits CG-enriched HIV-1 replication 
(A) Yield of infectious virus, in a single-cycle of replication following infection of siRNA 
transfected Hela cells with equal titers of HIV-1WT and LCG-HI mutant (mean ± sd n=3 
independent experiments). (B) Western blot analysis of ZAP expression following 
CRISPR mutation of ZAP exon 1 in MT4 cells. (C-G) Spreading replication of HIV-1 
mutants in control (ZAP+/+), ZAP-knockout (ZAP-/-) and doxycycline-inducible ZAP 
(ZAPDI) reconstituted MT4 cells, as measured by FACS enumeration of infected cells over 
time. (H) Western blot analysis (anti-Gag, anti-Env anti-GFP and anti-Tubulin) of viral, 
reporter and cellular protein expression in cells and virions 48h after a single-cycle 
infection of ZAP+/+ and ZAP-/- MT4 cells with WT and mutant HIV-1. (I) Q-RT-PCR 
quantification of unspliced RNA in MT4 cells in a single-cycle infection assay (mean ± sd 
n=3 independent experiments). (J, K) Luciferase expression following transfection of Hela 
(J) or HeLa ZAP-/- (K) with reporter plasmids incorporating the indicated HIV-1 RNA 
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We generated ZAP-/- MT4 cells lacking both major ZAP isoforms (ZAP-L and ZAP-S, 
Figure 5.8B) using CRISPR/Cas9-based approaches. Strikingly, this manipulation 
restored replication competence to all of the defective CG-enriched viruses, but did not 
affect HIV-1WT or LGC-HI replication (Figure 5.7C-G). Indeed, LCG-HI and EH were defective 
in unmanipulated MT4 cells, but replicated indistinguishably from HIV-1WT in ZAP-/- MT4 
cells. In single-cycle replication experiments, the deficits in Gag and Env protein levels 
observed with CG-enriched viruses were abolished in ZAP-/- cells (Figure 5.7H). 
Reconstitution of ZAP-/- MT4 cells with a CRISPR-resistant, doxycycline-inducible ZAP-S 
construct [ZAPDI] enabled doxycycline-dependent inhibition of CG-enriched virus 
replication, and protein expression in single cycle assays, but did not affect HIV-1WT 
(Figure 5.7C-G, Figure 5.8B, C). Moreover, the deficit in unspliced viral RNA that was 
evident in CG-enriched virus-infected cells was abolished in ZAP-/- cells, and reinstated 
in a doxycycline-dependent manner in [ZAPDI] reconstituted ZAP-/- cells (Figure 5.7I). 
Taken together, suggesting that ZAP is required for the inhibition of the CG-high viruses 
and through destabilizing the CG-high, with no detectable effect on the replication of the 
wild-type HIV-1. 
We transferred the L-mutant segment and its derivatives into a heterologous context, 
namely the 3’UTR of a reporter construct encoding a fluc gene from which we depleted 
CG-dinucleotides (Figure 5.9A). When these constructs were transfected into wild-type 
HeLa cells, he CG-enriched L-derived elements inhibited luciferase expression by ~5-fold 
(Figure 5.7J). Notably, these inhibitory effects were abolished when ZAP-/- HeLa cells 
were transfected, consistent with the notion that ZAP is inhibiting the expression of CG-
113 
high RNA. (Figure 5.7K; Figure 5.9B). Similar constructs containing 3’UTR fragments 
derived from naturally CG-suppressed vesicular stomatitis virus or influenza virus-derived 
RNA sequences (Cheng et al., 2013; Greenbaum et al., 2008) (Figure 5.9A, C) revealed 
that elevating CG-dinucleotide content of these sequences conferred sensitivity to 
inhibition by coexpressed ZAP-L in cotransfection assays (Figure 5.9D). Importantly, 
these studies demonstrate that ZAP is capable of inhibiting mRNA outside of the context 
of a replicating virus purely based on their CG-high content. 
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Figure 5.8: ZAP mediates deleterious effects of CG dinucleotides on HIV-1 
replication 
(A) Western blot analyses, using the indicated antibodies, following transfection of HeLa 
cells with the corresponding siRNAs, or control siRNAs, in the single-cycle replication 
assays described in Fig. 3a. Representative of 2 experiments. (B) Western blot analysis 
of ZAP expression in control, CRISPR-knockout MT4 cells and doxycycline-inducible 
ZAP-S-reconstituted MT4 cells. Asterisks indicate protein species that appeared in some 
CRISPR knockout clones, reacted with an anti-ZAP antibody and arose after extended 
passage. These are likely to represent truncated forms of ZAP-L whose translation 
initiated at methionine codons 3′ to the CRISPR target site (near the ZAP N terminus). 
Representative of three experiments. (C) Western blot analysis (anti-Gag, anti-Env, anti-
GFP and anti-tubulin) of viral and cellular protein levels in cells and virions, 48 h after 
single-cycle wild-type or mutant HIV-1infection of ZAP−/− MT4 cells that had been
reconstituted with a doxycycline-inducible ZAP-S expression construct (ZAPDI) and left 
untreated or treated with doxycycline. Representative of three experiments. 
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Figure 5.9: CG dinucleotides in 3’ UTR confer sensitivity to inhibition by ZAP 
(A) Schematic representation of a reporter construct encoding a CG dinucleotide-
depleted fluc cDNA into which were inserted the indicated sequences as 3′ UTRs. (B) 
Western blot analysis of ZAP expression following CRISPR mutation of ZAP exon 1 in 
HeLa cells. Representative of three experiments. (C) Number of CG dinucleotides present 
in a 200-nucleotide sliding window in the indicated viral cDNA sequences that were left 
unmanipulated (WT) or recoded with synonymous mutations to contain the maximum 
number of CG dinucleotides (CG+). (D) Luciferase expression following transfection of 
293T ZAP−/− cells with CG dinucleotide-depleted fluc reporter plasmids incorporating the
indicated VSV or influenza A virus (IAV) RNA sequences as 3′ UTRs, in the presence or 















































































































































ZAP binds directly and preferentially to CG-dinucleotide containing RNA 
ZAP has been reported to bind RNA, but no shared features of its reported target 
sequences are evident. To determine the RNA binding specificity of ZAP, we used 
crosslinking-immunoprecipitation-sequencing (CLIP-seq) assays in cells infected with 
HIV-1WT or mutant L.  Remarkably, ZAP bound to the HIV-1 genome predominantly at a 
location that precisely coincided with the CG-enriched segment in mutant L (Figure 5.10A, 
B). Conversely, ZAP bound less frequently to HIV-1WT and the unaltered portions of the 
L genome, but those binding sites coincided with the rare occurrence of CG dinucleotides 
(Figure 5.10A, B). 
Although the L mutant genome was the single most frequently bound RNA in infected 
cells, ZAP also bound cellular mRNAs (Figure 5.11B). CG-suppression is marked in 
human mRNA ORF and 3’UTR sequences (Figure 5.11C, D)  but was absent in the 
subset of these sequences that represented the 100 most preferred ZAP binding sites 
(Figure 5.11E). A more detailed analysis of dinucleotides that are underrepresented (CG 
and UA) or overrepresented (UG) in ORFs and 3’UTRs as well as an ‘inverted CG’ control 
dinucleotide (GC), revealed that ZAP binding sites were highly CG-enriched (Figure 
5.10C). Conversely, UA, UG or GC dinucleotides were present in preferred ZAP binding 
elements at frequencies typical of ORFs and 3’UTRs (Figure 5.10C). A control RNA 
binding protein showed no preference for CG-enriched elements (Figure 5.11G). 
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Figure 5.10: ZAP binds directly and preferentially to CG dinucleotide-containing 
RNA 
(A) CLIP analysis of the frequency with which L mutant and HIV-1WT RNA sequences are 
bound to ZAP in infected cells, versus their position in the viral genome. Positions of CG 
dinucleotides are indicated as blue lines. The L-mutant segment occupies positions 6307 
to 6805. (B) Expanded views of the CLIP graphs in (A), showing unaltered portions of the 
sequence (left, middle) and a portion containing the mutant L segment (right). (C) 
Frequency distributions of CG, GC, UA and UG dinucleotide observed/expected 
frequencies in human ORFs, 3’UTRs and top 100 ZAP-binding sites. P-values for 
comparisons of ZAP binding sites and ORFs or 3’UTRs were calculated using Welch’s 






















































































































































vs ORF   :  P<5x10-11
vs 3’UTR : P<5x10-16
vs ORF   :  NS
vs 3’UTR : NS
vs ORF   :  P<5x10-6
vs 3’UTR : NS
vs ORF   :  P<0.0005




Figure 5.11: Dinucleotide composition of ORFs, 3’UTRs, and preferred ZAP 
binding sites in cellular mRNAs 
(A) Sources of RNA reads bound to ZAP in a typical CLIP-seq experiment, done using 
HIV-1 infected cells (B-D), Ratio of the observed frequency to the expected frequency 
(obs/exp, based on mononucleotide composition) for each of the 16 possible 
dinucleotides, in ORFs (B), 3’ UTR (C) sequences as well as the 100 sites in cellular 
mRNAs that were most frequently bound by ZAP, based on CLIP read numbers (d). 
Plotted values are mean ± sd of all ORF and 3’UTRs in the respective libraries or n=100 
most preferred ZAP binding sites. (E) Frequency distributions of CG dinucleotide 
observed/expected frequencies in human ORFs, 3’UTRs and top 100, top 1,000 and top 
10,000 ZAP-binding sites in CLIP experiments. The top 100, top 1,000 and top 10,000 
ZAP-binding sites account for 6.7%, 18.9% and 46.7% of total reads. (F) Frequency 
distributions of CG, GC, UA and UG dinucleotide observed/expected frequencies in 
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Further examination of the group 3 viruses that did not possess a splicing defect, yet had 
a profound replication defect revealed that it was the coincidental addition of CG 
dinucleotides that were responsible for their replication defects. The addition of CG 
dinucleotides resulted in decreased levels of unspliced RNA that was restricted to the 
cytoplasm and exonic mRNA. We identified ZAP as the cellular restriction factor 
responsible for specifically inhibiting the replication of these CG-high viruses and 
destabilizing CG-high viral RNA. CLIP-seq analysis of ZAP reveals that has a strong 
preference for binding directly to CG dinucleotides in both cellular and viral RNA despite 
the CG suppression of the human transcriptome, suggesting that ZAP might function as 
an immune sensor that distinguishes self from non-self RNA based on the CG content. It 
remains unclear how ZAP destabilizes the CG-high RNA once bound, and what other 
cofactors might be required in order to do this. 
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Chapter 6. Mechanistic Insights into TRIM25 and ZAP restriction of CG-enriched 
viruses 
In our initial screen that identified ZAP as the protein responsible for the restriction of a 
CG-high HIV-1 also identified a protein that significantly rescued the replication of the 
CG-high virus, TRIM25. As discussed previously, TRIM25 is a member of the tripartite 
motif family of E3 ubiquitin ligases and is an essential cofactor of RIG-I (Gack et al., 2007). 
Two groups identified and confirmed that TRIM25 as a cofactor for ZAP and is not 
required for, but enhances the activity of ZAP (Jiang et al., 2016; Li et al., 2017; Zheng et 
al., 2017). As a follow-up to our initial studies on ZAP mediated restriction of CG-high 
viruses, we sought to better understand how TRIM25 might serve as a cofactor for ZAP 
and attempt to identify other cofactors that are important for ZAP mediated inhibition of 
CG-high viruses. 
RNA binding activity of ZAP in the absence of TRIM25 
It is reported that TRIM25 has an RNA binding domain comprised of seven lysine resides 
N-terminal to the SPRY domain, and these residues are important for the activity as a 
cofactor with RIG-I (Sanchez et al., 2018). Using CLIP-seq experiments we have shown 
that ZAP binds directly to CG dinucleotides in both viral RNA and cellular mRNA. Because 
both ZAP and TRIM25 have RNA binding activity we tested whether TRIM25 contributes 
to the ability of ZAP to recognize of CG-high RNA. To address this, we performed CLIP-
seq experiments either with TRIM25 in the presence and absence of ZAP, or with ZAP in 
the presence and absence of TRIM25 (Figure 6.1). CLIP experiments with TRIM25 
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initially sought to determine whether TRIM25 bound any RNA in 293T cells in the 
presence or absence of ZAP. We also tested these conditions in the presence of either 
wild-type HIV-1 or CG-high HIV-1 (Figure 6.1A). Surprisingly, our crosslinking 
immunoprecipitation of TRIM25 with 32P labeled RNA did not bind any detectable RNA 
under these conditions, indicating that in our experimental conditions, TRIM25 does not 
detectably bind RNA. 
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Figure 6.1: RNA binding activities of TRIM25 and ZAP 
(A) Input and TRIM25-RNA cross-linked complexes were immunoprecipitated from 293T 
cells knocked out for ZAP and TRIM25 reconstituted with TRIM25 and ZAP-L (first two 
lanes) or TRIM25 in the absence of ZAP-L (last two lanes), all cotransfected with either 
HIV-1 wild type or HIV-1 CG-high (as indicated). Cells were transfected to express 3xHA-
tagged-TRIM25 and then fed 4SU and UV-irradiated. Complexes were visualized by 
autoradiography (bottom) and western blot analysis using a polyclonal anti-HA or 
monoclonal anti-HSP90. (B) Input and ZAP-RNA crosslinked complexes 
immunoprecipitated from 293T cells knocked out for ZAP and TRIM25, reconstituted with 
ZAP-L from varies species (Homo sapien, Mus musculus, Eptesicus fuscus, Gallus gallus, 
Alligator mississippiensis, Danio rerio PARP12A, Danio rerio PARP12B, or empty), co-



















then fed 4SU and UV-irradiated. Complexes were visualized by autoradiography (bottom) 
and western blot analysis using a polyclonal anti-HA or monoclonal anti-HSP90.  
Using a similar approach, we tested whether the RNA binding activities of ZAP are 
dependent on the presence of TRIM25. In a crosslinking immunoprecipitation of ZAP in 
the absence of TRIM25, ZAP produced a robust RNA signal, indicating that the general 
RNA binding activity is independent of TRIM25 (Figure 6.1B). Sequencing the RNA pulled 
down by ZAP in the absence of TRIM25 provided further insights. In comparing the 
binding profile of ZAP to the CG-high HIV-1 genome it is clear that ZAP is only bound to 
the HIV-1 genome where a CG dinucleotide is present (Figure 6.2A). There are no peaks 
along the viral RNA in the absence of a CG dinucleotide and its binding is significantly 
enriched at the site of the 43 additional CG dinucleotides near the 5’ end of envelope. 
This indicates that ZAP is capable of recognizing CG dinucleotides in viral RNA 
independent of TRIM25. Analysis of the reads bound by ZAP in open reading frames 
demonstrated that ZAP maintained a strong preference for CG-high RNA irrespective of 
whether TRIM25 is present or absent. (Figure 6.2B). Finally, the species of RNA bound 
by ZAP was virtually identically with or without TRIM25, where the majority of reads going 
came from mRNA (Figure 6.2C). Collectively, these experiments indicate that ZAP is able 
to recognize CG-high mRNA independent of TRIM25. This suggests that TRIM25 
enhances the antiviral activity of ZAP in a mechanism other than aiding ZAP in recognition 
of CG-high RNA. 
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Figure 6.2: RNA targets of human ZAP-L in 293T without TRIM25 expression 
(A) Frequency distribution of nucleotide occurrence (read density) in reads that were 
mapped to the HIV-1NHG CG-high genome. (B) Density plot of the CG odds ratio from the 
top 100 PARalyzer clusters bound by ZAP-L in the presence (magenta) or absence (cyan) 
of TRIM25, compared against the CG odds ratio of the human genome ORFs (red). (C) 
hsZAP NHG CG High
TRIM25 KO





























Origins of individual reads that map to the human genome in ZAP-L CLIP experiments in 
the presence or absence of TRIM25 293T cells transfected with HIV-1NHG CG-high.  
Biological activities of TRIM25 required for activity with ZAP 
Because TRIM25 does not contribute to the ability of ZAP to bind RNA, we sought to test 
the other mechanisms by which TRIM25 could enhance the antiviral activity of ZAP. 
TRIM25 is composed of five domains: RING, B-box, coil-coil, RNA binding, and SPRY 
(Figure 6.3A). The RING domain possess E3 ubiquitin-ligase activity, but also contributes 
to the formation of higher order multimers (Sanchez et al., 2016). The function of the B-
box domain in TRIM25 remains unclear, but in another TRIM protein, TRIM5α, the B-box 
domain is involved in formation of higher order multimers (Li and Sodroski, 2008). The 
coil-coil domain allows the formation of elongated antiparallel dimers (Sanchez et al., 
2014). The SPRY domain has been shown to directly interact with the two proteins for 
which TRIM25 acts as a cofactor: ZAP and RIG-I (Gack et al., 2007; Li et al., 2017). 
Therefore, we tested these four biological activities of TRIM25: the ubiquitin ligase activity, 
formation of higher order multimers, RNA binding activity, and the requirement of the 
SPRY domain. 
To test each of these activities without disrupting the global structure of the protein we 
made point mutations that disrupt the E3 ubiquitin-ligase activity (R54A), higher order 
multimerization (L69A), and RNA binding (7KA), as well as a TRIM25 that does not have 
a SPRY domain (Sanchez et al., 2016; Sanchez et al., 2018). 293T cells that were 
knocked out for both ZAP and TRIM25 were co-transfected with plasmids expressing  (i.) 
either a wild-type or CG-high HIV-1, (ii.) ZAP-S, and (iii.) either a wild-type or mutant 
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TRIM25. The supernatants were filtered and titered on MT4 LTR-GFP cells to determine 
the viral yield. 
When a plasmid expressing either a wild-type or CG-high virus were transfected with 
plasmids expressing ZAP-S and wild-type TRIM25, 50-fold less virus was produced by 
the CG-high virus compared to wild-type HIV-1 (Figure 6.3B). This restriction of the CG-
high virus was dose dependent on amount of ZAP plasmid transfected. Additionally, ZAP 
was incapable of inhibiting the CG-high virus in the absence of TRIM25 (Figure 6.3B). 
The RNA binding mutant of TRIM25 (7KA), which has the patch of seven lysines mutated 
to alanines (Sanchez et al., 2018) was equally capable of restricting production of the 
CG-high HIV-1 as compared to the wild-type TRIM25 (Figure 6.3C). The E3 ubiquitin 
ligase mutant, which is unable to catalyze the addition of ubiquitin (Sanchez 2016), was 
also not reduced in its ability to restrict the CG-high virus when compared to the wild-type 
TRIM25 (Figure 6.3D). The TRIM25 mutant that is unable to form higher order multimers 
(L69A) was 10-fold less functional as a cofactor for ZAP (Figure 6.3E). Finally, the mutant 
of TRIM25 that had no SPRY domain had no detectable activity in this assay. Taken 
together, this data suggests that the RNA binding activity and E3 ubiquitin-ligase activity 
of TRIM25 are dispensable for its activity as a cofactor for ZAP (Figure 6.3F). Further, the 
SPRY domain and the ability of TRIM25 to form higher order multimers appear essential 
to its function as a cofactor for ZAP. 
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Figure 6.3: Antiviral activity of ZAP with different TRIM25 mutants 
(A) Schematic representation of the domains in human TRIM25, arrow and labels below 
indicate the point mutants or introduced into the protein for analysis below. (B-F) 
Infectious virion yield measured using MT4-GFP indicator cells following transfection with 
ZAP-L, TRIM25 mutants, and HIV-1NL4-3 wild-type or HIV-1NL4-3 CG-high (mean ± s.d., 
n=2). (B) TRIM25 wild-type (C) TRIM25 RNA binding mutant 7KA. (D) TRIM25 R54A 
deficient in E3 ubiquitin ligase activity. (E) TRIM25 L69A deficient in proper dimerization 
and formation of high order multimers. (F) TRIM25 truncated to exclude the SPRY domain. 
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Cell type differences of TRIM25 enhancement of ZAP 
The experiments shown above with ZAP and TRIM25 suggest that there might be cell 
type dependence concerning how the activity of ZAP requires TRIM25. siRNA knockdown 
of TRIM25 in HeLa cells only partially rescued the replication of the CG-high virus (Figure 
5.7A). In contrast, when ZAP was expressed without TRIM25 in the 293T double knockout 
cells, ZAP was inactive (Figure 6.3A). While this discrepancy might be to a due to an 
incomplete knockdown in HeLa cells compared to a complete knockout of TRIM25 in the 
293T cells, we wanted to further investigate whether the activity of ZAP differs based on 
the cell line. 
Using a CRISPR guide RNA against TRIM25, we generated TRIM25 knockout MT4 cells. 
With these cells, we sought to understand how ZAP knockout and TRIM25 knockout cells 
compare in restricting the replication of CG-high HIV-1. MT4 wild-type, MT4 ZAP 
knockout, and MT4 TRIM25 knockout cells were infected with either wild-type virus, a 
CG-high HIV-1 or a HIV-1 that has half as many CG dinucleotides as the CG-high virus, 
mutant LB. The MT4 cells were infected at an MOI of 1.0, resulting in approximately 66% 
of the cells becoming infected. Infected cells were analyzed for viral protein expression 
while supernatants were filtered and tested for infectious viral yield by titering the 
supernatants on MT4-GFP cells. 
The CG-high virus produced no detectable gp160 protein in wild-type MT4 cells, but there 
was a complete rescue of gp160 expression when ZAP was knocked out (Figure 6.4A). 
Interestingly, when TRIM25 was knocked out, the rescue in gp160 expression was 
modest. When comparing the expression of Gag under these same conditions, ZAP 
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knock out provided a complete rescue for the CG-high virus. In contrast, TRIM25 knock 
out did not result in any detectable rescue in Gag expression for the CG-high virus. 
Similarly, for the virus with half as many CG dinucleotides (mutant LB), ZAP knockout 
completely rescued all reductions in viral protein expression, while TRIM25 knockout only 
modestly increased the expression of gp160 and did not increase the expression of 
capsid (Figure 6.4A). Analysis of infectious virus yield from these infected cells revealed 
that TRIM25 had only a modest effect on the replication of the CG-high virus (Figure 6.4B). 
Knockout of TRIM25 increased the infectious virus yield from the CG-high virus by only 
3-fold, while ZAP knockout rescued the infectious virus yield by nearly 2,000-fold. For 
mutant LB, TRIM25 knockout increased the infectious virus yield by 10-fold when 
compared to the MT4 wild-type cells, while ZAP knockout increased the infectious virus 
yield by nearly 500-fold as compared to the MT4 wild-type cells. We also tested these cell 
lines and viruses in a spreading replication assay (Figure 6.4C - E). While ZAP knockout 
completely rescued the replication of both CG-high viruses, TRIM25 knockout in MT4 
cells did not permit either of the CG-enriched viruses to spread in culture. Collectively, 
these results suggest that TRIM25 is not required for the ZAP mediated restriction of CG-
high viruses in MT4 cells. 
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Figure 6.4: Infections of CG-enriched viruses in MT4 cells 
(A) Western blot analysis 48 h after a single-cycle infection of MT4 cells with the wild-type 
of mutant HIV-1, representative of three experiments. (B) Single-cycle infectious virus 
yield, following infection of MT4 cells with equal titers of  wild-type HIV-1 and mutants 
(mean ± s.d., n=3). (C-E) Replication of HIV-1 mutants in  wild-type MT4 cell, ZAP KO 
MT4 cells, or TRIM25 KO MT4 cells, as measured by FACS enumeration of infected cells. 
(C) HIV-1 wild-type, (D) HIV-1 CG-high, (F) HIV-1 LB.  
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Comparing MT4 and 293T TRIM25 knockout cells revealed that ZAP dependence on 
TRIM25 to restrict CG-high HIV-1 varies dramatically on the cell line. Previously we noted 
that cell lines vary in the magnitude with which they inhibited CG-high HIV-1. Comparing 
the virus yield of a CG-high HIV-1 to a wild-type HIV-1 in a single cycle of replication 
assay, MT4 cells are capable of restricting the CG-high HIV-1 1,000-fold, HeLa cells 
capable of restricting 100-fold, and A549 cells capable of restricting only 10-fold. To more 
precisely quantify this phenomenon, we set out to compare the infectious virus yield from 
a wild-type virus and the CG-high virus at a variety of MOI to measure the effects of ZAP 
and TRIM25 in different cell lines. HIV-1NHG was used and cells were infected with virus 
at different dilutions. Supernatants from the infections were collected and titered on MT4 
cells to determine the infectious virus yield. The infected cells were also analyzed by flow 
cytometry to determine the percentage of cells infected and calculate the MOI . For each 
cell line, virus and dilution, we calculated the IU/mL in the supernatant and plotted that 
against the MOI in that well. The adherent cell lines used were A549 wild-type and ZAP 
knockout (lung adenocarcinoma cells), HOS and U2OS (osteosarcoma cells) and HeLa 
wild-type and ZAP knockout (cervical cancer cells). The T-cell lines used were H9, SupT1, 
Jurkat, and MT4 cells (both ZAP knockout and TRIM25 knockout). 
The U2OS, HOS and A549 all behaved similarly, as the MOI approached 1.0 the cells 
infected with the CG-high virus yielded infectious progeny, at a level that was about 10-
fold less than cells infected with wild-type HIV-1 (Figure 6.5 A, C, E). At higher MOI the 
difference in yield between the CG-high virus and the wild-type virus became less 
pronounced. The HeLa cells behaved differently, even at an MOI of 1.0 they did not 
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produce any detectable infectious virus from the CG-high HIV-1, while producing more 
than 1x106 infectious units from the wild-type virus. The HeLa cells only produced 
detectable infectious virus from the CG-high virus as the MOI approached 10 (Figure 
6.5C). For the HeLa and A549 ZAP knockout cells, the CG-high and wild-type virus 
behaved identically, both producing comparable titers at each of the different MOI (Figure 
6.5 D, F). The data collected from the T-cell lines more closely resembled the pattern 
observed from the HeLa cells. Even at the highest MOI used to infect any of the wild-type 
T-cell lines, there was hardly any detectable infectious virus produced from the CG-high 
virus, despite the high titers virus generated by wild-type virus infected T-cell lines at the 
same MOI (Figure 6.6 A, B, C, D). The ZAP knockout MT4 cell line produced the same 
infectious virus yield at each of the MOI for the wild-type virus and the CG-high virus 
(Figure 6.6F). Interestingly, the MT4 TRIM25 knockout cell behaved unlike any of the T-
cell lines tested, but rather responded more similarly to the adherent cell lines (Figure 
6.6E). This cell line restricted the production of CG-high virus at a MOI < 1.0, but at MOI 
> 1.0 become strikingly permissive for the production of the CG-high virus. MT4 TRIM25 
knockout cells infected with the CG-high virus at an MOI approaching 10 produced nearly 
1x106 IU/mL, whereas the same virus in MT4 wild-type cells did not produce any 
detectable infectious virus even at an MOI above 10. 
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Figure 6.5: Comparison of virus yield and MOI in adherent cell lines by wild-type 
of CG-enriched HIV-1 
(A-F) Single-cycle infectious virus yield, following infection of adherent cell lines at 
different MOI. MOI was determined FACS infected cells in each well for expression of 
GFP reported expression from incoming virus. Black lines: wild-type HIV-1; Red lines: 
CG-high HIV-1. Virus yield was determined by infecting MT4-GFP reporter cells. (A) 
U2OS wild-type, (B) HOS wild-type, (C) HeLa wild-type, (D) HeLa ZAP KO, (E) A549 wild-
type, (F) A549 ZAP KO.  
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Figure 6.6: Comparison of virus yield and MOI in T-cell lines by wild-type of CG-
enriched HIV-1 
(A-F) Single-cycle infectious virus yield, following infection of t cell lines at different MOI. 
MOI was determined FACS infected cells in each well for expression of GFP reported 
expression from incoming virus. Black lines: wild-type HIV-1; Red lines: CG-high HIV-1. 
Virus yield was determined by infecting MT4-GFP reporter cells. (A) H9 wild-type, (B) 
SupT1 wild-type, (C) Jurkat wild-type, (D) MT4 wild-type (E) MT4 TRIM25 KO, (F) MT4 
ZAP KO. 
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The loss of TRIM25 in MT4 cells phenotypically transformed them to behave more 
similarly to the adherent cell lines tested, suggesting the possibility that the adherent cell 
lines might be more permissive to CG-high viruses at a higher MOI due to lower levels of 
TRIM25 (Figure 6.7A, B). To investigate this possibility, we examined at the differential 
expression of ZAP and TRIM25 in all of the cell lines previously tested. For each cell line, 
we counted 5x105 cells and lysed them in 0.5 mL of lysis buffer for analysis by western 
blotting. While the size of the cytoplasm is different for each of these cell lines, the size 
of their nucleus should be roughly similar (Figure 6.7C). For the reason, we blotted for 
both tubulin as a surrogate for the approximate size of the cytoplasm and the nuclear 
envelope marker LaminB1 as a loading control for equal cells lysed (Kane et al., 2018). 
All of the T cells tested had significantly less tubulin expression, which correlates with 
their significantly smaller cytoplasm. Comparing the levels of TRIM25 across these cell 
lines revealed that TRIM25 expression is more closely correlated with the tubulin levels 
rather than the ability to restrict a CG-high virus production. Notably, all of the adherent 
cell lines expressed high levels of TRIM25 despite relatively weak restriction. Comparing 
ZAP expression across all of the cell lines revealed that the short and long isoform are 
differentially expressed across the different cell lines in a manner that does not correlate 
with the tubulin levels. The long isoform of ZAP was expressed at relatively similar levels 
across all cell lines tested, despite the smaller cytoplasm in the T-cells. The short isoform 
was expressed at low levels in U2OS, HOS and A549 cells, but was expressed at high 
levels in HeLa cells and in all of the T-cell lines tested. Strikingly, this expression pattern 
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correlated with the ability to potently restrict CG-high viruses. Quantification of the ZAP-
S and tubulin expression across these cell lines further demonstrated that a high ratio of 
ZAP-S to tubulin, or the ratio of ZAP to the cytoplasmic volume, exhibited a strong 
correlation with the level of restriction of CG-high HIV-1 (Figure 6.7D). 
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Figure 6.7: Comparison of adherent and t cell lines 
(A) Single-cycle infectious virus yield, following infection of adherent cell lines (red), T-
cell lines (black) and MT4 TRIM25 KO (blue) tested at different MOI with wild-type HIV-1. 
(B) Single-cycle infectious virus yield, following infection of adherent cell lines (red), T-
cell lines (black) and MT4 TRIM25 KO (blue) tested at different MOI with CG-High HIV-1. 
(C) Western blot analysis of protein expression at steady state in adherent cell lines and 
T-cell lines. (D) Quantification of the ratio of ZAP-S to tubulin expression in all of the cell 
lines from western blots in (C).  
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To experimentally test whether ZAP-S is either more potent or less dependent on TRIM25 
than ZAP-L, we used the previously mentioned cotransfection assay. We transfected (i.) 
either plasmids expressing ZAP-S or ZAP-L, (ii.) either plasmids expressing TRIM25 or 
an empty plasmid, and (iii.) different dilutions of plasmids expressing wild-type or a CG-
high virus to mimic different MOI. In the absence of TRIM25, both isoforms were inactive 
against the CG-high virus at all of the proviral concentrations used, suggesting that both 
isoforms are dependent on TRIM25 in 293T cells (Figure 6.8 A, B). When a plasmid 
expressing TRIM25 was added to the cotransfection both ZAP isoforms potently restricted 
the CG-high virus at low concentrations of proviral plasmid, but both ZAP isoforms also 
became less potent as the amount of cotransfected proviral plasmid was increased. 
Collectively, this data suggests that in 293T cells both ZAP-S and ZAP-L are TRIM25 
dependent and equally potent against the CG-high HIV-1. 
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Figure 6.8: Virus yield assay in 293T cells comparing activity of ZAP isoforms 
(A,B) Infectious virion yield measured using MT4-GFP indicator cells following 
transfection with ZAP-L and ZAP-S, TRIM25 or empty plasmid, and HIV-1NL4-3 wild-type 
or HIV-1NL4-3 CG-high with different concentrations of virus. (A) HIV-1NL4-3 wild-type. (B) 
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Effects of interferon on ZAP restriction of CG-high viruses 
In the previous section, we detailed how the potency of ZAP mediated restriction of CG-
high HIV-1 can vary depending on the cell line infected. MT4 cells are the least permissive 
to replication of CG-high HIV-1, while 293T and A549 are the most permissive to 
replication of CG-high HIV-1. One possibility is the less permissive cell lines have an 
additional cofactor that increases the potency of ZAP. Interferon stimulated genes (ISGs) 
are known to restrict a wide array of viruses in different cell lines through a diverse range 
of mechanisms (MacDonald et al., 2007). Therefore, we added interferon to cell lines that 
are permissive to the replication of CG-high HIV-1 to determine if this would increase the 
potency of ZAP, a method that has been previously demonstrated to work with ZAP 
restriction of Sindbis virus before the discovery of TRIM25 as a cofactor (MacDonald et 
al., 2007). We hypothesized that the addition of IFN might induce the expression of a ZAP 
cofactor in these cell lines that is not constitutively expressed. For these experiments, we 
used A549 cells treated with different concentrations of IFNα and IFNγ. To avoid 
restriction of incoming virus that is not ZAP dependent, we added IFN 18 hours post 
infection so as to only express genes after the virus had integrated into the cell (Holmes 
et al., 2015). We assayed these infected cells for viral protein expression, specifically 
looking for effects on gp160 expression, the viral protein with CG dinucleotides we know 
the be most sensitive to ZAP. We used 500, 50 and 5 units of IFNα and IFNγ, and blotted 
for Mx2 as a positive control for IFNα treatment and phosphorylated STAT1 (p-STAT1) 
as a marker of IFNγ treatment (Figure 6.9 A). Under both IFN conditions we saw a robust 
and dose-dependent induction of our control genes by western blot. The expression the 
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gp160 and GFP in the wild-type HIV-1 was unaffected by the interferon treatment, 
indicating that we had introduced IFN at the proper time as to not have any effect on the 
wild-type virus. The gp160 expression by the CG-high virus was inhibited by the addition 
of both IFNα and IFNγ in a dose-dependent manner (Figure 6.9A). Notably, TRIM25 was 
expressed at slightly higher levels after treatment with either IFN at all doses, while ZAP-
S was also expressed at higher levels with either IFN treatment but the expression was 
dose-dependent. As a control cell line, we conducted the same experiment in A549 cells 
that were knocked out for ZAP and TRIM25 to demonstrate that these effects are 
dependent ZAP and TRIM25 activity. In these double knockout cells, IFN treatment had 
no effect on either the wild-type or CG-high virus (Figure 6.9B). While IFN treatment can 
increase the restriction of CG-high HIV in a dose-dependent manner, the concomitant 




Figure 6.9: Effect of IFN treatment on replication of CG-high virus in A549 cells 
(A,B) Western blot analysis 48 h after a single-cycle infection of A549 cells with wild-type 
or CG-High HIV-1 treated with IFN-α or IFN-γ at different concentrations. IFN was added 
to the cells 18 hours post infection at the time of replacing the media. MX2 represents the 
positive control for IFN-α treatment, p-STAT represents the positive control for IFN-γ 
treatment. (A) wild-type A549 cells. (B) ZAP and TRIM25 KO A549 cells.  




















Screening for novel ZAP cofactors 
The previous sections detailed the dramatic cell type dependent differences that exist in 
the restriction of CG-high HIV-1. MT4 cells are capable of restricting the replication of CG-
high HIV-1 independent of TRIM25 (at least at low MOI) while 293T cells are completely 
dependent on TRIM25 to restrict CG-high HIV-1. It is possible that this is due to nuances 
in the expression of each isoform or heterogeneity of ZAP expression in the cellular 
population. It is also possible that ZAP might depend on an additional cofactor besides 
TRIM25 that is not present in all of the cell lines we have tested. To test this latter 
hypothesis, we conducted a screen with siRNAs directed against possible cofactors. ZAP 
interacting proteins were identified in wild-type 293T cells in the  absence of viral infection 
(Goodier et al., 2015). ZAP was immunoprecipitated both in the presence and absence 
of ribonuclease treatment and a total of seventy-eight genes identified, all of which were 
included in our siRNA library. As performed previously (Figure 5.7A) genes were knocked 
down with siRNAs, the cells were infected at an MOI of 1.0 with either wild-type or CG-
high HIV-1, and the infectious virus yield produced was measured by tittering the 
supernatants on MT4-GFP cells. We tested this library in HeLa and A549 cells to validate 
that hits would be supported by results in multiple cell lines. As a positive control, siRNAs 
against ZAP and TRIM25 were included in the library and their knockdown reproducibly 
rescued the replication of the CG-high virus. ZAP knockdown completely restored the 
replication of the CG-high HIV-1 and TRIM25 knockdown partially rescued replication. 
We sought to ensure that any effects observed were due to an increase in virus yield in 
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this single cycle replication assay as opposed to an increase in incoming virus. To ensure 
our siRNA did not have an impact in the susceptibility of the cells to the incoming virus 
we also measured the percentage of cells that were infected for each knockdown. To do 
this we used HIV-1NHG so we could measure the percentage of cells infected by the GFP 
reporter. In the HeLa screen, other than ZAP and TRIM25, knockdown of no other genes 
significantly in increased the infectious virus yield from the CG-high HIV-1 with the 
exception of the well containing the siRNA labeled LARP1 (Figure 6.10). Upon further 
investigation of this gene, it became clear that the well in the siRNA screening plate was 
contaminated with an siRNA against TRIM25, and LARP1 knockdown alone did not 
actually rescue the replication of the CG-high virus (data not shown). 
We also screened this library with mutant LB, which has half as many CG dinucleotides 
as the CG-high HIV-1. Because mutant LB is significantly less attenuated than the CG-
high HIV-1, the dynamic range of this assay was decreased to 10-fold, but knockdown of 
ZAP still clearly rescued the replication of LB (Figure 6.11). Surprisingly, knockdown of 
TRIM25 did not affect the replication of the mutant LB, though previously in MT4 cells, 
loss of TRIM25 did affect the replication of mutant LB (Figure 6.4B). Similar to the initial 
screen with the CG-high virus, none of the genes knocked down in the library had large 
effects on the replication of the mutant LB. The same library tested in A549 cells did 
produce genes that rescued the replication of the CG-high virus when knocked down, 
namely USP9X and TUFM, both ubiquitin specific peptidases (Figure 6.12). Follow up 
work is currently ongoing to validate these hits as potential components to the ZAP 
pathway. 
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Figure 6.10: siRNA screen from Mass Spectrometry hits in HeLa cells 
Single-cycle infectious HIV-1 wild-type and CG-High yield from siRNA-transfected HeLa 




Figure 6.11: siRNA screen from Mass Spectrometry hits in HeLa cells 
(A) Single-cycle infectious HIV-1 wild-type and mutant LB yield from siRNA-transfected 
HeLa cells (mean±sd. (n=3)). (B) Percentage of HeLa cells transfected with siRNA and 




Figure 6.12: siRNA screen from Mass Spectrometry hits in A549 cells 
(A) Single-cycle infectious HIV-1 wild-type and CG-High yield from siRNA-transfected 
A549 cells (mean±sd. (n=3)). (B) Percentage of A549 cells transfected with siRNA and 





Figure 6.13: siRNA screen against cellular Ribonucleases in HeLa cells 
(A) Single-cycle infectious HIV-1 wild-type and CG-High yield from siRNA-transfected 
HeLa cells (mean±sd. (n=3)). (B) Percentage of HeLa cells transfected with siRNA and 













































































































































































































































































































































































































































































































































































































































































































































































Figure 6.14: siRNA screen against cellular Ribonucleases in HeLa cells 
(A) Single-cycle infectious HIV-1 wild-type or mutant LB yield from siRNA-transfected 
HeLa cells (mean±sd. (n=3)). (B) Percentage of HeLa cells transfected with siRNA and 






































































































































































































































































































































































































































































































































































































































































































































































































































































We have previously shown that ZAP causes a cytoplasmic depletion of CG-high viral RNA. 
We hypothesized that this depletion is due to a cellular ribonuclease acting downstream 
of ZAP binding to CG-high viral RNA. For this reason, we assembled an siRNA library 
targeting all known cellular proteins catalogued as having a ribonuclease activity based 
on Uniprot’s gene ontologies. The only ribonucleases that were found in Uniprot but 
excluded from our library on were those catalogued as having a specific activity against 
tRNAs. This library contained positive control siRNAs targeting ZAP and TRIM25, one 
negative control against GAPDH, one negative control that was non-targeting, and 92 
siRNAs against annotated ribonucleases. We tested this library in wild-type HeLa cells 
and had a 100-fold dynamic range with our negative control siRNAs. The positive controls 
against ZAP and TRIM25 significantly rescued the replication of the CG-high virus, while 
no other siRNAs tested generated a significant rescue (Figure 6.13). As with our previous 
library, we also used this library in HeLa cells with the less CG-enriched and therefore 
less attenuated mutant LB. Surprisingly, ZAP did not come up as the top hit in this screen, 
but rather RNASE12, a poorly characterized member of the Ribonuclease A family that 
is annotated as inactive (Figure 6.14). Notably, analysis of the infected HeLa cells showed 
that knockdown of RNASE12 significantly increase the percentage of infected cells, 
possibly explaining why it also seemingly increased the replication of mutant LB. Another 
gene that also increased the replication of the LB virus was EXOSC4, a member of the 
RNA exosome that has previously been implicated as a cofactor for ZAP. EXOSC4 was 
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also near the top hits when screened against the fully attenuated CG-high virus, but the 
rescue was not statistically significant. 
Summary 
We have demonstrated that TRIM25 is an important cofactor for ZAP in the restriction of 
CG-high HIV-1. Mechanistically, it appears that in order to act as a cofactor for ZAP the 
RNA binding and ubiquitination activity of ZAP are non-essential. Additionally, ZAP is able 
to recognize and directly bind to CG-high RNA in the absence of TRIM25. Between the 
cell lines tested there are dramatic differences in how potent ZAP is against a CG-high 
HIV-1, but whether this is due to an additional cofactor required for activity or merely 
reflects the total number of ZAP molecules present in the cytoplasm remains unclear. 
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Chapter 7. Discussion 
Splicing 
Through a global synonymous mutagenesis experiment we found that extensive portions 
of the HIV-1 genome could be synonymously mutated without major effects on viral 
replication (Group 1 mutants). In particular, synonymous mutations throughout the 
majority of the pol gene had a minimal or no effect on viral fitness, such that their effect 
was not measurable in our assays. Given the extent of the mutations that were introduced, 
and the improbability that most RNA secondary structures would be preserved in our 
mutants, it seems unlikely that undiscovered specific RNA secondary structures essential 
for replication exist in portions of the viral genome covered by Group 1 mutants. Even 
among mutants that were replication defective, Group 2 mutants could be restored to 
replication competence through single nucleotide reversion mutations that suppressed 
the utilization of cryptic or canonical splice sites, whose use was enabled or elevated in 
the global mutagenesis experiment. Again, this argues against the notion that 
undiscovered, specific RNA structures that are essential for replication are prevalent in 
Group 2 mutants, with the exception of those that regulate splicing. 
An important caveat to this conclusion is that replication was measured in permissive cell 
lines in the absence of competition. It is possible, even likely, that mutants or revertants 
with WT or near WT replication dynamics, have modest fitness deficits that would be 
evident in a more stringent environment or a competitive replication assay. For example, 
some of the HIV-1 accessory genes are important in vivo, but non-essential in vitro, 
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therefore defects in their expression would be expected to have minimal effects on 
replication in our assays. Thus, while we can reasonably conclude that RNA secondary 
structures in Group 1 and Group 2 revertant mutants are non-essential for replication per 
se, it is nevertheless possible that RNA structures play an accessory role in regulating or 
fine-tuning the levels or fates of mRNAs encoding certain accessory proteins. 
Nevertheless, synonymous mutations in some portions of the HIV-1 genome caused 
profound, near-lethal defects in these highly permissive T-cell lines (Group 2 and Group 
3 mutants). These mutations therefore perturbed essential, non-coding features of the 
HIV-1 nucleotide sequence. One noncoding feature of the HIV-1 genome that appeared 
important for replication that was uncovered by our Group 2a mutants was suppression 
of cryptic splice sites near the 5’ end of the RNA genome. For these mutants, the 
magnitude of the deviation from WT sequence appeared important for cryptic site 
activation. Simply subdividing the mutant sequence blocks into two mutant blocks 
approximately equal lengths (e.g. mutants AA, AB and BA, BB) reverted the mutant 
splicing phenotype. This finding suggests that activation of the existing cryptic splice sites 
resulted from multiple perturbations to the gag nucleotide sequence and that changes in 
predicted splice site strength were not sufficient to explain their activation. Moreover, in 
the case of mutant A, a single nucleotide revertant mutation that occurred distal to the 
activated cryptic splice sites corrected the splicing defect without affecting their MaxEnt 
scores. These findings might be best explained by the existence of multiple elements in 
the gag gene (secondary structures or protein binding sites) that act redundantly to 
suppress cryptic splice site utilization. The fact that the revertant mutation for mutant A 
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occurred at a position proximal to an existing RNA structure that includes D1 (Berkhout 
and van Wamel, 2000; Keane et al., 2015), may suggest a role for an extended secondary 
structure involving the 5’ leader and the gag gene in suppressing the utilization of potential 
cryptic splice sites in gag. The potential for the 5’ leader to form alternative structures that 
could affect splicing appears to be finely tuned (Keane et al., 2015), and therefore could 
possibly be perturbed by distal mutations in gag. Clearly, further work will be required to 
understand how the WT noncoding RNA sequence is selected to avoid utilization of 
cryptic splice sites. 
A detailed analysis of Group 2b mutants, that targeted the central portion of the genome, 
revealed several elements whose perturbation resulted in dramatic overuse of the 
canonical splice acceptors A1, A2, and A3. These mutant elements that resulted in 
oversplicing could be mapped to sequences of various lengths. Such sequences 
constitute candidate individual or clustered ESS elements. When combined with existing 
knowledge of splicing regulation, at A1, A2 and A3 (Madsen and Stoltzfus, 2006; Martin 
Stoltzfus, 2009), these and previous findings suggest a highly complex regulatory network 
of functional inputs that govern alternative splicing of the HIV-1 genome, as depicted in 
(Figure 7.1). 
The phenotypes of some mutant and revertant viruses (i.e. viruses with perturbed splicing 
whose replication was recovered by mutations at splice sites) is consistent with the notion 
that exon definition (i.e. coordinated recognition of a 5’ splice acceptor and a 3’ splice 
donor by the splicing machinery (Kharytonchyk et al., 2016) plays a central role in the 
regulation of HIV-1 alternative splicing. For example, the mutant (IA) that exhibits elevated 
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use of A1 and the downstream donor D2 (as well as the cryptic donor D2b) while the 
revertant (IA(T4904A)) occurred at A1 and reduced utilization of D2, and D2b as well as 
A1. Similarly, in IB, that exhibits elevated use of both A1 and A2, both downstream donors 
D3 and D2 are also overused. In this case, the revertant mutation (IB(G4912A)) at A1 
caused abolition of splicing at both A1 and D2 while splicing at A2 and D3 remain elevated. 
Consistent with the notion that splicing at A1 and D2 are coordinated, previous work has 
shown that the efficiency with which D2 is recognized can affect the frequency of splicing 
at A1(De Conti 2013). Similar communication occurs between A2 and D3. Indeed, for a 
mutant (JA) that exhibited profound oversplicing at A2 and D3, a reversion mutation 
(JA(G5463A)) that inactivated D3 also caused abolition of splicing at A2. Because not all 
splices at A2 lead to splicing at D3, this observation suggests that recognition of D3 by 
the splicing machinery is required for splicing at A2 even when D3 is not utilized, as has 
previously been suggested (Erkelenz et al., 2013; Martin Stoltzfus, 2009). Overall 
therefore, a major determinant of the use of a given acceptor or donor in the HIV-1 
genome was the use of a downstream donor or upstream acceptor, respectively. 
Our data is also consistent with the notion that splice acceptor sites compete with each 
other, with ‘cascading’ effects based on exon definition. For example, the mutant (JA) 
under-utilizes A1 and over-utilizes A2. Its revertant (JA(G54653A)) that abolishes splicing 
at both D3 and A2, causes over-utilization of A1. In a reciprocal example of A1-A2 
competition, abolition of A1 utilization in the revertant IB(G4912A), was accompanied by 
increased splicing at A2. Acceptor competition was also evident in the context of the 
mutant K, which exhibited oversplicing at A3 at the expense of splicing at A1, A2, A4b 
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and A5. In this case, the reversion mutation at A3 in K(C5774T) led to restoration of WT 
splicing frequency at all other sites in the central portion of the HIV-1 genome. 
Overall therefore, a key regulator of the use of a particular splice site is the presence and 
utilization of other splice sites, through coordinated recognition of acceptor and donor 
sites, along with competition between acceptor sites. Thus, disruption of the splicing 
regulatory signals whose existence is indicated herein can have complex effects on 
overall splicing, through the propagation of their effects from one splice site to another. 
Clearly the overall effect of these perturbations is best appreciated in the nextgen 
sequencing assay with all splice sites represented in a viral construct. 
That being the case, the RNA sequence elements that we have identified as apparent 
regulators of splice acceptor utilization (Figure 7.1) could work directly or indirectly. 
Specifically, they could act to directly inhibit access of the splicing machinery to the 
affected splice acceptors or indirectly through splice donors, inhibiting acceptor utilization 
by inhibiting exon definition. It is also possible that our mutations affect the ability of splice 
sites to effectively communicate with each other in the context of exon definition. Existing 
splicing regulatory sequences have been reported to exert their effect through binding of 
hnRNP or SR proteins, or through the formation of RNA secondary structures (Mandal 
2009). The sequences that we have identified are of varying sizes; some elements that 
had major effects on splicing appear sufficiently small (e.g. JC2 and KD2) to constitute 
specific protein binding sites. However, these elements did not appear to be enriched in 
canonical hnRNP binding motifs, as might be expected for splicing silencers (Mandal et 
al., 2009). Some of the effects on splicing that we found in our mutants, particularly within 
158 
the I and J fragments, appeared complex and not easily mapped to small discrete 
elements. Perhaps these effects are the result of combinatorial inputs from multiple 
binding sites or secondary structures that could act to occlude splice sites, or spatially 
separate 3’ donors from 5’ acceptors thereby inhibiting exon definition. Further work will 







Figure 7.1: Summary of splicing control in HIV-1 
(A) Schematic representation of the central portion of the HIV-1 genome with the positions 
of canonical splice sites indicated. Previously identified splicing control elements are 
indicated with grey lines. Sequences identified in this study whose mutation enhanced 
splicing are indicated with red lines and the splice acceptors on which they act are 
indicated with red arrows. (B) The sequences of the identified elements that affect splicing 
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TGC T A A A T T AG T A A T A ACA AC A T A T TGGGGT C TGC A T ACAGGAGA A AGAGAC TGGC A T T TGGGT CAGGGAGT C T CC A T AGA A TGGAGGA A A A AGAG A T A T AGCACACA AG T AGACCC TGAC






TGC T A A A T T AG T A A T A ACA AC A T A T TGGGGT C TGC A T ACAGGAGA A AGAGAC TGGC A T T TGGGT CAGGGAGT C T CC A T AGA A TGGAGGA A A A AGAG A T A T AGCACACA AG T AGACCC TGAC






TGC T A A A T T AG T A A T A ACA AC A T A T TGGGGT C TGC A T ACAGGAGA A AGAGAC TGGC T G GT CAGGG GT C CC A T A A A TG AGG A A AGAG T A T AG ACA AG A AC C T AC






AGTGAC A T A A A AG T AGTGCCA AGA AGA A A AGCA A AG A T C A T CAGGG A T






AGTGAC A T A A A AG T AGTGCCA AGA AGA A A AGCA A AG A T C A T CAGGG A T






TGC T A T A AGA A A T ACC A T A T






TGC T A T A AGA A A T ACC A T A T





T A ACA AGG T AGG A T C T C T ACAG T AC T TGGCAC T AGCAGC A T T A A T A






T A ACA AGG T AGG A T C T C T ACAG T AC T TGGCAC T AGCAGC A T T A A T A






T CAGCC T A A A AC TGC T TG T ACC






T CAGCC T A A A AC TGC T TG T ACC










































Perturbation of balanced splicing did not always lead to abolition of HIV-1 replication. For 
example, the mutants JB and JA(5463A) had perturbed splicing (overuse of A1 for JA, 
and abolition of SX2 utilization for JB) but their replication was only slightly delayed 
compared to WT. Similarly the IB(G4912A) revertant virus had near WT replication but 
completely lacked splicing to A1 and therefore abolished inclusion of SX1. These 
perturbations would be expected to lead to underexpression or overexpression of Vif and 
Vpr, neither of which are essential for replication in the particular cell type used in our 
experiments. Thus, the requirement for a particular balance of HIV-1 mRNAs could be 
highly context dependent. In our experiments, replication defects that resulted from over-
splicing were likely the result of depletion of the pool of unspliced RNA, thus leading to 
lower levels of synthesis of Gag, Pro, Pol, and other viral proteins, and lower levels of 
viral genomes for packaging. Thus, a key role of splicing inhibitory signals in the HIV-1 
genome is to maintain the unspliced RNA pool, as well as adequate levels of necessary 
viral proteins. 
Overall, our global synonymous mutagenesis experiment has revealed several RNA 
elements whose native sequence is important for HIV-1 replication. In particular, we have 
identified several RNA elements in the HIV-1 genome whose native sequence appears 
to be important for suppression of canonical splice sites, regulation of alternative splicing 
and maintenance of unspliced transcript levels. Additionally, our analysis revealed that 
some as yet unidentified property of RNA sequences in the gag gene suppresses 
utilization of cryptic splice sites. Understanding how RNA sequence affects splicing in the 
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context of HIV-1 may give insights into the general mechanisms by which alternative 
splicing is regulated and how splicing regulation evolve. 
ZAP recognition of CG dinucleotides 
The synonymous mutagenesis also led to the discovery that ZAP binds CG dinucleotides 
in RNA. This discovery brings together two previously separate areas of RNA biology: (i.) 
the outstanding question as to how ZAP recognizes non-self RNA and (ii.) the attenuation 
of RNA viruses through the addition of CG dinucleotides. While many groups had 
previously tried to identify an ZAP RNA target sequence through either analysis of 
sensitive viruses or iterative cloning to find a minimally sensitive element, no common 
features emerged. Analysis of the viruses previously determined to be sensitive and 
insensitive to ZAP reveal a clear pattern that differentiates them when comparing the CG 
dinucleotides odds ratios (Figure 7.2) (Bick et al., 2003; Cheng et al., 2013; Lin et al., 
2014; Mao et al., 2013; Muller et al., 2007). Strikingly, the genomes of the viruses that 
are sensitive to ZAP have a CG dinucleotide odds ratio (the ratio of the observed 
frequency to the expected frequency based on the mononucleotide composition) of at 
least 0.54 or higher. The genomes of the viruses insensitive to ZAP have an odds ratio of 
0.54 or lower. This analysis, though limited, suggests that the threshold for a ZAP 
sensitive virus might be somewhere in the range of a 0.54 odds ratio, though a number 
of additional factors likely also contribute to this sensitivity, including but not limited to: 
viral proteins that antagonize ZAP activity through re-localization or degradation, 
additional RNA compositional differences of viral genomes, and mRNA sequestration that 
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prevents ZAP from gaining access to viral mRNA. Further analysis of the regions of the 
SINV genome that were used to determine a minimally sensitive ZAP sequence also 
indicate that ZAP is targeting CG-high RNA (Guo et al., 2004). There is a strong and 
significant correlation between the odds ratio of CG dinucleotides multiplied by the length 
of the sequence and the fold inhibition by ZAP. This finding explains why has previously 
difficult to find a minimally sensitive ZAP fragment, not only did the RNA sequence need 
to have a certain threshold of CG dinucleotides, but it also needed to be long enough to 
efficiently recruit ZAP for repression. 
163 
Figure 7.2: Analysis of CG suppression in previously reported ZAP-sensitive and 
ZAP-resistant viruses and ZAP-sensitizing elements 
(A) CG suppression in RNA and reverse transcribing viruses previously reported to be 
ZAP sensitive (n = 9, open symbols) and ZAP resistant (n = 4, filled symbols)7,17–20.
The viruses included in the analysis and their degrees of CG suppression (CG 
observed/expected) are: ZAP-sensitive: Sinbis virus (0.90), Semliki forest virus (0.89), 
Venezuelan equine encephalitis virus (0.76), ebolavirus (0.60), hepatitis B virus (0.52), 
Moloney murine leukemia virus (0.51), Marburg virus (0.53), alphavirus M1 (0.89), Ross 
river virus (0.82); ZAP-insensitive: HIV-1 (0.21), yellow fever virus (0.38), vesicular 
stomatitis virus (0.48), poliovirus (0.54). The P value was calculated using Student’s t-test 
(two-sided, n = 9 ZAP-sensitive viruses and n = 4 ZAP-resistant viruses). Influenza virus 
(CG obs/exp = 0.44), which has been reported to be ZAP-resistant owing to the presence 
of an antagonist and ZAP-L- sensitive via an entirely distinct protein interaction-based 
mechanism, was excluded from this analysis. (B) Previous analysis by Guo et al on ZAP 
inhibition of reporter gene expression (Guo et al., 2004). Each RNA element derived from 
the indicated RNA viruses was placed in a 3′ UTR of a luciferase reporter plasmid and 
fold inhibition by coexpressed ZAP is plotted against the product of CG suppression (CG 
observed/expected) and length for each RNA element. A data point that is a quantitative 
outlier from the general trend (indicated in red) is from the Sinbis (SINV) genome, but is 
nevertheless included in the linear regression analysis. P value was calculated using the 
F-test (two-sided, n = 32 data points). 

























































While we have demonstrated that ZAP binds to CG rich RNA and results in the 
cytoplasmic depletion of that RNA, additional analysis of the data presented suggests 
that a complete understanding of how ZAP targets CG-high RNA is more complex. One 
example of this is the normal phenotype of Group 1 mutants from the original synonymous 
mutagenesis. Again, all of the mutants in this group are phenotypically indistinguishable 
from the wild-type virus in a spreading replication assay in either MT4 cells or CEM cells 
(Figure 3.2, 3.3). Curiously, in silico analysis of their CG enrichment reveals that while 
they do not have the same total number of CG dinucleotides as mutants L and M, the 
mutagenesis did significantly increase the number of CG dinucleotides. It was only after 
combining all of the mutations from mutants E through H, thus creating mutants EH that 
these CG dinucleotides rendered HIV-1 ZAP sensitive (Figure 5.1E; Figure 5.4 A, C, D). 
Despite having more than twice as many CG dinucleotides as mutant L, mutant EH is 
less sensitive to ZAP than mutant L when comparing decreases in levels of unspliced 
RNA, Pr55Gag expression and fitness in a spreading replication assay (Figure 5.3 B, D; 
Figure 5.4 C, D). This could be explained by a multitude of factors. One key difference 
between EH and L is the CG-high region is present in different sections of the coding 
sequence. For mutant EH, the CG dinucleotides are in the incorporated into the coding 
sequencing of the gag mRNA,  while for mutant L they are in the 3’UTR of the gag mRNA. 
Another difference might be in the distribution of CG dinucleotides. Mutant L has a higher 
density of dinucleotides compared to EH, even though it has fewer total. Without further 
experimentation, we cannot conclude which of factors contribute to the ZAP sensitivity of 
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a viral mRNA, but we can conclude that there are more aspects of CG-enrichment that 
determine ZAP mediated repression than we currently understand. 
Another observation that suggests ZAP targeting of mRNA is more complex comes from 
a deeper examination of mutant L expression of the Gag and Env proteins. Comparing 
the protein expression of these two different proteins during an infection of MT4 cells with 
mutant L, the Envelope protein is significantly more affected by ZAP compared to Gag. 
The CG rich region in the coding sequence of env, while it is the 3’UTR of gag, suggesting 
that ZAP is perhaps more active against coding regions that 3’UTRs. This is further 
supported by CLIP-seq data that indicates ZAP is more frequently bound to coding 
regions of mRNA than to 3’UTRs, though this might be explained by the fact that 3’UTR 
are slightly more suppressed for CG dinucleotides than coding regions (Figure 5.10C). 
Because ZAP probably destabilizes the mRNA that it binds to, it is possible that the CLIP 
data is skewed toward mRNA that is less targeted for destabilization. Additionally, the 
gag and env mRNA are translated in different locations, where env transcripts are 
translated in the rough ER while the gag transcripts are translated on free ribosomes in 
the cytoplasm. While microscopy of ZAP indicates that it is expressed in the cytoplasm 
with a punctate pattern, it is possible that ZAP somehow more efficiently targets mRNA 
in the rough ER than on free ribosomes. Alternately, it remains possible that ZAP is more 
active in targeting CG-rich mRNA when the CGs are in coding regions compared to 
3’UTRs. 
Further evidence for this distinction between CG dinucleotides effecting open reading 
frames and 3’ UTRs comes from the transient transfection assay. These assays used 
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different sequences as 3’UTR to a CG-depleted luciferase reporter (Figure 5.9). CG-
enriched viral sequences from IAV and VSV were used as 3’UTRs to luciferase and 
transfected into ZAP KO and wild-type HeLa cells. Despite the use of long sequences 
with CG-enrichment similar to that of mutant L, the expression of the CG high constructs 
is reduced by less than 10-fold in the presence of ZAP, still orders of magnitude above 
the limit of detection. This is in contrast to the expression of gp160, where protein 
expression is hardly detectable. It is possible that the limited restriction of these 
sequences might be due to compositional differences in either mononucleotides or 
dinucleotides as well as stability of the encoded protein. Though, it remains possible that 
these effects are due to the location of the CG dinucleotides in the mRNA, namely in the 
3’UTR. Previous studies have observed up to 40-fold restriction of similar constructs with 
SINV virus genes as the 3’UTR (Guo et al., 2004). In contrast, we have only observed a 
10-fold restriction of our luciferase constructs with CG-rich sequences as 3’UTR (Figure 
5.9D). One key differentiator between these two experimental designs is that our 
luciferase gene has been recoded so that it is depleted for CG dinucleotides while the 
luciferase used in Guo et al. is high in CG dinucleotides, likely contributing to the 
differences in ZAP sensitivity (Figure 5.9A).  In fact, it has been observed that removal of 
CG dinucleotides from the coding sequence of luciferase increases the expression of 
luciferase by nearly 10-fold (Atkinson et al., 2014). Taken together, it remains to be 
determined how the location of CG dinucleotides within an mRNA molecule might 
sensitize it to ZAP mediated restriction. 
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ZAP cofactor requirements 
Multiple studies have been published to suggest that they have determined a ZAP 
cofactor (Chen et al., 2008; Erazo and Goff, 2015; Guo et al., 2007), yet to date the only 
cofactor that has been substantiated by multiple studies is TRIM25 (Li et al., 2017; Zheng 
et al., 2017). The initial study to describe TRIM25 as a cofactor for ZAP suggested that 
all of the domains in TRIM25 are important for its function, and specially investigated the 
ubiquitination of ZAP by TRIM25 (Li et al., 2017). Yet, surprisingly, ablation of the resides 
in ZAP that are ubiquitinated does not affect its antiviral activity, potentially indicating that 
ZAP is not the functional target of the ubiqutination activity of TRIM25 (Li et al., 2017). 
Other groups have described a putative RNA binding domain in TRIM25 that is important 
for its biological function both in relation to ZAP and to RIG-I (Choudhury et al., 2017; 
Sanchez et al., 2018). Until this point, the precise mechanisms by which TRIM25 supports 
the antiviral activity of ZAP is not well understood.  Our inability to crosslink any RNA with 
TRIM25 in a mammalian cell is perplexing considering multiple other groups have claimed 
that it binds RNA. One possible explanation for this might be purely technical. We are 
using the modified nucleotide 4SU to more efficiently crosslink our RNA to TRIM25, as 
we do for all CLIP-seq experiments. If TRIM25 has absolutely no affinity for uridine 
nucleotides, and therefore is never proximal enough to a 4SU in the RNA, then 
crosslinking may be inefficient. However, we have done CLIP-seq experiments for 
multiple RNA binding proteins that do not bind U and always observe a good RNA 
crosslinking signal (Kutluay et al., 2014; York et al., 2016). Therefore, this possibility 
seems unlikely, but cannot be entirely discounted. This could also be due to the 
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differences between biochemical assays with two components (RNA and protein) and the 
rich heterogeneous mixture of polymers in a mammalian cell. Additionally, TRIM25 might 
have cellular cofactor that occludes the binding site from interacting with RNA, and this 
cofactor might be expressed differently based on the cell line used, explaining how some 
groups have pulled down RNA with TRIM25 (Choudhury et al., 2017). 
Regardless of the reason we were unable to pulldown RNA with TRIM25 in 293T cells, it 
is abundantly clear that ZAP does not require TRIM25 to recognize CG dinucleotides in 
RNA. Though we have shown that cell type differences have a profound impact on how 
ZAP and TRIM25 work together, we have done the CLIP-seq studies using ZAP in the 
absence of TRIM25 in a cell line that requires TRIM25 for proper function. This indicates 
that even though ZAP requires TRIM25 to restrict CG high viruses in 293T cells, TRIM25 
does not change RNA binding preference of ZAP, allowing us to confidently conclude that 
TRIM25 enhances the antiviral activity of ZAP though some other mechanism. Similarly, 
cotransfection experiments that reconstitute 293T double knockout cells with ZAP and a 
TRIM25 that has mutations in the putative RNA binding domain further suggest that RNA 
binding is not an important biological activity with regards to supporting the antiviral 
activity of ZAP. Further mutational analysis and reconstitution of TRIM25 in double knock 
out 293T suggests that ubiquitination is dispensable for function, while the formation of 
higher order multimers appears to be critical to the function as a cofactor for ZAP. 
While in 293T cells we have provided evidence that higher order multimerization is critical 
to the function of TRIM25, this finding must be taken in light of the evidence that also 
suggests a cell type dependence on the relationship between TRIM25 and ZAP. The 
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profound differences we observe between T-cell lines and adherent cell lines (with the 
exception of HeLa cells) are thus far unexplained. Along with these cell type differences, 
we do not observe a correlation between ZAP activity and TRIM25 protein expression. 
One explanation might be that there is an additional positively acting cofactor that is 
constitutively expressed in T-cells and HeLa cells, but IFN induced in other adherent cells 
such as A549 cells. It is also possible that there might be a negative regulator of ZAP and 
TRIM25 present in adherent cells, which is then downregulated by IFN in A549 cells. 
Historically, restriction factors are mostly positively acting and upregulated, though there 
are a significant number of genes are downregulated upon IFN treatment, so this 
possibility cannot be entirely ruled out (Kane et al., 2016; Schoggins et al., 2014). 
The failure of previously identified ZAP cofactors to be validated is likely do the how they 
were identified (Chen et al., 2008; Erazo and Goff, 2015). Often, cellular ribonucleases 
are overexpressed and determined to have a role in RNA degradation (Chen et al., 2008; 
Guo et al., 2007; Zhu et al., 2012). Preferably, experiments that knockdown or knockout 
genes of interest and demonstrate that ZAP is inactive without these genes would be 
more enlightening.  Additionally, these overexpression experiments were never done in 
the context of a ZAP knockdown or knockout, and therefore not conclusively linked to the 
ribonuclease activity in the ZAP pathway. Consistent with this, we have not corroborated 
any of the data that suggests additional factors such as XRN1, DDX17, DIS3 or PARN 
are not required for the antiviral activity of ZAP. One caveat to this conclusion is that our 
experiments were done in the context of an siRNA knockdown, which means the protein 
targets are not completely removed from the cell. If only a very small amount of residual 
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protein is needed to complement the activity of ZAP, as is the case with LEDGEF and IN 
(Llano et al., 2006), then our experimental set up would not identify the protein as a 
cofactor for ZAP. To confidently identify a cofactor would involve overexpressing the 
proposed cofactor in a cell line that is semi-permissive to the replication of a CG-high 
virus, resulting in the a greater attenuation of the CG-high virus. Additionally, the same 
experiment should be performed in a ZAP knockout cell line to confirm that the effects 
are ZAP dependent and overexpression in the absence of ZAP has no effect on the 
replication of the CG-high virus. An additional caveat to our approach in primarily focusing 
on gene knockdown is that there might be multiple ribonucleases that can act as a ZAP 
cofactor and degrade the CG-high RNA. If multiple proteins can act as the ribonuclease 
for ZAP, then knocking down only one of them is likely to have a small or no effect. If this 
is the case, identifying the cofactor might best be carried out using overexpression 
experiments, but a ZAP knockout would be an important control to confirm specificity. 
In this present study, we have identified many new cis-acting RNA elements that control 
the proper regulation of splicing in HIV-1. In addition, we have explained a primary 
function for the CG suppression of the HIV-1 genome, namely avoiding detection by ZAP. 
We have shown that ZAP binds to CG-high RNA, and this binding destabilizes the RNA, 
but how this destabilization is accomplished remains unclear. We have demonstrated that 
ZAP recognizes CG-high RNA independently of TRIM25, and that the multimerization 
activity of TRIM25 is important for its function as a ZAP cofactor. Much of our data 
indicates that an additional ZAP cofactor is yet undiscovered and heterogeneously 
expressed among cell lines. Overall, this global synonymous mutagenesis has yielded 
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many new insights into the non-coding functions within the coding sequence of HIV-1 
RNA, and opens the possibility that more elements remain to be discovered. 
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